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I 
Introduction 
___________________________________ 
 
1.1 Cytokines 
 
The term cytokine is derived from the Greek words κυτοζ (cell) and κινειν (kinesis) 
meaning as far as moving between cells. Cytokines are small proteins often glycoproteins 
with molecular weights ranging from 8 to 40 kD. They serve as biochemical messengers 
between cells and are involved in processes such as regulation of the immune response 
(host response to disease or infection), stress responses, cell growth/differentiation, and 
finally tissue repair and remodeling, respectively. 
The nomenclature of cytokines was often based on their cellular sources. Cytokines 
produced by mononuclear phagocytes were sometimes called monokines, and those 
produced by lymphocytes were commonly called lymphokines, a term first introduced in 
1969. But with the advent of molecular cloning it became evident, that several distinct cell 
lineages could produce the same mediator. Historically, the nomenclature for individual 
soluble factors was also based on their biological activity, and names were often 
abbreviated to acronyms that reflect the studied activity, e.g. tumor necrosis factor-α (TNF-
α). TNF-α previously has been shown to induce necrosis within tumors. Problems arose 
immediately when it became clear that more than one protein could share the same 
biological activity or one cytokine exerted numerous and varied biological activities. TNF-α, 
for instance, induces prostaglandins, IL-1 and NO. Therefore the generic term cytokines 
has become the preferred name of this class of mediators. Because many cytokines are 
made by leukocytes and act on other leukocytes most of these are also called interleukins 
(IL). The term interleukin with a numerical identifier was first introduced in 1979 (e.g. IL-1). 
It is imperfect since some of these mediators also serve to communicate signals between 
immune and nonimmune cells and even between non-immune cells [Dinarello and 
Moldawer, 2000; Abbas et al., 2000]. 
Because of their structural characteristics, cytokines can be divided into four groups: α-
helical cytokines, long-chain-β-sheet cytokines, α/β-cytokines, and finally mosaic cytokines. 
These different cytokine classes show only limited homology among each other. Moreover, 
the maximal homology between selected cytokines in one of these classes is not more than 
20 % to 30 %.  Although cytokines are in principle structurally diverse, they share several 
properties. Cytokine secretion is a brief, self-limited event. Their production is usually I. Introduction 
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initiated by transient de novo gene transcription as a result of cellular activation by immune 
signals or stress [Loppnow, 2001]. Furthermore the mRNAs encoding most cytokines are 
rather unstable. Additionally, the production of some cytokines may be controlled by RNA 
processing and posttranscriptional mechanisms, such as proteolytic release of an active 
product from an inactive precursor (e.g. pro-IL-1β or pro-IL-18). The actions of cytokines 
are often pleiotropic and redundant. Pleiotropism refers to the ability of one cytokine to act 
on different cell types mediating diverse biologic effects. This property limits their 
therapeutic use. On the other hand multiple cytokines have the same functional effects, so 
that the use of antagonist against a single cytokine may not have functional consequences. 
Another key property of cytokines is to influence the synthesis and actions of other 
cytokines. Two cytokines may interact to antagonize each other’s action or to produce 
additive or synergistic effects. Furthermore, the ability of one cytokine to induce the 
synthesis of others leads to cascades, in which a second or third cytokine may mediate the 
biologic effects of the upstream mediator. For instance, IL-18 induces TNF-α that itself 
mediates expression of matrix metalloproteinase-9 (MMP-9). In general cytokine actions 
are local and under certain conditions systemic. However, most of them act close to where 
they are produced in a autocrine or paracrine manner. 
Cytokines initiate their function by binding to specific membrane receptors on target cells. 
These receptors often bind their ligands with very high affinities (Kd = 10
-10 to 10
-12 M). As  a 
consequence only small quantities of a cytokine are sufficient to elicit maximal biologic 
effects. There are different classes of cytokine receptors namely class I-IV-cytokine-
receptors, the receptor-kinase-family, and the chemokine-receptors. Stimulation of T or B 
lymphocytes by antigens leads to increased expression of cytokine receptors. Receptor 
expression is also regulated by cytokines themselves permitting positive or negativ 
feedback regulation. In general cellular response to most cytokines mediates changes in 
gene expression, resulting in new cellular functions that may be accompanied by 
proliferation or differentiation. Two exceptions to this rule are chemokines, which elicit rapid 
cell migration without new gene expression, and tumor necrosis factor (TNF-α), which can 
induce cell death often without requiring new protein synthesis.  
 
1.2 Cytokines and inflammation 
 
Some cytokines initiate and aggravate inflammatory reactions in some cases making 
disease worse (proinflammatory cytokines) whereas others serve to reduce inflammation 
and promote healing (antiinflammatory cytokines). The balance of pro- and 
antiinflammatory cytokines determines kinetic and outcome of an inflammatory response, it 
is dynamic and ever-shifting. Cytokines also act in concert with specific cytokine inhibitors I. Introduction 
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(e.g. IL-1Ra) and soluble cytokine receptors (e.g. sIL-1R) to regulate the human immune 
response. Taken together, the net effect of any cytokine is dependent on the timing of 
cytokine release, the local milieu in which it acts, the presence of competing or synergistic 
elements, cytokine receptor density, and tissue responsiveness to each cytokine. The most 
prominent immunoregulatory cytokines are listed in the following figure. 
 
Proinflammatory
Cytokines
IL-1
TNFα
IL-12
IL-18
.
.
.
Antiinflammatory
Cytokines
IL-1Ra
IL-4
IL-10
IL-13
IL-18BP
TGF-β
Soluble cytokine
receptors
.
.
.
 
 
Figure A. 
 
Important cytokines with pro- and 
antiinflammatory properties 
 
Proinflammatory cytokines initiate 
and aggravate inflammatory 
reactions. They are important for 
host defense against infections. In 
contrast, antiinflammatory cytokines 
serve to reduce inflammation and 
promote healing. These cytokines 
control the proinflammatory cytokine 
response by virtue of their ability to 
suppress genes encoding for 
proinflammatory cytokines. 
 
 
1.2.1 Proinflammatory cytokines 
 
Proinflammatory cytokines induce a cascade of gene products usually not produced in 
healthy persons. Examples for such genes are the type IIA phospolipase (PL) A2, 
cyclooxygenase (COX)-2, inducible NO-synthase (iNOS), adhesion molecules, and 
chemokines. They are coding for enzymes responsible for increased synthesis of platelet-
activating factor (PAF), prostaglandins, leukotrienes, NO, O2
-, and proteases, etc.. These 
mediators of inflammation finally mediate the classical cardinal symptoms of inflammation: 
heat, redness, swelling, pain, and loss of function which finally may end in sclerosis (figure 
B) [Dinarello, 2000]. IL-1, TNFα and IL-18 have the potential to initiate this cascade of 
inflammatory mediators. These cytokines are induced by infection, tissue damage or 
ischemia. They themselves induce secondary cytokines e.g. IFNγ  and are known to direct 
and maintain T cell development  along a TH1 pathway.  IL-1 and TNF-α are prototype 
proinflammatory cytokines. When administered to humans, they produce fever. Excessive 
production leads to inflammation, tissue destruction, and, in some cases shock and death 
as seen in septic shock patients. Proinflammatory cytokines activate important regulators of 
gene transcription (e.g. NF-κB, AP-1, NF-IL-6). Their overproduction is a frequent 
characteristic of human autoimmune diseases such as: Crohn’s disease, lupus 
erythematosus, and rheumatoid arthritis. I. Introduction 
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IL-1, TNFα, IL-18
PLA2, COX-2, Lipoxygenases, iNOS,
Adhesion Molecules, Chemokines
Redness, Swelling, Pain,
Loss of Function and Sclerosis
Mediators of Inflammation: PAF, Prostaglandins,
Leukotrienes, NO,  O2-, Proteases, ...
Infection Tissue
damage
 
 
Figure B.  The inflammatory cascade. 
 
 
 
1.2.1.1 Interleukin-12 
 
IL-12 is a principal mediator of the early innate immune response to intracellular microbes 
and is a key inducer of cell-mediated immunity, the adaptive immune response to these 
microbes. This secreted cytokine stimulates the differentiation of CD4
+ helper T 
lymphocytes into IFN-γ-producing TH1 cells. The stimuli for IL-12 production are LPS, 
infection by intracellular bacteria, such as Listeria and mycobacteria, and virus infections. 
In addition, antigen-stimulated helper T-cells induce the production of IL-12 by 
macrophages and dendritic cells (CD40/CD40-ligand interactions). Originally this cytokine 
was identified as inducer of NK cell mediated cytotoxicity, but its most important action is to 
stimulate IFN-γ production by T cells and NK cells. Vice versa IFN-γ produced by NK cells 
or T cells also stimulates IL-12 production. This induction of IFN-γ by IL12 requires IL-18. It 
is likely that the ability of IL-12 to induce IFN-γ includes up-regulation of receptors for IL-18 I. Introduction 
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[Yoshimoto  et al., 1998] as well as activation of ICE (Caspase-1), a protease that is 
involved in the processing of the inactive precursor of IL-18 (pro-IL-18). Furthermore, IL-12 
is highly inflammatory because it induces TNF-α, which appears to be involved in 
mediating the effects of IL-12 on NK cells. Finally, IL-12-induced IFN-γ activates 
macrophages to kill phagocytosed microbes which underlines the importance of IL-12 in 
cell-mediated immune defense. IL-12 enhances not only the cytolytic functions of activated 
NK cells but also of CD8
+ cytolytic T lymphocytes. The heterodimeric glycoprotein IL-12 
consists of the two subunits p40 and p35. The p40 subunit of murine IL-12 has been shown 
to specifically antagonize the effects of the IL-12 heterodimer in different assay systems 
thereby function as an endogenous specific inhibitor for the IL-12 heterodimer [Mattner et. 
al., 1993]. This classical TH1 cytokine is an important link between innate and adaptive 
immunity, being produced by macrophages and dendritic cells during early innate immune 
reactions against intracellular microbes. Moreover, IL-12 stimulates adaptive immune 
responses that protect the host against these microbes through specific T cell 
differentiation. 
  Large amounts of IL-12 are produced in severe gram-negative sepsis, resulting in 
excessive production of IFNγ, which synergizes with LPS to stimulate macrophage 
production of TNF-α, one principal mediator of septic shock. IL-12-deficient mice are 
impaired but not completely lack the ability to produce IFN-γ following endotoxin 
administration and to mount a TH1 T-helper cell response in vivo. IL-12 has been shown to 
inhibit the growth of a variety of experimental tumors in vivo most likely via induction of IFN-
γ and inhibition of angiogenesis. 
 
 
1.2.1.2 Interleukin-18 
 
IL-18 has been introduced as a novel member of the IL-1 family of cytokines due to its 
structural properties.  It participates in both innate and acquired immunity. As opposed to 
IL-1, IL-18 appears to be a pivotal mediator of the TH1 cytokine response [Dinarello et al., 
1998; Dinarello, 1996; Okamura et al., 1995]. However, both cytokines also share a variety 
of functions like induction of inflammatory cytokines [Puren et al., 1998]. IL-18 was first 
described in 1989 as IFN-γ inducing factor (IGIF) [Nakamura et al., 1989.]. It is produced by 
macrophages in response to LPS and other microbial products and in concert with IL-12, 
IL-2, or antigenic stimulation IL-18 induces IFN-γ production by T-cells [Okamura et al, 
1995] and natural killer cells [Tsutsui et al., 1996]. A variety of immune and non-immune 
cells express IL-18, including monocytes and macrophages, Kupffer cells, T-cells and B-
cells,  dendritic  cells,  osteoblasts,  epidermal  keratinocytes,  intestinal  epithelial               I. Introduction 
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cells, corneal epithelial cells, glucocorticoid-secreting adrenal cortex cells, astrocytes, and 
microglia [Dinarello, 2000]. IL-18 lacks a classical signal sequence necessary for secretion 
via the Golgi apparatus [Okamura et al., 1998; Ushio et al., 1996]. Like IL-1β, IL-18 is 
synthesized as an inactive precursor (pro-IL-18) that has to be cleaved by caspase-1 (ICE) 
to generate its biological active form mature-IL-18. But also other proteases like proteinase 
3 (Myeloblastin)  [Sugawara  et al., 2001]  certain MMPs, mast cell chymase as well as 
cathepsin D  may provide activation pathways for pro-IL-18. IL-18 primarily seems to 
function as a costimulant for TH1 cytokine production. It has been found to inhibit 
production of the TH2 response promoting cytokine IL-10 in concanavalin A-stimulated 
human PBMCs. Recent data imply that IL-18 in the absence of IL-12, may also facilitate the 
development of TH2 responses [Nakanishi et al., 2001] IL-18 can directly induce TNF-α, 
FasL, as well as chemokines, e.g. IL-8 [Puren et al.,1998]. The bioactivities of IL-18 are 
modulated by the secreted IL-18 binding protein a (IL-18BPa). 
 
IL-18 bioactivity is connected with the pathogenesis of different inflammatory diseases, for 
example, septic shock, colitis, Crohn’s disease, myasthenia gravis, multiple sclerosis, 
rheumatoid arthritis, atherosclerosis and organ transplant rejection. By stimulating immune 
cells IL-18 exhibits a strong antitumoral activity, protecting experimental animals against 
repeated challenges with tumor cells [Micallef et al., 1997]. Transgenic knockout mice 
lacking expression of IL-18 have been generated by Wei et al., [1999]. These mice are 
viable and fertile, they do not show any evident histopathologic abnormalities. However, 
they produce significantly lower levels of IFN-γ following infection by the protozoan parasite 
Leishmania major. IL-18-deficient mice were also employed to investigate the role of IL-18 
in LPS-induced liver injury and endotoxic shock in mice primed with Propionibacterium 
acnes [Sakao et al., 1999]. These mice showed resistance to LPS-induced liver injury, but 
were highly susceptible to LPS-induced endotoxin shock. The latter effect was due to 
remarkably high levels of TNF-α, which were produced in IL-18 knockout mice compared to 
wild-type mice after LPS challenge [Akira, 2000]. The following figure summarizes the main 
functions of the TH1 response prime mediator IL-18. 
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Figure C. Overview about IL-18 action and its naturally occuring counterpart IL-18BP. 
 
 
1.2.2 Antiinflammatory cytokines 
 
Antiinflammatory cytokines are involved in controlling the proinflammatory cytokine 
response by virtue of their ability to suppress genes for proinflammatory cytokines such as 
IL-1, TNF, and chemokines [Opal and DePalo, 2000]. In the presence of antiinflammatory 
cytokines like IL4, IL-6, and IL-10 activated naive T cells develop along a TH2 pathway. 
 
1.2.2.1 Cytokine  inhibitors 
 
Not only cytokine receptor antagonists like the IL-1Ra, but also membrane-bound or 
soluble decoy receptors are important tools to counterregulate an inflammatory immune 
response. These are providing potential targets for the treatment of chronic or excessive 
inflammatory responses. At high molar ratios, some soluble receptors inhibit their 
corresponding cytokines and have been used as immunosuppressors in patients, e.g. 
soluble TNF-αR for the treatment of rheumatoid arthritis (RA). In contrast, at low 
concentrations these soluble receptors may function as stabilizers of cytokines and 
enhance their activity [Novick et al., 1999]. Interestingly microbial pathogens may actually 
use components of the cytokine network for their own advantage. Viral-encoded inhibitory 
cytokines appear to assist the virus in the promotion of viral replication and evasion of host-
derived clearance mechanisms. Furthermore, several bacterial pathogens and viruses 
have the capacity to alter host cell cytokine synthesis, degrade proinflammatory cytokines, 
or use cytokine receptors as portals of entry for cellular invasion, e.g. Malaria falciparum 
[Pogo et al., 2001], HIV-I (CCR5, CXCR4) [Dragic, 2001]. I. Introduction 
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1.2.2.1.1  Interleukin-18 binding protein (IL-18BP) 
 
IL-18BP is a secreted protein that functions as a natural antiinflammatory and 
immunosuppressive molecule by neutralizing the effects of IL-18 during inflammation. This 
highly glycosylated protein suppresses the production of IL-18-induced IFN-γ resulting in a 
reduced TH1 immune response. IL-18BP was first isolated from 500 l of human urine by 
affinity chromatography. IL-18BP does not have transmembrane domain and hence is not 
anchored to the cell membrane [Novick et al., 1999]. There are at least four human (hIL-
18BPa/b/c/d) and two mouse (mIL-18BPc/d) isoforms resulting from mRNA splicing. These 
were found in various cDNA libraries with hIL-18BPa cDNA as the most abundant clone. 
The human isoforms IL-18BPa and IL-18BPc exhibited the greatest affinity for IL18 with 
dissociation constants Kd of 399 pM and Kd of 2.94 nM, respectively. A large mixed 
electrostatic and hydrophobic binding site in the immunoglobulin domain of IL-18BP has 
been found to be responsible for its high affinity binding to the ligand. On contrary, the 
other two isoform IL-18BPb and IL-18BPd only possess an incomplete immunoglobulin-
domain. By virtue of this structural difference these variants are unable to neutralise IL-18 
[Kim et al., 2000]. 
IL-18BPa is the major form constitutively expressed in human spleen (Novick et al., 1999). 
It has been identified as IFN-γ-inducible gene in a variety of human cell types such as: 
colon carcinoma epithelial cells, renal mesangial cells, immortalized and primary 
keratinocytes, endothelial cells, endometrical epithelia cells, and monocytes. Levels of IL-
18BP are upregulated in patients with septic shock [Novick et al., 2001] and Crohn’s 
disease [Corbaz et al., 2002]. In mice, injection of human IL-18BPa inhibits LPS-induced 
circulating IFN-γ by > 90% [Novick et al., 1999]. Furthermore it has been shown that 
therapeutically employed IFN-α induces IL-18BP in chronic hepatitis C patients [Kaser et 
al., 2002]. 
IL-18BP is a member of a novel family of soluble proteins, which also includes Poxvirus-
encoded decoy receptors for many cytokines. These receptors are instrumental in viral 
evasion of immune responses, as demonstrated by reduced virulence following their 
deletion (Spriggs et al., 1996; Ploegh et al., 1998). For instance, M contagiosum viral 
proteins MC53 and MC 54 share a significant homology to mammalian IL-18BP [Novick et 
al., 1999]. These proteins possess the ability to bind and neutralise human IL-18 in a 
fashion similar to that of IL-18BP [Xiang et al., 1999]. It has been hypothesized that IL-
18BP evolved from a primordial cell-surface protein which lost its membrane anchoring 
domain [Novick et al., 1999]. 
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1.2.2.1.2  IL-1 receptor antagonist (IL-1Ra) and antagonistic IL-1 receptors 
 
Two different membrane receptors  for IL-1 (IL-1R) have been characterized. Both are 
members of the Ig superfamily. Binding of IL-1 to the type I receptor (IL-1RI) forms a signal 
transducing complex. IL-1RAcP (IL-1R Accessory Protein) participates in the signaling by 
this complex. In contrast binding of IL-1 to the cell-bound type II receptor (IL-1RII) does not 
lead to signal transduction, because this receptor lacks such an intracellular signaling 
domain. During inflammatory conditions soluble forms of IL-1 receptors (particularly the 
type II receptor) can be detected in human sera and likely control excessive IL-1 bioactivity 
associated with inflammatory diseases. Soluble IL-1RII is a decoy receptor that can capture 
IL-1 thereby preventing its binding to the type I receptor and thus suppresses IL-1 
bioactivity. Mononuclear phagocytes produce a natural competitive inhibitor of IL-1 called 
IL-1R antagonist (IL-1Ra) that is structurally homologous to IL-1. IL-1Ra binds to the same 
receptor but does not translate into receptor activation, since IL-1Ra does not recruit the IL-
1RAcP to form the heterocomplex required to trigger a signal [Sims et al., 2002]. The type I 
receptor is expressed on almost all cell types and is seen as the major receptor for IL-1-
mediated responses. In contrast the type II receptor is constitutively expressed on B cells 
but may be induced in other cell types, e.g. by antiinflammatory glucocorticoids [Re et al., 
1994]. The cytoplasmatic portion of the type I receptor is homologous to that of a 
Drosophila cell surface receptor called Toll that is involved in defense against microbial 
infections. 
 
1.3 Infection and inflammation 
 
1.3.1 Innate immunity 
 
Defense against microbes is mediated by the early reactions of innate immunity and the 
later responses of adaptive immunity. The components of innate immunity recognize 
structures that are characteristic of microbial pathogens and not present on mammalian 
cells. Inhibiting or eliminating the mechanisms of innate immunity markedly increases 
susceptibility to severe infection, even when the adaptive immune system is intact and 
functional. The innate immune system is unable to recognize nonmicrobial chemical 
substances or macromolecules, in contrast to the adaptive immune system that recognizes 
foreign antigens produced by microbes or other sources, including synthetic antigens. It 
relies primarily on cell surface receptors, called Toll-like receptors (TLR), and secreted 
proteins to recognize carbohydrate, lipid, protein, and DNA structures associated with 
microbial infection. Probably the most well-described cell surface receptor system for I. Introduction 
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recognition by the innate immune system is the lipopolysaccharide (LPS) recognition 
complex composed of CD14 (Cluster of Differentiation) and the TLR family, which also 
recognize other microbial products apart from LPS [Wright et al., 1990]. Whereas LPS (in 
Gram-negative bacteria) appears to be the principle ligand for TLR4, lipoteichoic acids and 
peptidoglycans from yeast and Gram-positive bacterial pathogens are potential ligands for 
TLR2 [Brightbill et al., 1999; Schwandner et al., 1999; Yoshimura et al., 1999]. The 
microbial components recognized by the innate immune system are often essential for 
survival of the microbes. This host adaption ensures that the targets of innate immunity 
cannot be discarded by microbes in an effort to evade recognition by the host. The 
receptors of the innate immune system are encoded in the germline without recombination 
as seen for receptors of the adaptive immune system, which limits the repertoire of 
specificities. Therefore they only can distinguish classes of microbes. 
The principal effector cells of innate immunity are neutrophils, mononuclear phagocytes, 
and natural killer (NK) cells. Macrophages and NK cells secrete cytokines that activate 
phagocytes and stimulate inflammation associated with innate immunity. Inflammation 
consists of recruitment of leukocytes into a site of infection and their activation to eliminate 
the infectious agent. The process of leukocytes migration is mediated by leukocyte homing 
receptors and endothelial ligands for these receptors. TNF-α and IL-1 secreted by 
macrophages stimulates endothelial cells to sequentially express adhesion molecules (E-
selectin, ICAM-1, and VCAM-1), that mediate the preferential attachment of different types 
of leukocytes to the endothelium. Selectins mediate the initial loose attachment of 
neutrophils and other leukocytes to venules at sites of inflammation. In the presence of 
flowing blood, the loosely adherent leukocytes are propelled to roll along the endothelial 
surface (“multistep model”). In the next step, TNF-α mediates expression of vascular cell 
adhesion molecule-1 (VCAM-1, the ligand for VLA-4 integrin) and ICAM-1 (or CD 54; the 
ligand for LFA-1 and Mac-1 integrins) on the inflamed endothelium. Integrins on the 
leukocytes then can mediate the stable attachment of leukocytes to the endothelium via 
interaction with VCAM-1 and ICAM-1. Stable adhesion is followed by their migration 
through the interendothelial spaces into extravascular tissue. Chemokines are of pivotal 
importance for leukocyte recruitment to sites of infection. They work to promote leukocyte 
binding to endothelium and stimulate the chemotaxis of leukocytes within the tissues. 
Chemokines increase the affinity of leukocyte integrins for their ligands, which stabilizes 
their attachment to the endothelium and promotes subsequent extravasation. 
Cytokine-mediated leukocyte recruitment and activation are responsible for the injury to 
normal tissues that often accompanies innate immune reactions to infection. These 
primarily macrophage-derived cytokines, especially TNF-α, IL-1, IL-12 and IL-18 are also 
responsible for the systemic manifestations of infection. I. Introduction 
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1.3.1.1 Epithelial  barriers 
 
Epithelial barriers represent a component of the innate immune system. Intact epithelial 
surfaces form physical barriers between microbes in the external environment and host 
tissue. The three main interfaces are the skin, and the mucosal surfaces of the 
gastrointestinal and respiratory tracts. They all are protected by continuous epithelia that 
serve to prevent the entry of microbes. Epithelia not only secrete several cytokines that 
function in innate immunity but also produce peptides that have a natural antibiotic function. 
The best known of these peptides are defensins present in the skin of many organisms. 
Defensins are broad-spectrum antibiotics. Their synthesis is increased in response to 
inflammatory cytokines (IL-1 and TNF). Barrier epithelia and serosal cavities contain 
intraepithelial T lymphocytes and the B-1 subset of B cells, respectively. These cells may 
recognize and respond to commonly encountered microbes. The third population of cells 
present within many epithelia are mast cells, which respond to microbes and various 
mediators by release of inflammatory substances. 
 
 
1.3.1.2  Phagocytes: neutrophils and macrophages 
 
The function of ingesting and destroying microbes is mediated by phagocytes, which 
include neutrophils early in the innate immune response (hours after infection) and 
macrophages later in the response (1 or 2 days after infection). The latter typical respond 
to microbes nearly as rapidly as neutrophils do but persist much longer at sites of 
inflammation, because macrophages are more long lived than neutrophils (circulate in the 
blood for only 6 hours), additionally macrophages can undergo cell division at an 
inflammatory site. Monocytes are the circulating precursors of macrophages. After entering 
into tissue, monocytes differentiate into tissue macrophages. Neutrophils and macrophages 
recognize microbes by several receptors that function to stimulate migration of the cells to 
the site of infection, promote phagocytosis of microbes, and stimulate the production of 
microbicidal substances to kill the microbes. These receptors are: seven α-helical 
transmembrane receptors, Toll-like receptors, and phagocytic receptors. Ligands for seven 
α-helical transmembrane receptors, which function mainly to stimulate leukocyte migration 
into sites of infection, are N-formylmethionyl peptides, chemokines, and lipid mediators. 
Toll-like receptors recognize e.g. the LPS/LPS-binding protein complex in cooperation with 
CD14. Finally phagocytic receptors Fc are necessary for microbe recognition by neutrophils 
and macrophages, examples are the mannose receptor and receptors for Fc portions of 
IgG antibodies. The latter are responsible for microbe coating and additionally promote 
phagocytosis. The mannose receptor consists of a lectin that binds terminal mannose and I. Introduction 
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fucose residues of glycoproteins and glycolipids, sugars typically found in microbial cell 
walls. Neutrophils and macrophages ingest microbes into vesicles, in order to kill them by 
fusion of lysosomes with phagosomes to so-called phagolysosomes. The lysosomes 
contribute proteolytic enzymes that come in contact with and destroy phagocytosed 
microbes. Neutrophil lysosomes are particularly rich in elastase. The primary free radical-
generating system is the phagocyte oxidase system. The phagocyte oxidases located in 
the plasma membrane of activated phagocytes and in the phagolysosomal membrane 
reduce molecular oxygen and produce reactive oxygen intermediates (ROIs) such as 
superoxide radicals. A second free radical-generating system is the inducible nitric oxide 
synthase (iNOS) system. This enzyme is absent in resting macrophages but can be 
induced in response to LPS in combination with IFN-γ. Subsequently, it catalyzes the 
conversion of arginine to citrulline, and freely diffusible nitric oxide gas is released. These 
radicals mediate killing of ingested microbes (ROI, NO, and their reaction product 
peroxynitrite). 
 
 
1.3.1.3  Natural killer (NK) cells 
 
NK cells are a subset of bone marrow-derived lymphocytes, distinct from B or T cells. The 
principal physiologic role of NK cells is in defense against infections by viruses and some 
other intracellular microbes. NK cells proliferate, show increased cytolytic activity and IFN-γ 
production in response to IL-15 and IL-12, which are mainly produced by macrophages. IL-
18 potently augments most likely also actions of IL-12. The effector function of NK cells are 
to lyse virus-infected cells and most likely also tumor cells. NK cells have lytic granules that 
contain the protein called perforin, which can create pores in target cell membranes. 
Moreover, NK cells release a protein called granzyme, which is a serine protease. 
Granzymes enter target cells through perforin pores and induces apoptosis in these cells 
through activation of intracellular caspases. NK cells also produce an antibiotic peptide 
called granulysin, which can pass through the mentioned pores to directly kill intracellular 
microbes [Boman, 1995]. Some tumors are targets of NK cells (especially those of 
hematopoietic origin), likely because the tumor cells do not express normal levels of class I 
MHC molecules. Lack of MHC-expression appears to label cancer cells for the attack by 
NK cells. 
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1.3.2 Roles of T cell cytokines in adaptive immunity 
 
Adaptive immunity is a highly evolved defense mechanism stimulated by exposure to 
infectious agents. It increases in magnitude and defensive capabilities with each 
successive exposure to a particular microbe. This form of immunity develops as a response 
to infection and adapts to the infection. In response to the protein antigens of microbes, 
CD4
+ helper T cells may differentiate into special subsets of helper T cells called TH1 and 
TH2 cells. These T cell populations are distinguished most clearly by the cytokines they 
produce. These not only determine the T cell effector function, but also participate in the 
development and expansion of the respective subsets. For instance, IFN-γ secreted by TH1 
cells promotes further TH1 differentiation and inhibits the proliferation of TH2 cells in parallel. 
Conversely, IL-4 produced by TH2 cells promotes TH2 differentiation. IL-10, also produced 
by TH2 cells inhibits activation of TH1 cells. Thus, each subset amplifies itself and cross-
inhibits the reciprocal subset. For this reason once an immune response develops along 
one pathway, it becomes increasingly polarized in that direction. Chronic immune reactions 
are often dominated by either TH1 or TH2 populations. The pattern of T cell differentiation  is 
determined by stimuli present early during immune responses. The most important 
differentiation-inducing stimuli are cytokines, with IFN-γ, IL-12, and IL-18 being the major 
inducer of TH1 cells (for cell-mediated immune response) and IL-4, IL-6, and IL-10 of TH2 
cells (for humoral response). The induction of IFN-γ and IL-12 is dominated by IL-1, TNF-α, 
and IL-18, produced by accessory or antigen presenting cells such as macrophages or 
dendritic cells, thereby linking the acquired and innate immune responses. The TH1 
differentiation pathway is stimulated by many intracellular bacteria, such as Listeria and 
mycobacteria, and by some parasites, such as Leishmania, all of which infect 
macrophages. It is also stimulated by viruses. Many organ-specific autoimmune diseases 
and inflammatory reactions such as granulomas are due to excessive activation of TH1 
(e.g. rheumathoid arthritis and Crohn’s disease). In contrast, TH2 differentiation occurs in 
response to helminths and allergens, which cause chronic T cell stimulation, often with little 
macrophage activation. The principal effector function of TH2 cells is in IgE and 
eosinophil/mast cell-mediated immune reactions. TH2 cells are responsible for defense 
against helminthic and arthropod infections and for allergic reactions as well. 
 
1.3.3 Interferon-γ γ γ γ 
 
Originally identified 30 years ago as an agent with antiviral activity, IFN-γ has since been 
characterized as a homodimeric glycoprotein with pleiotropic immunologic functions in cell-
mediated immunity against intracellular microbes. It is primarly secreted by activated T I. Introduction 
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cells and NK cells. IFN-γ can promote the microbicidal function of macrophages by 
stimulating the synthesis of ROI and NO. These effects are mediated by activating 
transcription and/or assembly of the enzymes phagocyte oxidase and iNOS. These 
reactive molecules are produced within lysosomes to destroy microbes contained within 
phagolysosomes. IFN-γ enhances MHC-associated antigen presentation and amplifies the 
recognition phase of immune responses by increasing expression of ligands necessary for 
T cell interaction with APC (antigen presenting cells). This cytokine also activates vascular 
endothelial cells and potentiates many of the actions of TNF on endothelial cells promoting 
T lymphocyte adhesion and extravasation to sites of infection. Furthermore, it has been 
found that IFN-γ promotes the differentiation of naive CD4
+ T cells to the TH1 subset and 
inhibits the proliferation of TH2 cells in parallel. This TH1 inducing effect is mediated 
indirectly by activating mononuclear phagocytes to produce IL-12, a typical TH1 cytokine. In 
mice IFN-γ also enhances expression of the signaling chain of the IL-12 receptor. The 
combination of IL-12 and IL-18 induces IFN-γ expression in human PBMCs as performed in 
our coculture experiments. It induces antibody responses that also participate in 
phagocyte-mediated elimination of microbes, in concert with its described macrophage-
activating effects. The B-cell IgG subclasses induced by IFN-γ bind to Fcγ receptors on 
phagocytes and activate complement. Both these mechanisms promote the phagocytosis 
of opsonized microbes. Furthermore, IFN-γ activates neutrophils and enhances the 
cytotoxicity of NK cells. 
 
IFN-γ specifically induces the transcription of a number of genes (e.g. IL18BPa, IP-10, and 
iNOS), using special IFN-γ responsive sites such as γ-IRE (γ-interferon responsive 
element), and GAS (gamma-activated site) for direct activation, and ISRE (IFN-stimulated 
response element) for indirect activation mediated by IRF-1 (Interferon regulating factor-1). 
Interferon-γ employes the JAK/Stat (JAK1/2; Stat1) pathway to transduce its signaling 
events [Tau and Rothman, 1999]. The net effect of all these activities is to promote 
macrophage-rich inflammatory reactions while inhibiting IgE-dependent eosinophil-rich 
reactions. Knockout mice lacking IFN-γ or the IFN-γ receptor are susceptible to infections 
with intracellular microbes, such as mycobacteria, because of defective macrophage 
activation. Moreover, patients with inherited disorders of IFN-γ-mediated immunity also 
appear to be specifically vulnerable to mycobacterial infections [Dupuis et al., 2000]. 
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1.4 Effects of IFN-γ γ γ γ, IL-18 and NO in carcinogenesis 
 
The response of the body to cancer has many parallels with inflammation. There is 
evidence that inflammatory cells and cytokines found in tumors are more likely to contribute 
to tumor growth, progression, and immunosuppression than they are to mount an effective 
host antitumor response. Deletion or inhibition of inflammatory cytokines inhibits 
development of experimental cancer. Inflammatory bowel diseases demonstrate that 
inflammation can be a cofactor in carcinogenesis leading to colorectal cancer. 
Nevertheless, IFN-γ exerts potent antitumor effects. IFN-γ production promotes immune 
recognition of tumor cells by enhancing the expression of MHC molecules and stimulates 
cytotoxicity of NK cells, T lymphocytes as well as macrophages [Billiau et al., 1996]. It also 
may have an anti-proliferative effect on tumor cells [Xu et al., 1998]. In part IFN-γ is 
responsible for a TH1 polarization of the immune response that has been shown to be a 
factor of good prognosis in certain types of cancer [Tartour et al., 1998; Fridman et al., 
1998]. Contrary, TH2 responses are ineffective against tumors and viruses. IL-18 is a prime 
inducer of a TH1 response. IL-18 production in human colon may play an important role in 
homeostasis and tumor immune surveillance, by enhancing IFN-γ production and Fas-L-
dependent cytotoxicity of immune cells. In colon cancer, the synthesis of the active form of 
IL-18 may be decreased or abolished. Inhibition of tumor angiogenesis appears to be a 
major mechanism of IL-18 antitumor activity [Coughlin et al., 1998]. Many lines of evidence 
support the hypothesis that tumor growth and metastasis are angiogenesis dependent [Kim 
et al., 1993]. It has been shown that the anti-angiogenic activity of IL-18 in part appears to 
be specifically mediated by IFN-γ [Coughlin et al., 1998], which induces interferon-inducible 
protein 10 (IP-10) [Angiolillo et al., 1995] and monokine induced by γ-IFN (MIG) [Sgadari et 
al., 1997]. Both anti-angiogenic chemokines can initiate tumor necrosis. But IFN-γ also has 
other activities that may promote tumor regression [Boehm et al., 1997], such as inhibition 
of cell proliferation, and proapoptotic effects, particularly in combination with TNF-α. 
Furthermore, the tumor suppressive pathway of IL-18 may not be completely mediated by 
IFN-γ signaling, but also through FAS-L mediated killing. Additional IL-18 antitumor effects 
are mediated by CD4
+ T cells and NK cells, but in an most likely IFN-γ and IL-12 
independent manner [Osaki et al., 1998]. 
NO plays an ambivalent role in tumorigenesis depending on NOS activity and resulting NO 
concentrations. Although there are some reports showing induction of tumor cell apoptosis 
and cytostasis by high levels of NO [Xie and Fidler, 1998], an increasing number of reports 
shows a positive correlation between NO and tumor progression [Thompsen and Miles, 
1998]. The induction of inducible NO-synthase (iNOS or NOS II) is an important part of 
macrophage cytotoxicity against tumor cells. iNOS is generally inducible by pro-I. Introduction 
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inflammatory stimuli and mediates a high-output long-lasting release of NO. It is frequently 
expressed constitutively in human malignancies including colorectal cancer [Ambs et al., 
1998/1999]. If NO concentrations do not reach a cytotoxic level, NO favors tumor growth, 
neovascularization as well as invasiveness by induction of p53 tumor suppressor gene 
mutations and upregulation of angiogenic factors such as vascular endothelial growth 
factor (VEGF) and IL-8. Contrary high levels of NO trigger p53 accumulation, of which wild-
type form is known to be an inhibitor of angiogenesis [Dameron et al., 1994]. High 
concentrations of NO are known to be antiproliferative leading to apoptosis. 
 
1.5 Aim of this study 
 
I intended to investigate the regulation of IL-18BPa expression and release induced by 
IFNγ in different human cell types that are associated with the ethiology of colon 
carcinogenesis and autoimmune diseases such as Crohn’s disease (CD) and rheumatoid 
arthritis (RA). II. Materials and Methods 
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II 
Materials and Methods 
___________________________________ 
2.1 Materials 
 
2.1.1 Chemicals 
 
Acrylamide/bisacrylamide-solutions Roth,  Karlsruhe 
Actinomycin D  Sigma Biochemicals, Deisenhofen 
Agar  Gibco Life Technologies, Eggenstein 
Agarose Biozym,  Oldendorf 
Ammoniumpersulfate  Sigma Biochemicals, Deisenhofen 
Ampicillin  Sigma Biochemicals, Deisenhofen 
Aprotinin   Roche Biochemicals, Mannheim 
[γ-
32P]ATP  Amersham Pharmacia, Braunschweig 
Bovine serum albumin  Sigma Biochemicals, Deisenhofen; 
Brefeldin A  Sigma Biochemicals, Deisenhofen 
5-Bromo-4-chloro-3-indolyl-β-D-galactoside  Roth, Karlsruhe 
Cell culture media  Gibco Life Technologies, Eggenstein 
Complete (protease inhibitor)  Roche Biochemicals, Mannheim 
Coomassie  Sigma Biochemicals, Deisenhofen 
DETA-NONOate Alexis,  Grünberg 
Diethylpyrocarbonate  Sigma Biochemicals, Deisenhofen 
Dithiothreitol  Sigma Biochemicals, Deisenhofen 
Ethidium bromide  Sigma Biochemicals, Deisenhofen 
Ficoll  Sigma Biochemicals, Deisenhofen 
FuGENE 6 Transfection Reagent  Roche Biochemicals, Mannheim 
Glutathione  Sigma Biochemicals, Deisenhofen 
Isopropylthiogalactoside   Roth, Karlsruhe 
Leupeptin  Roche Biochemicals, Mannheim 
Lipopolysaccharide  Sigma Biochemicals, Deisenhofen 
β-Mercaptoethanol  Sigma Biochemicals, Deisenhofen 
Molecular weight markers (DNA) 1 kb/100 bp  MBI Fermentas, St. Leon-Rot 
Molecular weight markers (protein)  Amersham Pharmacia, Braunschweig; 
Roth, Karlsruhe 
N-naphtylethylendiamine  Sigma Biochemicals, Deisenhofen 
Nucleotide triphosphates  Applied Biosystems Applera, Weiterstadt II. Materials and Methods 
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Okadaic acid  Calbiochem-Novabiochem, Bad Soden 
Oligonucleotides  MWG Biotech, Ebersberg; 
Santa Cruz Biotechnologies, Heidelberg 
Pepstatin  Roche Biochemicals, Mannheim 
Peptone  Gibco Life Technologies, Eggenstein 
Phenol/Chloroform Roth,  Karlsruhe 
Ponceau S  Sigma Biochemicals, Deisenhofen 
Roti Load1  Roth, Karlsruhe 
RNasin   Promega, Mannheim 
Sodium butyrate  Sigma Biochemicals, Deisenhofen 
Skim milk (non fat)  Fluka, Deisenhofen 
Sulfanilamide  Sigma Biochemicals, Deisenhofen 
Triton X-100  Sigma Biochemicals, Deisenhofen 
tRNA, RNase free  Roche Biochemicals, Mannheim 
Trypan blue  Gibco Life Technologies, Eggenstein 
Tween 20  Sigma Biochemicals, Deisenhofen 
[α-
32P]UTP  Amersham Pharmacia, Braunschweig 
Yeast extract  Gibco Life Technologies, Eggenstein 
 
Acetone, chloroform, ethanol, ether, methanol, isopropanol, acids and lyes were provided by the 
central store of the university hospital Frankfurt. All other, not listed chemicals were supplied from 
Merck (Darmstadt), Roth (Karlsruhe) or Sigma Biochemicals (Deisenhofen). 
 
2.1.2  Other materials and kits 
 
DNAZOL  Molecular Research Center, Cincinnati 
ECL Detection Kit/Films  Amersham Pharmacia, Freiburg 
Endofree Plasmid Maxi Kit (Qiagen-tip 500)  Qiagen, Hilden 
LDH Assay  Roche Biochemicals, Mannheim 
Luciferase Assay System  Promega, Mannheim 
Nanoquant Roth,  Karlsruhe 
Nick Columns  Amersham Pharmacia, Braunschweig 
NucleoBond PC 100 Kit (AX 100)  Macherey & Nagel, Düren  
NucleoSpin Extract 2 in 1  Macherey & Nagel, Düren 
OptEIA Elisa Kits for IFN-γ, TNF-α and, IL-8 detection  BD PharMingen, Heidelberg 
Polystyrene plates   Greiner, Frickenhausen 
TGFβ1 ELISA  R&D Systems, Wiesbaden 
TOPO TA Cloning  Invitrogen, Groningen (Netherlands) 
Transwell-Clear inserts 6-well polystyrene-plates  Costar, Bodenheim 
Trizol  Sigma Biochemicals, Deisenhofen II. Materials and Methods 
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2.1.3   Buffers and solutions: Immunoblot-analysis 
 
 
 
 
2.1.4  Buffers and solutions: β β β β-gal assay 
 
 
 
 
 
 
 
 
 
2.1.5  Buffers and solutions: Mini preparation  
 
CTAB/NaCl  5% (w/v) Cetyltrimethyl- 
ammonium bromide 
0.2 M NaCl 
 
STET  8% (w/v) Saccharose 
50 mM Tris/HCl pH 8.0 
50 mM EDTA pH 8.0 
0.1% (w/v) Triton X-100 
4x Laemmli-buffer  125 mM Tris/HCl pH 6.8 
10% (w/v) SDS 
50 mM Dithiothreitol 
30% (v/v) Glycerol 
0.01% (w/v) Bromphenol blue 
 
10x PAGE  250 mM Tris 
1% (w/v) SDS 
520 mM Glycin 
 
50x TBST  0.1 M Tris pH 8.0 
1.5 M NaCl 
5% (v/v) Tween 20 
 
Transfer buffer  25 mM Tris 
192 mM Glycine pH 8.3  
20% (v/v) Methanol     
 
Triton-X100 lysis-buffer 
 
300 mM NaCl 
50 mM TrisHCl pH 7.6 
0.5% Triton X-100 
(supplemented with protease 
inhibitor cocktail Complete) 
 
Protein molecular weight marker  1 µl molecular weight marker (Roth) 
5 µl 4x Loading-Dye (Roth) 
14 µl H2O 
100x Mg
2+-buffer                           100 mM MgCl2 
5 mM 2-mercaptoethanol 
 
0.1 M NaP04-buffer                       100 ml of 0.1 M Na2HPO4 adjusted to 
pH 7.3 at 37°C using 0.1 M NaH2P04 
 
ONPG-solution                              4 mg/ml in OJM NaP04-buffer 
 
Stop-solution                                  1 M Na2CO3 solution II. Materials and Methods 
 
  20
2.1.6  Buffers and solutions: EMSA and nuclear extracts 
 
Deionizised formamide (EMSA)  500 ml Formamide 
+50 g Mixed-bed resin (Bio-Rad 501-X8) 
incubation at 4°C for 30 min, afterwards filtered, 
stored at –20°C 
 
3x Hybridisation buffer (EMSA)  12% (w/v) Ficoll 
60mM Hepes ph7,9 
150mM KCl 
3mM EDTA 
3mM DTT 
3mM PMSF 
0.75mg/ml BSA 
stored at –20°C 
 
Puffer A (cytosolic extract)  10mM Hepes (pH 7,5) 
10 mM KCl 
0.1 mM EDTA 
0.1mM EGTA 
Complete protease inhibitor (freshly added) 
 
Puffer B (nuclear extract)  20mM Hepes (pH 7.5) 
0.4M NaCl 
1mM EDTA 
1mM EGTA 
1mM DTT 
Complete protease inhibitor (freshly added) 
 
 
 
2.1.7  Buffers, media and sera for cell culture 
 
Dulbecco´s modified Eagles medium  Gibco, Berlin 
Fetal calf serum  Gibco, Berlin 
Human AB serum  Sigma, Deisenhofen 
Phosphate buffered saline  Gibco, Berlin 
Penicillin/Streptomycin Gibco,  Berlin 
RPMI 1640  Gibco, Berlin 
Trypsin/EDTA Gibco,  Berlin 
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2.1.8  Buffers and media for bacteria culture 
 
Medium components 
 
LB medium* 
(sterilized) 
SOB medium* 
(sterilized) 
SOC medium* 
(sterilized) 
Bacto-tryptone  1.0% (w/v)  2.0% (w/v)  2.0% (w/v) 
Bacto-yeast extract  0.5% (w/v)  0.5% (w/v)  0.5% (w/v) 
NaCl  1.0% (w/v)  10 mM  10 mM 
KCl  ---  2.5 mM  2.5 mM 
MgCl2  ---  10 mM  10 mM 
MgSO4  ---  10 mM  10 mM 
Glucose ---  ---  20  mM 
 
*For solid agar plates, the different media were supplemented with 1.5% (w/v) Agar! 
 
TB – Buffer (pH 6.7)  
for competent bacteria: 
10mM Pipes, 15mM CaCl2, 
250mM KCl, 55mM MnCl2 
 
 
2.1.9  Additional buffers and solutions 
 
10x PBS (pH 7.4)  1.3 M NaCl 
30 mM NaH2PO4 
70 mM Na2HPO4 
 
50x TAE  2 M Tris 
1 M Acetic acid 
50 mM EDTA 
 
10x TBE  0.45 M Tris 
0.45 M Boric acid 
10 M EDTA 
 
 
2.1.10 DEPC-treatment 
Solutions for RNA based methods were treated with diethyl pyrocarbonate (DEPC) to 
inactivate RNases. Note that DEPC reacts with amines such as Tris. Hence, Tris and 
similar buffers were made from DEPC treated water, but not treated with DEPC directly. 
DEPC treated water was obtained by adding 1 ml DEPC per liter of Aq. dest. After mixing 
in an overnight step at RT, the solution was autoclaved. 
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2.1.11 Laboratory equipment 
 
ABI-Prism 310 Genetic Analyser  Applied Biosystems Applera, Weiterstadt 
Gel dryer 583  Bio-Rad, München 
GeneAmp 2400/9600 Thermocycler  Applied Biosystems Applera, Weiterstadt 
Gene Quant II  Amersham Pharmacia, Braunschweig 
Herasafe clean bench  Heraeus, Hanau 
Hyperprocessor  Amersham Pharmacia, Braunschweig 
Incubator Heraeus BBD 6220  Heraeus, Hanau 
AutoLumat LB953  Berthold, Pforzheim 
Microplate reader Benchmark  Bio-Rad, München 
PhosphoImager BAS 1500  Raytest, Straubenhardt 
TRI-CARB 2100 TR β-counter  Canberra-Packard, Dreieich 
 
 
2.1.12 Enzymes 
 
Alkaline shrimps phosphatase  Roche Biochemicals, Mannheim 
DNA polymerase T4  MBI-Fermentas, St. Leon-Rot 
Turbo Pfu/Pfu-DNA Polymerase   Stratagene, Heidelberg 
Proteinase K  Roche Biochemicals, Mannheim 
Restriction Enzymes 
 
NEB, Frankfurt a.M.; 
MBI-Fermentas, St. Leon-Rot 
Reverse Transcriptase  Applied Biosystems Applera, Weiterstadt 
T3 RNA Polymerase   Roche Biochemicals, Mannheim 
T7 RNA Polymerase  Roche Biochemicals, Mannheim 
RNase A   Roche Biochemicals, Mannheim 
RNase T1  Roche Biochemicals, Mannheim 
T4-DNA Ligase  Gibco Life Technologies, Eggenstein 
Taq-DNA polymerase  Applied Biosystems Applera, Weiterstadt 
Taq-Gold-DNA polymerase (Hot Start)  Applied Biosystems Applera, Weiterstadt 
 
 
 
2.1.12.1  Pretreatment of enzymes  
 
 
Proteinase K 
The lyophilized enzyme was dissolved in Aquadest (10 mg/ml), incubated for 30 min at 37°C 
and aliquoted. The aliquots were stored at –20°C until use. 
 II. Materials and Methods 
 
  23
RNase A 
RNase A was dissolved to a final concentration of 10 mg/ml in RNase-buffer [Tris/HCl (10 
mM, pH 7.5), NaCl (15 mM)]. The enzyme solution was incubated for 30 min at 95°C and 
cooled to room temperature over night. Aliquots were stored at –20°C until use. 
 
 
2.1.13 Antibodies and antisera 
 
anti-human IL18 (rabbit, polyclonal)  PeproTech, Frankfurt 
anti-human iNOS (rabbit, polyclonal)  Santa Cruz Biotechnologies, Heidelberg 
anti-mouse IgG (horseradish-peroxidase coupled)  Bio-Rad, München 
anti-rabbit IgG (horseradish-peroxidase coupled)  Bio-Rad, München 
hIL18BP 147A (rabbit, polyclonal)  Eurogentech, Seraing (Belgium) 
IFNγ neutralizing antibody monoclonal + control AB  PharMingen, NALE Quality, Hamburg 
Stat1 9H2 (mouse, monoclonal)  Cell Signaling, distributed by NEB, 
Frankfurt a.M. 
 
 
2.1.14 Recombinant and purified proteins 
 
IFN-γ (human)  PeproTech, Frankfurt 
IL-12  R&D Systems, Wiesbaden 
IL-18 PeproTech,  Frankfurt 
IL-1β  Cell Concepts, Umkirch 
TGF-β1  Roche Biochemicals, Mannheim 
 
 
2.1.15 Plasmids 
 
2.1.15.1 Vectors 
 
pBluescript II KS (+)  Stratagene, Heidelberg 
pCR 2.1 TOPO  Invitrogen, Groningen (Netherlands) 
pCR II TOPO  Invitrogen, Groningen (Netherlands) 
pCR 4 TOPO  Invitrogen, Groningen (Netherlands) 
pGL3-Basic Vector  Promega, Mannheim 
β-Gal (pcmv)  Stratagene, Heidelberg 
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2.1.15.2 Recombinant plasmids 
 
 Reference  Purpose 
pBKS(+)GAPDH (human, nucleotides 148-302)  Tokunaga et al. 1987  RPA 
pBKS(+)IL-18 (human, nucleotides 335-627)  Ushio et al. 1996  RPA 
pBKS(+)IL-18BP (human, nucleotides 457-644)  Novick et al. 1999  RPA 
pBKS(+)iNOS (human)  kindly provided by 
Dr. H. Kleinert, Mainz 
RPA 
pBKS(+)TGF-β  (murine, nucleotides 1735-1974)  EMBL Acc. No. NM011577  RPA 
pBKS(+)VEGF (human, nucleotides 339-498)  Weindel et al. 1992  RPA 
pORF IL18BPa  InvivoGen, San Diego (USA)  Overexpression ⇒  
TCA-Precipitation 
 
 
2.1.15.3 Recombinant IL18BP promoter-constructs 
 
IL-18BP promoter luciferase vectors  Genomic position of cloned cDNA 
(Chromosome 11q13)     5’ ⇒ ⇒ ⇒ ⇒ 3’ 
pGL3 + IL18BProm Frag4  nucleotides 2405990 ⇒ 2407104 
pGL3 + IL18BProm Frag5  nucleotides 2406459 ⇒ 2407104 
 
Pub Med human genome: URL 
 
http://www.ncbi.nlm.nih.gov:80/cgi-bin/Entrez/map_search.cgi?chr=hum_chr.inf&advsrch=off&query=il18bp 
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2.1.16 Bacterial strains 
 
    Genotype 
E.coli DH5α α α α  Gibco Life Technologies, Eggenstein  supE44 ∆lac U169 (∅80lacZ∆M15) hsd 
R17 recA endA1 gyrA96 thi-1 relA1 
E.coli XL-1 blue  Stratagene, Heidelberg  supE44 hsdR17 recA1 endA1 gyrA46thi 
relA1 lac
- F`[proAB
+ lacI
q lacZ∆M15 
Tn10(tet
r)]   
TOP10  Invitrogen, Groningen (Netherlands)  F
- mcrA ∆(mrr-hsdRMS-mcrBC)Φ80lacZ 
∆M15  ∆lacX74 recA1 deoR araD139 
∆(araleu)7697 galU galK rpsL (Str
R) 
endA nupG 
 
 
 
2.1.17 Eukaryotic cell lines 
 
Caco-2  Colon carcinoma cell line (German Collection of Microorganisms and Cell 
Cultures, Braunschweig, Germany) 
DLD-1  Colon carcinoma cell line (Centre for Applied Microbiology & Research, 
Salisbury, United Kingdom) 
HaCaT  provided by Dr. N.E. Fusenig [Boukamp et al., 1988] 
HCT116  Colon carcinoma cell line (American type tissue collection, Manassas, VA, USA) 
LoVo  Colon carcinoma cell line (American type tissue collection) 
 
 
 
2.1.18 Oligonucleotides 
 
2.1.18.1  Cloning of IL18BP Promoter-Fragments 
 
Fragment Number  Forward Primer (MluI)  Reverse Primer (BglII) 
Frag4 IL18BProm  5’IL18BProm forB MluI  3’IL18BProm BglII rev 
Frag5 IL18BProm  5’IL18BProm FragB MluI  3’IL18BProm BglII rev 
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Forward Primer (MluI ACG CGT)*  Sequence 5’ ⇒ ⇒ ⇒ ⇒ 3’ 
5’IL18BProm forB MluI  CTG TCA CCA CGC GTT GCA CCC TCC 
5’IL18BProm FragB MluI  CCT AGA GGG ACG CGT CTG GAA AGG 
 
Reverse Primer (BglII AGA TCT)*   
3’IL18BProm BglII rev  TTC AGC ACC AGA TCT GCT TCT GGG 
 
* Mutated sequences for generating artificial restriction sites are shown in italic characters! 
 
2.1.18.2  Semiquantitative PCR (human specific) 
 
  Fragment size (bp)  Sequence 5’ ⇒ ⇒ ⇒ ⇒ 3’ 
GAPDH for  ACC ACA GTC CAT GCC ATC AC 
GAPDH rev 
 
452  TCC ACC ACC CTG TTG CTG TA 
IL18 for  ACC AAG TTC TCT TCA TTG ACC 
IL18 rev 
 
293  TTG CAT CTT ATT ATC ATG TCC 
IL18BPa for  CCT CTA CTG GCT GGG CAA TGG 
IL18BPa rev 
 
295  TTA ACC CTG CTG CTG TGG AC 
iNOS for  GGT GCT GTA TTT CCT TAC GAG GCG AAG AA 
iNOS rev 
 
258  GGT GCT ACT TGT TAG GAG GTC AAG TAA AGG 
IP-10 for  AGT GGC ATT CAA GGA GTA CC 
IP-10 rev 
 
289  ATC CTT GGA AGC ACT GCA TC 
 
 
2.1.18.3 Sequencing  primer 
 
  Sequence 5’ ⇒ ⇒ ⇒ ⇒ 3’ 
IL18BProm Seq1  GTT GAG CCA GTC CGC CTC TTC 
IL18BProm Seq2  GTA TGG CAT TGA GCC TGA AGT GGT CC 
IL18BProm Seq3  GGT AGA TTA GAG ATC CCA GTC TGG 
M13 for  CAG GAA ACA GCT ATG AC 
M13 rev  GTA AAA CGA CGG CCA G 
pGL3 Basic for  CTA GCA AAA TAG GCT GTC CC 
pGL3 Basic rev  CTT TAT GTT TTT GGC GTC TTC CA 
 
 
2.1.18.4   IL18BP promoter GAS sites (EMSA) 
 
Stat1 binding sites  Sequence 5’ ⇒ ⇒ ⇒ ⇒ 3’ 
EMSA GAS1 for ss   CAG TGC TTT CCC AGA AGG ATT GC 
EMSA GAS1 rev ss  GCA ATC CTT CTG GGA AAG CAC TG II. Materials and Methods 
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Stat1 p84/p91 Mutant Oligonucleotide 
(Santa Cruz Biotechnologies, Heidelberg) 
        CAT GTT ATG CAT ATT GGA GTA AGT G 
3’ -- GTA CAA TAC GTA TAA CCT CAT TCA G -- 5’ 
Stat1 p84/p91 Consensus Oligonucleotide 
(Santa Cruz Biotechnologies, Heidelberg) 
        CAT GTT ATG CAT ATT CCT GTA AGT G 
3’ -- GTA CAA TAC GTA TAA GGA CAT TCA C -- 5’ 
 
 
2.1.19 Computer software 
 
DNA/Protein homology search  BLAST search (National Center of Biotechnology, 
USA; URL: http://www.ncbi.nlm.nih.gov); 
DNA analysis software  Analyze 
Graphic processing  Corel Draw 8.0/10.0 
Presentations Powerpoint  2000 
Statistical analysis  Sigma Plot 4.0 (Students T-Test) 
Text processing  Microsoft Word 2000 
 
Programs belonging to special devices are mentioned separately in the appropriate sections. 
 
 
2.2 Methods 
 
2.2.1 Microbiologic  methods 
 
2.2.1.1 Bacterial  culture 
 
The E. coli strains DH5α (Gibco Life Technologies) and XL1-blue (Stratagene) were used 
for amplification of plasmid DNA. Both strains were either grown in liquid LB (Lauria-
Bertani) or SOC medium (2.1.8). For selection, the media contained ampicillin (50 µg/ml). 
Agarplates were generated with LB-ampicillin medium supplemented with agar (15 g/l). For 
long-term preservation of transformed bacteria, cells were mixed with sterile glycerol [30% 
(v/v)] and stored at –80°C. 
 
2.2.1.2  Competent bacteria for transformation 
 
To yield high transformation efficiencies from plasmid DNA in bacteria, cells have to be 
pretreated chemically. To this end, 250 ml SOB-Medium (2.1.8) were inoculated with 200 µl 
of an overnight bacterial culture and grown at 18°C until the suspension reaches an optical 
density of 0.5 (OD600 nm). The bacterial growth was stopped by storing the suspension for II. Materials and Methods 
 
  28
10min on ice. Bacterial cells were concentrated by centrifugation (15 min, 2500g, 4°C; 
Heraeus Megafuge 1.0, rotor 7570F). The cellular pellet was subsequently resuspended in 
80 ml solution TB (2.1.8), mixed and incubated on ice for 10 min. The bacterial suspension 
was centrifuged again (15 min, 2500 g, 4°C), the pellet was gently resuspended in 20 ml of 
solution TB + 7% DMSO, and incubated on ice for additional 10 min. Thereafter, aliquots of 
competent bacteria were snap frozen in liquid nitrogen and stored at –80°C. 
 
 
2.2.1.3 Transformation 
 
100 µl of a competent bacteria suspension was thawed on ice and 5 µl of the ligation 
reaction (2.2.3.11) was added. The bacteria/DNA mixture remained on ice for additional 30 
min followed by an incubation at 42°C for 1 min. The bacteria were chilled on ice again for 
2 min, before 300 µl of SOC-medium were added. For initial expression of the plasmid 
encoded ampicillin resistance, bacteria were incubated for 1 h at 37°C on a shaker. 
Subsequently, 20 - 200 µl of this transformation solution was plated on ampicillin containing 
agar plates depending on the efficiency of transformation. To enable a blue/white screening 
for recombinant clones (pBSII(KS)+/pCR TOPO), the agar plate was supplemented with 50 
µl X-Gal (2% in DMSO) and 50 µl IPTG (0.1 M in Aquadest). The plates were incubated 
overnight at 37°C. 
 
 
2.2.2 Cellbiologic  methods 
 
2.2.2.1  Cultivation of DLD-1, Caco-2, LoVo, HCT116, and HaCaT cells 
 
Human DLD-1 (Centre for Applied Microbiology & Research, Salisbury, United Kingdom), 
HCT116 (American type tissue collection, Manassas, VA, USA), Caco-2 (German 
Collection of Microorganisms and Cell Cultures, Braunschweig, Germany) colon carcinoma 
cells, and HaCaT keratinocytes (provided by Dr. N.E. Fusenig) were grown in DMEM 
supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin, and 10% heat-inactivated 
FCS (GIBCO-BRL, Eggenstein, Germany). LoVo (American type tissue collection) colon 
carcinoma cells were maintained in RPMI 1640 supplemented with 100 U/ml penicillin, 100 
µg/ml streptomycin, and 10% heat-inactivated FCS (GIBCO-BRL). 
All these cell lines were cultured at 37°C in a humidified atmosphere containing 5% CO2 
(Heraeus BBD 6220 incubator). For subcultivation, cells were washed twice in phosphate 
buffered saline (PBS), subsequently trypsinized (Trypsin, EDTA) and diluted dependent on 
their growth properties in a 1:10 and 1:20 ratio. II. Materials and Methods 
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For long-term storage, the cells were treated as subsequently described: after 
trypsinization, cells were concentrated (5 min at 1100 rpm, Heraeus Megafuge 1.0, rotor 
75750F), diluted in freezing medium (growth medium supplemented with 10% DMSO) and 
stored in cryotubes (Nunc). The cryotubes were cooled down slowly overnight to –70°C 
and finally stored in liquid nitrogen. 
For TCA precipitation of cell culture supernatants, cells on polystyrene plates (Greiner, 
Frickenhausen) were washed twice with PBS and incubated in the aforementioned DMEM 
medium without FCS. 
 
 
2.2.2.2  Cultures of colonic intestinal biopsy specimens 
 
The study protocol and consent documents were approved by the ‘Ethik Kommission’ of 
the Klinikum der Johann Wolfgang Goethe-Universitat, Frankfurt am Main. Informed 
consent was obtained from the donors. All patients required a colonoscopy for medical 
reasons. For the experiments a macroscopically non-diseased biopsy site was chosen. 
Cultivation was performed as recently described [Reimund et al., 1996]. Within a maximal 
lag of 0.5 hours after biopsy, specimens were washed carefully in PBS (GIBCO-BRL). 
Thereafter, tissues were placed in 24-well tissue culture plates (Greiner) and maintained in 
DMEM without phenol red (GIBCO-BRL, 1 ml/well) supplemented with 100 U/ml penicillin, 
100  µg/ml streptomycin (GIBCO-BRL) and 1% (v/v) heat-inactivated human AB serum 
(Sigma). Stimuli were added and after the indicated incubation periods cells were 
harvested for RNA isolation. 
 
 
2.2.2.3  Isolation of PBMC 
 
The study protocol and consent documents were approved by the ´Ethik Kommission´ of 
the Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt am Main.  Healthy 
volunteers abstained from using any drugs during 2 weeks before the study. 
Blood was drawn into heparinized syringes (10 U/ml final concentration) and subsequently 
PBMC were isolated by centrifugation through Ficoll (Histopaque-1077, Sigma Bio-
chemicals) for 15 min at 1900 rpm without brake (Heraeus Megafuge 1.0, rotor 75750F). 
PBMC were washed three times with PBS and resuspended in RPMI 1640 supplemented 
with 25 mM HEPES, 100 U/ml penicillin, 100 µg/ml streptomycin (GIBCO-BRL) and 1% 
(v/v) heat-inactivated human AB serum (Sigma, Deisenhofen, Germany) and seeded at 2 x 
10
6 cells/ml in round-bottom polypropylene tubes. 
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2.2.2.4  Cocultures of PBMC/DLD-1 
 
For indirect (transwell-assay) cocultures, PBMC (5 x 10
6 cells per insert) were seeded into 
Transwell-Clear inserts (0.4 µm pore size, Costar, Bodenheim). Inserts were placed onto 
confluent DLD-1 cells, grown in 6-well polystyrene-plates (Costar).  Incubations were 
performed in RPMI 1640 supplemented with 25 mM HEPES, 100 U/ml penicillin, 100 µg/ml 
streptomycin (GIBCO-BRL) and 1% (v/v) heat-inactivated human AB serum (Sigma, 
Deisenhofen, Germany).  In some of these experiments, DMEM supplemented with 100 
U/ml penicillin, 100 µg/ml streptomycin and 1% (v/v) heat-inactivated human serum was 
used instead of the RPMI medium specified above.  This change of medium was necessary 
due to the high content of nitrate in the RPMI medium which interferes with determination 
of nitrate production by activated cells.  The choice of medium did not affect iNOS induction 
in DLD-1 cells of cocultures.  
After 45h inserts with PBMC and the supernatants were carefully removed.  Thereafter, 
adherent DLD-1 cells in the polystyrene wells were washed twice with PBS followed by 
cell-lysis for RNA-isolation or immunoblot analysis (2.2.3.6/2.2.4.4). 
 
 
2.2.2.5 IFNγ γ γ γ production by IL-12/IL-18-stimulated PBMC 
  cultivated in DLD-1 cell-derived conditioned media 
 
To investigate whether conditioned medium from IFNγ-stimulated DLD-1 cells may contain 
IL-18BPa activity, the following experimental protocol was performed: DLD-1 cells were 
kept as unstimulated control, or were stimulated with IFNγ (20 ng/ml), with sodium butyrate 
alone (5 mM), or with IFNγ plus sodium butyrate for 14 h using DMEM medium (containing 
10 % FCS) in order to induce expression of IL-18BPa. Thereafter, cultures were thoroughly 
washed three times with PBS. After an additional 48 h incubation period in control DMEM 
without FCS, cells were lysed for isolation of total RNA. Cell-free culture supernatants were 
either TCA-precipitated (for SDS-PAGE) or concentrated 5-fold using Ultrafree-4 Biomax 
10K centrifugal filters (Millipore, Bedford, MA). Concentrated conditioned media were 
preincubated for 30 min without stimuli or with IL-12 (20 ng/ml)/IL-18 (20 ng/ml) at 37
°C. 
PBMC were then resuspended in these conditioned media and after an additional 24h of 
incubation, IFNγ production was assessed by ELISA (Pharmingen, Hamburg).  
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2.2.2.6  Reporter gene assays 
 
The regulation of gene expression can be examined using a reporter-gene-assay. For this 
purpose DNA sequences carrying putative regulatory elements were cloned in front of a 
reporter gene, in this case the gene encoded luciferase enzyme [Alam and Cook, 1990]. By 
liposomal transfection newly generated constructs were transferred into the eukaryotic 
target cells. Thereafter transfected cells were stimulated with IFN-γ. After transfection and 
stimulation, cells were harvested to measure the amount of synthesized reporter gene 
products. To assess the influence of a certain sequence on IL-18BP gene regulation, 
reporter gene expression in IFN-γ-stimulated cells and unstimulated cells were compared. 
 
 
2.2.2.6.1  Transient transfection of DLD-1 cells with luciferase constructs 
 
Confluent grown DLD-1 cells were trypsinized and cultured in fresh medium. The cells 
should have reached a confluency of about 50 - 60%. The cells were seeded in 2 ml 
medium per well onto 6-well-culture-plates and incubated for 18 - 24 h under standard 
conditions. IL-18BP promoter luciferase expression contructs (2 µg DNA/35 mm well) were 
transfected into DLD-1 cells using Fugen 6 Transfection Reagent (Roche Biochemicals) 
according to the manufacturer’s instruction. The transfection conditions for this cell line had 
to be optimized. A final volume of 4.5 µl of Fugene 6 Transfection Reagent was used per 
well of a 6-well plate. These 4.5 µl were diluted 90 µl using serum-free DMEM and 
incubated for 5 min. Meanwhile 2 µg plasmid DNA and 500 ng of pCMV-β galactosidase 
DNA (2.1.15.1), for controlling the transfection efficiency, were brought to a final volume of 
10 µl also employing serum-free medium. Subsequently both solutions were combined and 
mixed gently. In the following 15 min the formation of DNA-liposome complexes took place 
at room temperature. 
DLD-1 target cells were rinsed two times with PBS and maintained in 2 ml of fresh serum- 
containing medium. Cells were transfected with 100 µl DNA-liposome complexes and 
incubated for 42 h without replacing the transfection mixture. After the 42 h transfection 
period, cells were washed twice with PBS. Subsequently DLD-1 cells were either kept as 
unstimulated control or stimulated with IFNγ (20 ng/ml). 6 h later, cells were harvested to 
determine luciferase (Promega Luciferase Assay System) and β-Gal activity (2.2.2.6.3), 
respectively. 
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2.2.2.6.2 Luciferase  assay 
 
The luciferase of the Firefly ( Photinus pyralis) catalyses the oxidation of luciferin. During 
this reaction photons are released at a wavelength of  562 nm. By employing a 
luminometer (AutoLumat LB953, Berthold) a quantitative measurement of the emitted light 
was performed. Cells were transiently transfected with a luciferase-construct, stimulated 
and harvested in 1x Reporter-Lysisbuffer (Promega) as described by the manufacturer. 
The solutions needed for measurement were prewarmed at RT. 20 µl of cell-extract were 
pipetted  in a polystyrene-tube. Subsequently, the reaction was started in the Luminometer 
by injection of 100 µl Luciferase-Assay-Reagent (Promega) (20 mM Tricin, 1.07 mM 
(MgCO3)Mg(OH)2  x 5 H20, 2.67 mM MgSO4, 0.1 mM EDTA, 33.3 mM DTT, 270 µM 
Coenzym A, 470 µM Luciferin, 530 µM ATP pH 7.8). The emitted light was measured for 10 
s with a Photomultiplier and expressed in Relative Light Units short (RLUs) by the 
luminometer. 
 
2.2.2.6.3 ß-Galactosidase  assay 
 
The ß-galactosidase is an bacterial enzyme which catalyses the breakdown of lactate. It is 
encoded by the bacterial lacZ gen in the lac-Operon. Besides lactate also X-Gal is 
substrate for this decomposition process, which product leads to yellow colour. Therefore, 
the transfection efficiacy can be determined by transferring the lacZ gene into a cell under 
control of a constitutive promoter. Using this method the amount of ß-galactosidase was 
measured in lysates of cells transfected with β-Gal and luciferase genes. Activation of the 
luciferase gene in cells was normalized using the β-Gal counts. 
For this experimental set up the following reagents (2.1.4) were combined: 100 µl of cell 
extract (extraction as previously described in  2.2.2.6.2), 3 µl of 100x Mg-buffer, 66 µl 
ONPG solution and NaP04-buffer were added to a final volume of 300 µl. The reaction was 
incubated from 30 min up to several hours at 37°C until a yellow color became visible. 
Finally, the reaction was terminated by adding 0.5 ml of stop solution. The color reaction 
was quantified photometrically at 410 nm and 595 nm for reference. 
 
2.2.2.7  Measurement of cell parameters 
 
2.2.2.7.1  Cell viability: LDH assay 
 
Cell viability was also determined by a lactate dehydrogenase (LDH) activity assay 
according to the manufacturer’s instructions (Roche Molecular Biochemicals). LDH is 
usually located intracellularly in viable cells. During cell death this enzyme is released into 
the cell culture supernatant where its activity can be detected.  II. Materials and Methods 
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2.2.2.7.2  Nitric oxide synthase activity: Griess assay 
 
Nitrite (NO2
-) is a stable NO oxidation product, that has been used as a direct readout for 
nitric oxide synthase activity using the Griess-assay as recently described (Mühl et al., 
1997). Detection limit for nitrite in this assay was 1.5 µM. 
Cell culture supernatants were cleared by centrifugation (5 min at 400 g). 200 µl of the 
cleared lysates or supernatants were mixed with an equal volume of ready-to-use Griess 
Reagent (Roche, Mannheim). After 5 min at room temperature, the absorbance was 
measured at 540 nm with a reference wavelength at 690 nm. 
For detection of total nitrite/nitrate a colorimetric assay kit was used according to the 
manufacturer’s instructions (Alexis Biochemicals). Detection limit for nitrite/nitrate was 3 µM 
in this assay. 
 
 
2.2.3  Molecular biology methods 
 
2.2.3.1  Reverse transcriptase reaction (RT) 
 
The enzyme reverse transcriptase, originally discovered in RNA tumor viruses, synthesizes 
a complementary DNA strand using RNA as a template. This enzymatic activity provides 
access to the generation of cDNA. Random hexamers (50 µM) were used as internal 
enzyme start sites. 
 
 
Reverse transcriptase reaction:  X µl (max. 3 µl)  RNA (1 µg)     
4 µl  MgCl2 (25 mM) 
2 µl  10x PCR-Buffer 
2 µl  dATP (each 10 mM) 
dCTP 
dGTP 
dTTP 
1 µl  RNase Inhibitor (20U/µl) 
1 µl  Random Hexameric Primers (50 µM)
1 µl  Reverse Transcriptase 
(50U/µl; Muloney Virus) 
Applied Biosystems Applera 
X µl  DEPC H2O 
20 µl  Total Volume 
 
 
1 µg of total RNA was added to the reagents as listed in the table. The reaction was 
performed for 30 min at 42°C. Subsequently the mix was terminated by incubation for 5 min 
at 99°C and cooled to 4°C. Aliquots of the cDNAs were stored at 4°C. II. Materials and Methods 
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2.2.3.2  Polymerase chain reaction (PCR)  
 
This method enables the in vitro amplification of DNA fragments without time consuming 
cloning and identification steps [Mullis & Foloona, 1987]. The method is based on the 
availability of heat-stable DNA polymerases which allow multiple denaturing of template 
DNA, annealing of driver sequences (primer) and synthesis of DNA by amplification steps 
within one tube. 
 
Polymerase chain reaction:  2 µl
X µl
X µl
RT-product (2.2.3.1) or 
Plasmid-DNA Template (5-10 ng) or 
genomic-DNA Template (250 ng) 
5 µl 10x PCR-Buffer 
3 µl MgCl2 (25 mM) 
1 µl dATP (each 10 mM) 
dCTP 
dGTP 
dTTP 
5 µl Forward/Reverse Primer-Mix (5 µM) 
0.4 µl Taq-Gold Polymerase (5U/µl) 
X µl DEPC H2O 
50 µl Total Volume 
 
The reaction was performed in a thermocycler (GeneAmp 2400 or 9600, PE Biosystems). 
Conditions varied dependently on the gene of interest, the type of polymerase used for 
amplification and the experimental set up. For semi-quantitative gene analysis taq-gold 
polymerase has been used. This enzyme has to be activated by a single incubation for 10 
min at 94°C (hot start!). 
In general, 25-30 cycles of the following steps have been carried out: 1 min 94°C, 1 min 
e.g. 60°C (primer-annealing) and 2 min 72°C (endelongation). The amplification was 
completed by a final 7 min incubation step at 72°C. Depending on special conditions of 
template, primers and type of cell the protocol was adapted individually (see table below). 
The samples were stored at 4°C and analyzed by gel electrophoresis. 
 
Semi-quantitative gene analysis for  Annealing temperature   Cycle number 
GAPDH 60°C  23-25 
hiNOS 62°C  30-32 
IL8 60°C  28 
IL18 58°C  30-32 
IL18BP 58°C  31 
IP10 60°C  30 
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For amplification of genomic DNA taq and (turbo)-pfu-polymerase have been used, since 
genomic DNA is damaged by long term heatment needed for taq-gold polymerase 
activation. In contrast to taq polymerase the (turbo)-pfu polymerase provides proofreading 
activity, but at a reduced rate of synthesis. 30–35 cycles were sufficient to amplificate 
genomic IL18BP promoter fragments by using to following PCR program: 1 min 94°C, 1 
min 65°C and 4 min 72°C. Finally the amplification was completed by a 7 min incubation 
step at 72°C. 
 
 
2.2.3.3  Real-time quantitative PCR: analysis of IL-18BPa expression 
 
Real-time PCR analysis of cDNA is based on the direct detection of amplicons by 
fluorescence. Changes in fluorescence are caused by the Taq-polymerase degrading the 
probe that contains a fluorescent dye (FAM for IL-18BPa, VIC for GAPDH) and a quencher 
(TAMRA). Primers and probe for IL-18BPa were designed using the Primer Express 
software from Applied Biosystems according to the published sequence (XM 035063.1): 
forward 5´-acc tcc cag gcc gac tg-3´; reverse 5´-cct tgc aca gct gcg tac c-3´; probe 5´-cac 
cag ccg gga acg tgg ga-3´. The possibility to amplify contaminating genomic DNA was 
eliminated by selecting an amplicon which crosses an exon/intron boundary. For GAPDH, 
we used a pre-developed assay reagent including primers and probe (Applied Biosystems). 
Specificity of PCR products was tested by classic PCR using the aforementioned primers. 
1 µg of total RNA was transcribed in RT reaction using random hexameric primers and 
Muloney virus RT (Applied Biosystems Applera) according to the manufacturer´s 
instructions. Real-time PCR was performed on the AbiPrism 7700 Sequence Detector 
(Applied Biosystems Applera) as follows: One initial step at 50°C for 2 minutes and 95°C 
for 10 minutes was followed by 40 cycles at 95°C for 15 seconds and 60°C for 1 minute. 
Detection of the dequenched probe, calculation of threshold cycles (Ct values), and further 
analysis of these data were performed by the Sequence Detector software. All results for 
IL-18BPa were normalized to GAPDH.  
 
2.2.3.4  Cloning of PCR products in cloning vectors (pBSII(+)KS/TOPO)  
  and luciferase vector (pGL3) 
 
After amplification, PCR products were cloned into the pBluescript II (+) KS vector 
(Stratagene), into the TOPO-Cloning Vectors (Invitrogen), or directly ligated to the target 
vector pGL3 (Promega). PCR inserts in pBSII/TOPO were restricted by type II 
endonucleases (MluI/BglII) and separated from these cloning vectors by gel 
electrophoresis and subsequent gel elution using a column gel extracting kit (NucleoSpin II. Materials and Methods 
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Extract 2 in 1 by Macherey & Nagel), followed by ligation into the prepared luciferase-
vector pGL3. These luciferase constructs were used to transfect DLD-1 cells. 
 
 
2.2.3.5  Preparation of plasmid DNA: CTAB Miniprep 
 
Isolation of plasmid DNA was performed as described by Del Sal et al (1989) with slight 
modifications. 1.5 ml cells of an overnight culture were collected at 15.000 g (1 min, 4°C). 
The bacterial pellet was resuspended in 200 µl Lysis-STET-buffer (2.1.5; supplemented 
with a final concentration of 1 mg/ml lysozyme) and incubated for 10 min at room 
temperature. After a boiling step (1 min at 95°C), the mixture was centrifuged for 10 min at 
15,000 g. The pellet containing cell debris, protein, and genomic DNA, was removed using 
a tip. 10 µl 5% (w/v) cetyltrimethylammonium bromide (CTAB) / 0.2 M NaCl (2.1.5) was 
added for 3 min to precipitate RNA and plasmid DNA. After centrifugation (15 min, 15,000 
g), the pellet was resuspended in 300 µl 1.2 M NaCl containing 5 µg/ml RNase A, 
incubated for 15 min at 37°C (or 0.5 - 1 h at room temperature, to ensure a complete 
degradation of RNA), and subsequently precipitated with 750 µl ethanol for 1 h at –20°C. 
The precipitated plasmid DNA (15 min, 15,000 g) was dissolved in 20 µl Aquadest. 
 
Midiprep: Higher amounts of plasmid DNA (expected yields: 75 - 100 µg) were obtained 
using the NucleoBond PC 100 Kit (AX 100) as described by the manufacturer. 
 
Maxiprep: To obtain endotoxinfree plasmid DNA for transfection experiments we employed 
Endofree Plasmid Maxi Kit (Qiagen-tip 500) according to the manufacturer’s instruction. 
 
 
2.2.3.6  RNA isolation from cultured cells 
 
RNA isolation was performed with TRI-Reagent according to the protocol from the 
manufactor (Sigma Biochemicals). Cells were grown and stimulated as described above 
(2.2.2.1). Last traces of media were removed by a pipette tip attached to a vacuum line. 
Subsequently, cells were lysed with 1 ml of TRI-Reagent per well using 6-well-plate. The 
lysate was transferred into an Eppendorf tube. After addition of 200 µl chloroform, the 
samples were inverted for 30 s. The inverted tubes were stored RT for 10 min and 
subsequently centrifuged (15,000 g, 15 min at 4°C). Afterwards the aqueous upper phase 
was transferred into a fresh tube. RNA was precipitated using 500 µl of isopropanol and 
stored again for 10 min at RT. Finally a single centrifugation step (15,000 g) was carried 
out for 15 min at 4°C to pellet the precipitated RNA. Then the RNA pellet was washed with 
cold 70% ethanol (with DEPC-treated water), followed by centrifugation (15,000 g, 10 min II. Materials and Methods 
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at 4°C). The final RNA pellet was resuspended in 20 – 25 µl DEPC-treated water. After  a 
10 min incubation at 55°C, the amount of isolated RNA was quantified photometrically 
(2.2.3.7). 3 µg of the isolated RNA was controlled for integrity by agarose gel 
electrophoresis (1%, 1x TBE buffer). 
 
 
2.2.3.7  Quantification of nucleic acid concentrations 
 
Concentrations of nucleic acids were determined photometrically using a wavelength of  
260 nm (Gene Quant II, Amersham Pharmacia). An optical density (OD) of 1 corresponds 
to approximately 50 µg/ml double-stranded DNA or 40 µg/ml for single stranded DNA and 
RNA [Sambrook et al. 1989]. The ratio between the readings at 260 nm and 280 nm 
(OD260/OD280) provides an estimation of the purity of the nucleic acid preparation. Highly 
pure DNA or RNA are characterized by ratios between 1.8 and 2.0. Concentrations were 
calculated according to the following equation: 
 
c [µg/ml] = OD260 x V x F  V = dilution factor 
  F = multiplication factor (dsDNA = 50; RNA = 40) 
 
Low amounts of DNA were estimated by agarose gel electrophoresis (2.2.3.8) in 
comparison with a known standard. 
 
 
2.2.3.8  Agarose gel electrophoresis of nucleic acids 
 
Nucleic acids were separated by gel electrophoresis using agarose gels. The agarose 
concentration was dependent on the molecular weight of the analyzed nucleic acids. For 
separation of DNA molecules from 0.5 to 2 kbp usually 1% agarose gels (w/v) were 
employed. Smaller DNA fragmentes ( 100 bp – 500 bp) were separated in high density gels 
(1.5 - 2% agarose gels ) [Sambrook et al., 1989]. Agarose (Roth/Gibco Life Siences) was 
dissolved in 1x TBE gel electrophoresis buffer. Ethidium bromide was added to a final 
concentration of 500 ng/µl. Ethidium bromide binds to DNA or RNA by intercalation 
between the bases and, thus enables an ultraviolet fluorescence illumination of nucleic 
acids. The DNA/RNA samples were diluted with loading buffer [6x loading buffer: 30% 
glycerol (v/v), 0.25% bromophenol blue (w/v), 0.25% xylenecyanole (w/v), 60% 10x TBE 
buffer (v/v)] and transferred into the appropriate gel wells. Electrophoresis was performed 
in 1x TBE buffer with a voltage of 10 V/cm electrode distance. DNA fragment sizes were 
estimated using molecular weight markers (MBI Fermentas).  II. Materials and Methods 
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2.2.3.9  DNA isolation from agarose gels 
 
The use of the NucleoSpin Extract 2 in 1 Kit (Macherey & Nagel) enables a pure extraction 
of DNA fragments directly from agarose gels. The system is based on a silica membrane, 
which binds single and double stranded DNA. The DNA fragments of interest were cut from 
the gel with a razor blade and further processed according to the instructions of the 
manufacturer. 
 
 
2.2.3.10 Restriction 
 
Type II endonucleases isolated from bacteria specifically bind palindromic sequences with 
a subsequent cleavage of the DNA molecule at their recognition site. This process 
generates either blunt-end fragments or overhanging cohesive ends, which allow the 
generation of recombinant DNA by enzymatic ligation. The standard approach for DNA 
digestion is subsequently listed. After incubation at the appropriate temperature, DNA 
cleavage was checked by agarose gel electrophoresis (2.2.3.8). 
 
DNA digestion:  X µl   DNA (3 µg) target-vector 
2.0 µl   10x buffer 
1.8 µl   restriction enzyme (10U/µl) 
X µl   H2O 
50 µl   Total volume 
 
 
2.2.3.11 Ligation 
 
Generation of covalent phosphodiester bonds between the 5´-phosphate and the 3´-OH of 
DNA fragments is catalyzed by T4-DNA ligase. The ligation reaction was performed with 
restricted or PCR amplified DNA. The DNA was separated in a agarose gel. Subsequently 
the DNA fragment of interest was isolated using a column gel extracting kit by Macherey & 
Nagel. The gel extracted fragment was added to the ligation reaction. The mixture was 
incubated overnight at 16°C. Afterwards, an aliquot of this reaction was transformed into 
competent bacteria as described in section 2.2.1.3 . 
 
DNA ligation:  X µl   target vector DNA (70 ng) 
X µl   gel-extracted DNA fragment (130 ng) 
2 µl   5x ligase buffer 
0.5 µl   T4-DNA ligase (1U/µl) 
X µl   H2O 
10 µl   total volume II. Materials and Methods 
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2.2.3.12 DNA  sequencing 
 
DNA sequencing was performed using the ABI-Prism 310 Genetic Analyser (Applied 
Biosystems Applera) based on the dideoxynucleotide chain termination method [Sanger et 
al. 1977]. In the termination labeling mix, the four dideoxy terminators (ddNTPs) were 
tagged with different fluorescent dyes. This technique allows the simultaneous sequencing 
of all four reactions (A, C, G, T) in one reaction tube. The probes were separated 
electrophoretically using a micro capillary. As each dye terminator emits light at a different 
wavelength when excited by laser light, all four colors corresponding to the four nucleotides 
can be detected and distinguished within a single run. Raw data were evaluated by the Abi 
Prism sequencing analysis software on a Power G3 Macintosh computer. The sequencing 
reaction, as listed in the table, was performed in a thermocycler (GeneAmp 2400, Applied 
Biosystems Applera) with 25 cycles of the following temperature steps: 96°C for 10 sec, 
55°C for 5 sec, 60°C for 2 min. For the detection process, probes were prepared as 
described by the manufacturer. 
 
DNA sequencing:  X µl   DNA 
(250 ng plasmid DNA or 
50 ng PCR derived DNA) 
2 µl   sequencing premix 
0.5 µl   primer (200 µM) 
X µl   H2O  
6 µl   total volume 
 
 
2.2.3.13  RNase protection assay 
 
This method was used to quantify the amounts of specific RNA transcripts from total 
cellular RNA. Compared to Northern blot analysis, this technique possesses increased 
sensitivity and specificity. The assay is based on the principle, that double stranded RNA 
hybrids are protected from cleavage by RNases A and T1. 
 
2.2.3.13.1   Preparation of a radiolabeled antisense probe 
 
The desired probes (150-450 nt in length) were cloned into the transcription vector 
pBluescript II KS (+) as described in section 2.2.3.4. The recombinant plasmids (see 
2.1.15.2) were linearized with restriction enzymes, phenol/chloroform extracted, 
precipitated and dissolved in Aquadest to a final concentration of 1 µg/µl. A pure single 
stranded, [α-
32P]UTP radiolabeled antisense transcript was synthesized using T3 or T7 
RNA polymerase dependent on insert direction. The reaction mix was prepared as listed in 
the following table and incubated for 1 h at 37°C: II. Materials and Methods 
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In vitro transcription:  1.1 µl  DEPC H2O 
  1.0 µl  nucleotides (ATP, CTP, GTP; each 5 mM)  
  2.0 µl  transcription buffer (5x) 
  0.4 µl  RNasin (40 U/µl) 
  0.5  µl  T3 or T7 RNA polymerase, depending on 
insert direction 
 3.5  µl  [α-
32P]UTP (800 Ci/mM) 
  0.5 µl  linearized template (1 µg/µl) 
 
 
Subsequently 90 µl DEPC-H2O were added. The reaction was extracted with an equal 
volume of phenol/chloroform and centrifuged (15,000 g, 2 min). The radiolabeled RNA was 
precipitated from the aqueous phase using 40 µl of 7.5 M ammoniumacetate, 1.5 µl of 
tRNA (10 µg/µl) and 350 µl of ethanol for 15 min at –20°C. Following a 15 min 
centrifugation step at 4°C, the radiolabeled pellet was dissolved in 20 µl FLB 80 and 
purified using an acrylamide/urea gel (5% acrylamide/bisacrylamide, 29:1; 8 M urea; 1x 
TBE). Electrophoresis (1x TBE buffer, 300 V) was terminated after 90 min. The 
radiolabeled probe was located by autoradiography, cut out and eluted into 300 µl elution 
buffer (0.1x TBE, 0.2% SDS). The incorporated activity of the freshly prepared radiolabeled 
probe was determined using a β-counting device (TRI-CARB 2100 TR, Canberra-Packard). 
 
 
Buffer components  FLB 80 buffer  FAB buffer  RNase buffer 
Formamide (deionized)  80% (v/v)  80% (v/v)  --- 
EDTA (pH 8.0)  1 mM  1 mM  5 mM 
PIPES (pH 6.4)  ---  40 mM  --- 
NaCl ---  400  mM  --- 
NaOAc (pH 7.0)  ---  ---  300 mM 
Tris/HCl (pH 7.5)  ---  ---  10 mM 
TBE (1x)  0.01% (w/v)  ---  --- 
Bromophenol blue  0.05% (w/v)  ---  --- 
Xylenecyanole 0.05%  (w/v)  ---  --- 
 
 
2.2.3.13.2   Hybridization and cleavage 
 
20 µg of total RNA from cell culture (see 2.2.3.6) were used for the experiments. Total RNA 
and 100,000 cpm of the radiolabeled probe were co-precipitated using a 2.5-fold excess of 
ethanol/0.1 M NaOAc. The samples were incubated at –20°C for 15 min and subsequently II. Materials and Methods 
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centrifuged (15,000 g, 10 min). The supernatants were removed and the RNA/antisense 
probe pellet was resuspended carefully in 30 µl FAB hybridization buffer. Samples were 
subsequently denatured for 10 min at 85°C and hybridized overnight (42°C in a water 
bath). Following hybridization, samples were treated with 300 µl RNase T1/A-mix (RNase 
buffer supplemented with 10 µg of RNase A and 200 units of RNase T1) for 1 h at 30°C 
[Melton et al. 1984]. Under these conditions, every single mismatch was recognized by the 
RNases. RNases were inactivated by an addition of 6.6 µl SDS (10%) and 4.4 µl proteinase 
K (10 µg/ml) for 15 min at 42°C. The samples were extracted with phenol/chloroform and 
centrifuged (15,000 g, 2 min). Protected double-stranded RNA hybrids were precipitated 
using 880 µl of ethanol and 1.5 µl of tRNA (10 µg/µl). After centrifugation, (15,000 g, 15 
min), the pellet was resuspended in 25 µl FLB 80 buffer, heated for 5 min at 95°C and 
loaded onto the gel. 
 
 
2.2.3.13.3   Analytical gel electrophoresis and signal detection 
 
The protected RNA fragments were separated on acrylamide/urea gels (5% 
acrylamide/bisacrylamide, 29:1; 8 M urea; 1x TBE). 1000 cpm of the radiolabeled antisense 
probe served as a size marker. Electrophoresis (300 V, 1x TBE buffer) was stopped after 
60 min. The gel was fixed on Whatman 3MM paper and subsequently dried on a gel drying 
system (Bio Rad). The radiolabeled gel was exposed to a phosphoimager plate (BAS-MP 
2040S, Fuji) and analyzed using a Fuji PhosphoImager BAS-1500. 
 
 
2.2.3.14  Electrophoretic mobility shift assay (EMSA) 
 
EMSA is used to investigate protein/dsDNA interaction using nuclear extracts. It is based 
on the binding of a particular protein providing a special 3D structure (e.g. transcription 
factor) to a specific radiolabeled dsDNA sequence (see GAS1 2.1.18.4). This labeled 
protein/dsDNA complex can be separated from non protein-bound dsDNA on a native 
acrylamide gel.  
An additional proof for modified gel mobility of the dsDNA bound to protein is the socalled 
Super-Shift, which identificates the protein being involved in dsDNA binding. In this 
experimental set up an antibody is added to the reactionmix that specifically binds to the 
putative dsDNA bound protein. Does the shifting antibody successfully detects the 
protein/dsDNA complex a Super-Shift becomes visible which is characterized by a higher 
molecular weight compared to the single shift.     II. Materials and Methods 
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2.2.3.14.1   Nuclear extracts 
Subconfluent cells on 10 cm dishes were stimulated for 0.5 – 2 h washed twice with cold 
PBS and scraped in ice cold 1.5 ml PBS/EDTA (0.1mM/pH8.0). All steps were performed 
strictly in cold enviroment at 4°C. The cells were pelleted by centrifugation in a pre-cooled 
centrifuge at 13000 rpm for 5 min. Afterwards the pellet was resuspended in 300 µl cold 
buffer A + 0.6% NP40 and incubated for 15 min by vigerous shaking at 4°C. Subsequently, 
nuclei and cell fragments were pelleted by centrifugation (13000 rpm, for 15 min at 4°C). 
The supernatant consists of cytosolic extract which can be investigated by western-blot 
analysis. In contrast the DNA-binding proteins are located in their active form in the 
nucleus. Therefore the pellet has to be resuspended in 70 µl ice cold buffer B containing 
protease inhibitor and incubated for additional 20 min by vigerous shaking at 4°C. Nuclei- 
and cellfragments were pelleted by centrifugation (13000 rpm, for 5 min 4°C). Finally, the 
supernatant contains the nuclear extract. Protein content was determined using the 
Nanoquant (Roth) protein assay. The protein solutions were aliquoted, shock frozen in 
liquid nitrogen and stored at –80°C until use. 
  
2.2.3.14.2   Labeling of oligonucleotides 
 
The identified GAS site (GAS1) in the active IL-18BP promoter fragments have been 
synthesized by MWG Biotech. Control consensus oligonucleotides for Stat1 p84/p91 sites 
(wildtype/mutated control) used in the binding reactions as additional competitors were 
obtained from Santa Cruz Biotechnology (Santa Cruz, USA). Sequences of all these 
double-stranded oligonucleotides are listed in 2.1.18.4. Complementary oligonucleotides 
were end labeled by T4 polynucleotide kinase using [γ-
32P]ATP (3000 Ci/mmol). 
 
Oligo labeling:  2 µl  dsGAS1oligonucleotides (pgml/µl) or 
ds control  consensus oligonucleotides 
2 µl  10x Polynucleotid Kinase Buffer 
1 µl  T4 Polynucleotidkinase 
5 µl  [γ-
32P] ATP 
10 µl  H2O 
 
 
The reaction mix was incubated for 1 h at 37°C. Afterwards the enzyme was heat-
inactivated at 75°C for 10 min and slowly cooled down overnight. The labeled probe was 
cleaned up using Nick Columns (Amersham, Pharmacia) according to the manufacturer’s 
protocol. The incorporated radioactivity of the freshly prepared radiolabeled probe was 
determined using a β-counting device (TRI-CARB 2100 TR, Canberra-Packard). II. Materials and Methods 
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2.2.3.14.3   Binding reaction, analytical gel electrophoresis and signal detection 
 
Binding reactions were performed for 40 min on ice with 10 µg of protein in 20 µl of binding 
buffer containing 4% Ficoll, 20 mM HEPES (pH 7.9), 50 mM KCl, 1 mM EDTA, 1 mM DTT, 
1 mM PMSF, 0.25 mg/ml BSA, 2 µg of poly(dI-dC), and 10,000 - 15,000 cpm of 
32P-labeled 
ds oligonucleotide. For Stat1 Super-Shift analysis nuclear proteins were preincubated for 
40 minutes at room temperature with the monoclonal AB Stat1 9H2 (mouse; Cell Signaling, 
distributed by NEB, Frankfurt a.M.). DNA-protein complexes were separated from unbound 
oligonucleotide by electrophoresis through a 4% polyacrylamid gels using 0.5x TBE buffer. 
 
 
Component volumes (ml) per 36 ml gel 
Solution components   
4% 
 
 
6% 
 
 
8% 
 
H2O 28.3  27  24.1 
Acrylamide mix 
(30%/0.8%) 
5.4 7.2  9.6 
10 x TBE  1.8  1.8  1.8 
APS (10%)  0.4  0.4  0.4 
TEMED 0.3  0.3  0.3 
 
 
Thereafter, gels were fixed and analyzed by PhosphoImager analysis (Fuji). Competition 
experiments were performed by coincubation with a 100-fold excess (20 pmol) of unlabeled 
double-stranded oligonucleotides (GAS1 and wildtype/mutated control oligonucleotides by 
Santa Cruz) in the DNA-protein binding reaction. 
 
 
2.2.3.14.4 Cloning of IL-18BP promoter fragments 
 
Synthesis of the different IL-18BP promoter fragments was carried out by PCR (2.2.3.2) 
using genomic DNA template isolated from DLD-1 cells (DNAZOL, MRC). In order to 
generate artificial restriction sites for directed ligation to the target vector pGL3, mutated 
oligonucleotides (2.1.18.1) were constructed. Forward primer were supplied with a MluI 
site, whereas reverse primer were modified by generating a BglII site. The maximal 
amplificated IL-18BP promoter fragment (pGL3 + IL-18BProm Frag4) contains a genomic 
region of 1114 bp (nucleotides 2405990 ⇒ 2407104, see 2.1.15.3). 
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2.2.4 Biochemical  Methods 
 
2.2.4.1  Preparation of cell lysates 
 
Cells were grown and stimulated as described above (2.2.2.1). For harvesting, cells were 
washed twice with ice-cold PBS. Last traces of PBS were removed by a pipette tip attached 
to a vacuum line. DLD-1 cells were treated with Triton X-100 lysis-buffer (300 mM NaCl, 50 
mM TrisHCl, pH 7.6, 0.5% Triton X-100) supplemented with protease inhibitor cocktail 
(Roche Biochemicals). To remove cellular debris, probes were centrifuged (15,000 g, 20 
min at 4°C). Finally the supernatants were stored at –80°C until use. Protein content was 
determined using the Roth Nanoquant Protein Assay. 
 
 
2.2.4.2  Trichloroacetic acid (TCA) precipitation  
 
This method was used to concentrate proteins from a defined volume of cell culture 
supernatant (without serum!) for Western blot analysis. Cell culture supernatants were 
cleared from cellular contaminations using a single centrifugation step (1000 rpm, 5 min at 
4°C; Heraeus Megafuge 1.0, rotor 7570F). Subsequently, 0.1 volume of 70% trichloroacetic 
acid (TCA) was added to 1 ml of conditioned cell culture supernatant, mixed and incubated 
for 30 min on ice. TCA-precipitated proteins were concentrated by centrifugation (15,000 g, 
30 min, 4°C). The protein pellet was washed with 200 µl of ice-cold acetone, again 
centrifuged for 5 min at 15,000 g and finally resuspended in 1:4 Roti Load1 (Roth). After 
neutralization (1 µl of 1 M Tris/HCl, pH 8.5), the samples were ready to use for Western 
blot analysis. Their protein content was normalized by Ponceau S staining. 
 
 
2.2.4.3  Determination of protein concentration 
 
The amount of protein in cellular lysates was determined using the Roth Nanoquant Protein 
Assay (Bradford method). 50 µl of the samples (1:5 - 1:200 prediluted in Triton X-100 lysis-
buffer) were pipetted in duplicate into appropriate wells of a 96-well ELISA plate. Different 
BSA concentrations (20-100 µg/ml) were used as a standard. 200 µl of Roti Nanoquant 
(Roth, 1:5 diluted in Aquadest) were added to each well. After 10 min of incubation, the 
optical density was measured at a wavelength of 595 nm and reference wavelength 450 
nm using a microplate reader (Bio Rad). The absorption values were calculated using the 
Microplate Manager 4.0 software (Bio Rad). 
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2.2.4.4  Western blot analysis 
 
The Western blot technique represents a sensitive method to detect specific polypeptides 
within a complex mixture of proteins. Proteins are separated electrophoretically and 
transferred to a membrane, which is subsequently incubated with antibodies specific for the 
protein of interest. Finally, the bound antibody is recognized by a second anti-
immunoglobulin that is coupled to horseradish peroxidase or alkaline phosphatase. The 
detection limit of this method ranges between 1-5 ng of an average-sized protein using the 
ECL-Detection Kit  by Amersham Pharmacia (Freiburg). 
 
 
Buffer 
components 
Laemmli buffer 
(4x) 
Electrophoresis buffer 
(1x) 
Transfer buffer 
(1x) 
TBST buffer 
(10x) 
 
Tris/HCl  125 mM (pH 
6.8) 
25 mM  25 mM  100 mM (pH 
8.0) 
SDS  10% (w/v)  0.1% (w/v)  ---  --- 
Glycine  ---  250 mM  192 mM  --- 
Dithiothreitol 50  mM  ---  ---  --- 
Bromophenol 
blue 
0.01% (w/v)  ---  ---  --- 
Glycerol 30%  (v/v)  ---  ---  --- 
Methanol ---  ---  20%  (v/v)  --- 
Tween  20  --- --- ---  5%  (v/v) 
NaCl  --- --- ---  1.5  M 
 
 
2.2.4.4.1  SDS gel electrophoresis 
 
Electrophoretic separation of proteins was carried out in the discontinuous buffer system 
for SDS polyacrylamide gels as originally described by Laemmli [1970]. For detection of 
intracellular proteins 20 - 100 µg of total protein were dissolved in 4x Roti Load1 (Roth). 
However, for detection of TCA precipitated proteins the whole supernatants were used. 
After heating for 5 min at 95°C, samples were loaded onto a mini gel. Subsequently, it was 
run at a current of 20 mA for a period of 1 - 2 hours. 
 
Component volumes (ml) 
per 20 ml gel 
   
Resolving gel:  6% 
(> 120 kDa)
10% 
(60-120kDa)
12% 
(< 60 kDa) 
 
H2O 10.6  7.9  6.6 
Acrylamide mix (30%)  4.0  6.7  8.0 
Tris/HCl (1.5 M, pH 8.8)  5.0  5.0  5.0 
SDS  (10%)  0.2 0.2 0.2 
APS  (10%)  0.2 0.2 0.2 
TEMED  0.016 0.008 0.008 II. Materials and Methods 
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Component volumes (ml) 
per gel volume of 
 
 
 
Stacking gel :  2 ml  5 ml  10 ml 
 
H2O  1.4 3.4 6.8 
Acrylamide mix (30%)  0.33  0.83  1.7 
Tris/HCl (1.5 M, pH 6.8)  0.25  0.63  1.25 
SDS (10%)  0.02  0.05  0.1 
Ammonium persulfate 
(10%) 
0.02 0.05  0.1 
TEMED 0.002  0.005  0.01 
 
 
 
2.2.4.4.2  Transfer to PVDF membrane 
 
After gel electrophoresis, proteins were transferred to a polyvinylidene fluoride (PVDF) 
membrane by electroblotting (Hoefer SemiPhor, Amersham Pharmacia). Prior to use, the 
PVDF membrane was activated in isopropanol for 15 s and subsequently rinsed in 
deionized water for additional 2 min. Three pieces Blotting PAPER (Sigma) were soaked in 
transfer buffer and positioned on the anode side of the transfer apparatus. The PVDF 
membrane was placed directly on the stack of blotting paper. The SDS gel containing the 
separated proteins was taken off the glasplates, rinsed shortly in transfer buffer, and placed 
on the top of the PVDF membrane. Finally, the gel was covered with three additional, 
transfer buffer-soaked Blotting PAPER. Air bubbles were squeezed out by a roller 
apparatus. The upper electrode (cathode) was positioned on the top of the stack and a 
current of 0.8 mA/cm
2 (nearly 60 mA per mini gel) was applied. Transfer of proteins was 
carried out at room temperature and terminated after 75 min. After blotting, the membrane 
was checked by Ponceau S staining for correct electrophoretic transfer and equal loading. 
The successful protein transfer can also controlled by staining the blotted SDS gel with 
Coomassie-Brilliant-Blue (2.5 mg/ml Coomassie-Brilliant-Blue G250, 45% Methanol, 45% 
H2O and 10% acetic acid). 
 
2.2.4.4.3 Immunodetection 
 
After blotting the PVDF membrane was directly shaked in a TBST-buffered non-fat skim 
milk solution (10%) for 1 h at room temperature (or overnight at 4°C) to block non-specific 
binding sites. The membrane was subsequently exposed to primary antibodies (diluted 
1:500 - 1:2000 in 1x TBST buffer) specific for the protein of interest and incubated 
overnight at 4°C. The blot was washed four times for 10 min in 1x TBST. Specific binding of 
primary antibody was detected by incubation of the membrane with a secondary antibody II. Materials and Methods 
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coupled to horseradish peroxidase (diluted 1:10,000 in 1x TBST) for 2 h at room 
temperature. For detection of the corresponding bands, we used the enhanced 
chemiluminescence (ECL) detection kit (Amersham Pharmacia) according to the 
instructions of the manufacturer. The membrane was exposed to a special ECL film 
(Amersham Pharmacia) and developed (Hyperprocessor, Amersham Pharmacia). 
Developed films were scanned (GS 700 Imaging Densitometer, Bio Rad) and analyzed 
using the Molecular Analyst software from Bio Rad. 
 
 
2.2.4.5  Enzyme-linked immunosorbent assay (ELISA) 
 
The enzyme-linked immunosorbent assay (ELISA) technique is the most sensitive method 
to specifically determine protein concentrations from different sources. Sensitivity is 
approximately 100-fold increased compared to the Western blot technique. The ELISA was 
performed according to the instructions of the manufacturers’ (R&D Systems and 
PharMingen). Briefly, microtiter plates were coated with a monoclonal antibody or a specific 
receptor. Equal volumes of samples were pipetted into the wells of the microtiter plate and 
incubated for 2 h. Subsequently, wells were washed. An enzyme-linked antibody specific 
for the target protein was added for additional 2 h. The wells were subsequently washed for 
three times and afterwards incubated with substrate solution. The color reaction develops 
in direct proportion to the amount of bound antigen. The optical densities were calculated 
using the Microplate Manager 4.0 software from Bio Rad. 
 
 
Used ELISAs:  • human IFNγ (PharMingen) 
• human IL-8 (PharMingen) 
• human TGFβ1 (R&D Systems) 
• human TNFα (PharMingen) 
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III 
Results 
___________________________________ 
 
3.1  Expression and release of IL-18BPa in response to IFN-γγγγ  
 
Colon epithelial cells have been identified as a potential source of IL-18. Its expression is 
upregulated not only during the course of Morbus Crohn [Takeuchi et al., 1999; Pizarro et 
al., 1999], but also in other inflammatory diseases such as rheumatoid arthritis [Dinarello et 
al., 1998; Gracie et al., 1999] and psoriasis [Ohta et al., 2001]. Furthermore, IL-18 appears 
to be modulated in colorectal cancer [Pages et al., 1999]. We therefore intended to 
investigate the expression of its natural occuring inhibitor IL-18BPa in different colon 
carcinoma cell lines and organ cultures of colonic intestinal biopsy specimens. Moreover, 
HaCaT keratinocytes as well as synovial fibroblasts isolated from rheumatoid arthritis 
patients were investigated. 
 
3.1.1 IFNγγγγ  induces expression and release of IL-18BPa in the colon 
  carcinoma cell lines DLD-1 and Caco-2, as well as in HaCaT  
 keratinocytes 
 
We recently reported on induction of IL-18BPa gene expression by IFN-γ  in human 
nonleukocytic cells [Mühl et al., 2000]. In the present study we focussed on the colon 
carcinoma/epithelial cell line DLD-1 and sought to extend the abovementioned 
observations by including the level of IL-18BPa protein release and function. IFN-γ -induced 
IL-18BPa mRNA (Fig.1A, lower panel) was paralleled by secretion of the corresponding 
protein as detected by immunoblotting analysis of TCA-precipitated cell culture 
supernatants (Fig. 1A and B). IL-18BPa appeared as IFN-γ -inducible immunoreactivity in 
the expected molecular weight range between 40 kD and 50 kD [Novick et al., 1999; Kim et 
al., 2000]. This heterogeneity in the molecular weight agrees with a high degree of 
glycosylation as has been reported (Novick et al., 1999). Strong immunoreactivity was 
observed when human IL-18BPa was transiently expressed in DLD-1 cells (Fig. 2A). In 
contrast, control transfection with empty vector did not result in any immunoreactivity (data 
not shown). IL-18BPa immunoreactivity induced by IFN-γ  consisted of two major bands. 
This was particularly evident when lower amounts of proteins were separated on a 12% 
SDS-PAGE (Fig. 1A, Fig. 2B: lane 2). The doublet was also observed when lower amounts 
of IL-18BPa transiently expressed in DLD-1 cells were subjected to SDS-PAGE (data not III. Results 
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shown). Addition of immunizing peptide to the antiserum impaired immunodetection of IL-
18BPa (Fig. 2C). No immunoreactivity was detectable when preimmune serum was used 
(data not shown). To exclude that effects of IFNγ  were due to endotoxin which is heat 
stable, IFNγ  was heat-inactivated by boiling (99 
oC, 30 minutes) before use. 
Immunoreactivity disappeared after heat-inactivation of IFNγ  ( Fig. 2D). In addition, LPS (10 
µ g/ml) did not induce IL-18BPa in DLD-1 cells (data not shown). IL-18BP is synthesized 
with a 28 residue signal peptide and is supposed to be secreted via the endoplasmatic 
reticulum/Golgi pathway [Novick et al., 1999]. Accordingly, Brefeldin A abrogated release of 
IL-18BPa (Fig. 2E). However, despite readily detectable immunoreactivity of IL-18BPa in 
supernatants of IFN-γ -treated cells, we could not demonstrate intracellular IL-18BPa by 
immunoblotting when whole cell lysates were analyzed from IFNγ -treated cells (Fig. 2F) or 
from cells treated with IFN-γ /Bref A (data not shown). This discrepancy between cell lysates 
and TCA-precipitated supernatants is likely to be due to the huge enrichment factor 
immanent to the method of TCA precipitation. 
 
 
 
Figure 1.  Time course and dose-
response analysis of IFN-γγγγ -in-
duced IL-18BPa. 
 
(A) DLD-1 cells were kept as 
controls or stimulated with IFN-γ  (20 
ng/ml) for the indicated time periods. 
TCA-precipitated supernatants were 
analyzed by immunoblotting. Lower 
panel: IL-18BPa mRNA was 
evaluated by RT-PCR in these same 
experiments. One representative of 
four independently performed 
experiments is shown. 
 
 
 
 
 
 
 
 
 
(B) DLD-1 cells were kept as 
controls or stimulated for 24h with 
the indicated concentrations of IFN-
γ.  TCA-precipitated supernatants 
were analyzed by immunoblotting. 
Membranes were stained by 
Ponceau S (A&B). 
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Figure 2.  IL-18BPa immunoreactivity as 
detected using a polyclonal antiserum. 
 
(A) DLD-1 cells were transiently transfected with 
pORF-hil18bpa. TCA-precipitated supernatants of 
IFN-γ -stimulated (20 ng/ml) cells were run in 
parallel. 
(B) DLD-1 cells were stimulated with IFNγ  (50 
ng/ml) for the indicated times periods. TCA-
precipitated supernatants were analyzed by 
immunoblotting. Arrows indicate IL-18BPa 
immunoreactivity (second lane). 
(C) DLD-1 cells were kept as controls or stimulated 
with IFN-γ  (20 ng/ml) for 24h. TCA-precipitated 
supernatants were analyzed by immunoblotting.   
One half of the blot was stained with IL-18BPa 
antiserum, the other with IL-18BPa antiserum plus 
immunizing peptide (2.5 µ g/ml). 
(D) DLD-1 cells were kept as controls, stimulated 
with IFN-γ  (20 ng/ml), or with IFN-γ  (20 ng/ml) 
which had been inactivated by boiling. After 42h, 
TCA-precipitated supernatants were analyzed by 
immunoblotting. 
(E) DLD-1 cells were kept as controls, stimulated 
with IFN-γ  (20 ng/ml) alone, with Bref A (1 µ g/ml), 
or with IFN-γ  (20 ng/ml)/Bref A (1 µ g/ml). After 24h, 
TCA-precipitated supernatants were analyzed by 
immunoblotting. Similar results were obtained 
using Bref A at 0.25 µ g/ml (data not shown). 
(F) DLD-1 cells were kept as controls or stimulated 
with IFN-γ  (20 ng/ml) for 24h. TCA-precipitated 
supernatant proteins and whole cell lysates were 
prepared and analyzed by immunoblotting. 
(G) DLD-1 cells were kept as controls, stimulated 
with IFN-γ  (20 ng/ml), or exposed to okadaic acid 
(OA) (50 nM) for 68h. TCA-precipitated 
supernatants were analyzed by immunoblotting. 
Cell viability was determined in these same 
experiments by LDH activity analysis. 
 
 
 
 
There was no induction of cytotoxicity in IFN-γ -treated cultures as examined by 
determination of LDH activity in culture supernatants: viability was 98.3 ±  0.4% versus 97.5 
±  0.4% for control versus IFNγ -treated cells (20 ng/ml, 42h, n = 3). Ponceau S staining of 
membranes after blotting revealed no differences in the total amounts of proteins loaded 
onto the gels (Fig. 1A and B). Moreover, induction of cell death by okadaic acid did not 
result in release of immunoreactivity, despite a 36.7% loss of cell viability (Fig. 2G). 
Altogether, these observations argue against IFN-γ -induced cytotoxicity with passive 
release of cellular proteins as the driving force behind IL-18BPa immunoreactivity in TCA-
precipitated supernatants. 
To investigate whether IFNγ -induced secretion of IL-18BPa is restricted to DLD-1 cells or is 
of more general relevance, experiments were performed using additional colon 
carcinoma/epithelial cell lines. As shown in Fig. 3, IFN-γ -induced IL-18BPa mRNA 
accumulation (A and B, left panel) was associated with secreted IL-18BPa 
immunoreactivity (A and B, right panel) in the respective culture supernatants of LoVo (A) III. Results 
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and Caco-2 (B) colon carcinoma cells. Similar data were obtained using HCT116 colon 
carcinoma cells (data not shown). We also investigated the keratinocyte cell line HaCaT 
(Fig. 3C). Induction of IL-18BPa mRNA (left panel) was paralleled by appearance of IL-
18BPa in IFN-γ -conditioned culture supernatants (right panel). 
 
 
 
Figure 3. IFN-γγγγ -induced IL-18BPa 
in LoVo and Caco-2 colon 
carcinoma cells, as well as in 
HaCaT keratinocytes. 
 
LoVo cells (A), Caco-2 cells (B), or 
HaCaT keratinocytes (C) were kept 
as unstimulated controls or 
incubated with IFN-γ  (20 ng/ml). 
After 24h, IL-18BPa mRNA was 
evaluated by RT-PCR (left panel) 
and TCA-precipitated supernatants 
were analyzed by immunoblotting 
(right panel). One representative of 
two independently performed 
experiments is shown for each cell 
line. 
 
 
 
3.1.2  Sodium butyrate inhibits IFN-γγγγ -induced IL-18BPa 
  in colon carcinoma  cell lines cell lines 
 
Butyrate is a short-chain fatty acid that is produced by intestinal bacteria and is supposed 
to be an important regulator of colonic epithelial cell biology [Wächtersheimer and Stein, 
2000]. Sodium butyrate (B) at 5 mM efficiently suppressed IFN-γ -induced IL-18BPa protein 
release as well as mRNA induction (Fig. 4A and B). It is important to take into account that 
peak concentrations of butyrate in the colon can reach 20 mM [Wächtersheimer and Stein, 
2000]. Sodium butyrate alone did not change background expression of IL-18BPa. 
Biological activity of IL-18 is supposed to be determined by local concentrations of IL-18 
versus IL-18BP. Therefore, we determined the effect of sodium butyrate on expression of 
IL-18 in these same experiments. Notably, sodium butyrate (5 mM) did not change IL-18 III. Results 
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expression in DLD-1 cells exposed to IFN-γ  (Fig. 4C). Sodium butyrate is supposed to 
trigger apoptosis in colon carcinoma cells [Wächtersheimer and Stein, 2000]. Thus, cell 
viability was determined in these experiments. Sodium butyrate at 5 mM alone or in 
combination with IFN-γ  did not modulate cell viability in DLD-1 cells during a 24h incubation 
period (Fig. 4D). In contrast, cell death was detectable when DLD-1 cells were incubated 
for 48h with sodium butyrate at 25 mM. Again, cell death was not associated with 
appearence of IL-18BPa immunoreactivity in these supernatants. Inhibition of IFN-γ -
induced IL-18BPa expression by sodium butyrate was also observed in the colon 
carcinoma cell lines HCT116 (Fig. 4E), LoVo, and Caco-2 (data not shown). 
 
 
Figure 4.     Sodium butyrate suppresses IFN-γγγγ -induced 
                    IL-18BPa expression, but not expression of IL-18.  
 
DLD-1 cells were kept as controls, stimulated with sodium butyrate (B) (5 mM), with IFN-γ  (20 ng/ml), or with IFN-γ  
(20 ng/ml) plus the indicated concentrations of sodium butyrate. After 24h, TCA-precipitated supernatants were 
analyzed by immunoblotting (A) and IL-18BPa mRNA was evaluated by RNase protection assay (B). One 
representative of three independently performed experiments is shown. (C) DLD-1 cells were kept as control, 
stimulated with IFN-γ  (20 ng/ml), with sodium butyrate (5 mM), or with IFNγ  (20 ng/ml)/sodium butyrate (5 mM). 
After 24h, cell-lysates were analyzed for IL-18 by immunoblotting. IL-18 mRNA expression was evaluated by 
RNase protection assay. One representative of three independently performed experiments is shown. (D) In these 
experiments viability was determined by LDH activity analysis. % viability ± SD is shown (n = 3). (E) HCT116 colon 
carcinoma cells were kept as unstimulated control, or stimulated with IFN-γ  (20 ng/ml), with sodium butyrate (5 
mM), or with the combination IFN-γ  plus sodium butyrate. After 24h, IL-18BPa mRNA expression was evaluated 
by RT-PCR. One representative of two independently performed experiments is shown.  III. Results 
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3.1.3 IFNγγγγ -stimulated DLD-1 cells release an activity which 
 impairs  IFN-γγγγ  production by IL-12/IL-18-stimulated PBMC 
 
As shown in Fig. 5A2, compared to conditioned media obtained from unstimulated cells, 
conditioned media from IFN-γ -stimulated DLD-1 cells impaired production of IFN-γ  in PBMC 
exposed to IL-12/IL-18. To confirm that IL-18BPa is actually detectable in these conditioned 
media, immunoblot analysis was performed. As shown in Fig. 5B, a 14 h stimulation with 
IFN-γ  was sufficient to trigger detectable release of IL-18BPa during an additional 48 h 
incubation period in control medium. Notably, in these DLD-1 cells augmented levels of IL-
18BPa mRNA were still detectable after this 48 h incubation in control medium. This is 
consistant with a long half-life (> 8 h) of IFN-γ -induced IL-18BPa mRNA in DLD-1 cells as 
detected in actinomycin D experiments (data not shown). We also investigated effects of 
sodium butyrate using this experimental protocol. However, conditioned media from DLD-1 
cells stimulated with sodium butyrate alone significantly reduced later IFN-γ  production of 
IL-12/IL-18-activated PBMC by 60.1 ± 12.4 % (n = 3, p < 0.05). This indirect inhibitory 
effect of sodium butyrate interfered with efficient recovery of IL-12/IL-18-induced IFN-γ  in 
PBMC by use of conditioned media from DLD-1 cells exposed to the combination IFN-γ  
plus sodium butyrate (data not shown).  
 
 
Figure 5.         IFN-γγγγ -stimulated DLD-1 cells release an activity which 
                        impairs IFN-γγγγ  production by IL-12/IL-18-stimulated PBMC. 
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IFNγγγγ
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IL-12 IL-18
IFNγγγγ      −−−− ELISA
14 h IFNγ or control DMEM 48 h control DMEM
Conditioned medium
used to resuspend PBMC
Incubation for 24 h with
3 x PBS wash
DLD-1 cells
IFNγγγγ
DLD-1 cells
IL-18BP release in the supernatant
PBMC
IL-12 IL-18
IFNγγγγ      −−−− ELISA
 
 
(A1)  Scheme of experimental design: Control conditioned and IFN-γ -conditioned media from DLD-1 cell 
cultures (generated as outlined in the materials and methods section) were used to resuspend control PBMC 
and IL-12 (20 ng/ml)/IL-18 (20 ng/ml)-stimulated PBMC, respectively. After a 24 h incubation period, IFN-γ  
production was determined by ELISA. 
 III. Results 
 
  54
 
 
 
 
 
(A2) Data are mean ± SEM (n 
= 3); **p < 0.01 versus use of 
conditioned media from IFN-γ -
treated DLD-1 cells. 
 
H2O
B
C     IFNγ
IL-18
BPa
IL-18BPa
mRNA
GAPDH
mRNA
C     IFNγ
45kD-
66kD-
97kD-
 
 
(B) Control conditioned and 
IFN-γ -conditioned media from 
DLD-1 cell cultures (generated 
as outlined in the materials and 
methods section) were TCA-
precipitated and analyzed for 
IL-18BPa expression by 
immunoblotting. IL-18BPa 
mRNA of this same experiment 
was evaluated by RT-PCR 
analysis. 
 
 
 
 
3.1.4 IFN-γγγγ  mediates gene expression of IL-18BPa in organ 
  cultures of colonic intestinal biopsy specimens 
 
Colonic intestinal biopsy specimens obtained from five different donors were cultivated as 
unstimulated control, or exposed to either IFN-γ  alone, or the combination IFN-γ /sodium 
butyrate.  Upregulation of IL-18BPa mRNA by IFN-γ  was observed after an 8 h incubation 
period (Fig. 6). Transcripts remained elevated for at least another 15 h of stimulation (data 
not shown). In accord with data obtained using colon carcinoma cell lines, sodium butyrate 
suppressed IFN-γ -induced IL-18BPa expression in all organ culture experiments performed 
(n = 5). In contrast, expression of IL-18 mRNA in these same IFN-γ -treated organ cultures 
was not modulated by coincubation with sodium butyrate (Fig. 6). 
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Figure 6. Induction of IL-18BPa by IFN-γ  
in cultures of colonic biopsy specimens: 
modulation by sodium butyrate. 
 
Cultures of colonic biopsy specimens 
from five different donors were kept as 
unstimulated control, or stimulated with 
IFN-γ  (40 ng/ml) alone, or in combination 
with sodium butyrate (B) (10 mM) for 
different time periods (8h, 16h, 22h). 
Thereafter, IL-18BPa and IL-18 mRNA 
expression was evaluated by RT-PCR. 
No differences dependent on the duration 
of stimulation (8h, 16h, 22h incubation) 
were observed. One representative 
experiment is shown (8h stimulation). 
 
 
 
 
 
3.1.5 IFN-γγγγ  induces expression of IL-18 binding protein 
  in fibroblast-like synoviocytes 
 
3.1.5.1  Detection of IL-18BPa by immunoblotting 
 
IFN-γ  induces IL-18BPa mRNA expression in rheumatoid arthritis fibroblast-like 
synoviocytes (RA-FLS). This induction was paralleled by secretion of the corresponding 
protein as detected by immunoblotting analysis of TCA-precipitated cell culture 
supernatants (Fig. 7A). Immunoreactivity appeared with a molecular mass of about 45 kDa, 
which is in keeping with previous reports (Kim et al., 2000).  
 
 
3.1.5.2 IFN-γγγγ  production by IL12/IL-18-stimulated PBMC 
  cultivated in RA-FLS-derived conditioned medium 
 
To investigate whether conditioned media from IFN-γ -stimulated RA-FLS may contain IL-
18BPa activity, RA-FLS were kept as control or stimulated with IFN-γ  (20 ng/ml, 16 h). 
These conditioned media were used to resuspend control PBMC and IL-12/IL-18 
stimulated PBMC, respectivley. After a 24 h incubation period, IFN-γ  production was 
determined by ELISA. Compared to conditioned media obtained from unstimulated cells 
conditioned media from IFN-γ -stimulated RA-FLS showed reduced production of IFN-γ  in 
PBMC exposed to IL-12/IL-18 (Fig. 7B). 
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Figure 7.  IFN-γγγγ  mediates 
release of IL-18BPa from 
FLS. 
 
(A) RA-FLS cultures from 
RA patients were kept as 
unstimulated controls or 
stimulated with IFN-γ  (5 
ng/ml). After 48 h, secreted 
IL-18BPa was detected by 
immunoblotting. 
Representative results from 
RA-FLS cultures of two 
patients are shown. The 
right figure shows over-
expressed and TCA precipi-
tated IL-18BPa as positiv 
detection control. 
 
 
 
 
 
 
 
(B) Control- and IFN-γ -
conditioned media from RA-FLS 
were used to resuspend control 
or IL-12/IL-18-PBMC cultures 
(compare method section 
2.2.2.5). IFN-γ  production was 
determined after 24 h by ELISA. 
Data are expressed (as % of 
IFN-γ  production  ±  SEM) by 
IL12/IL-18-stimulated PBMC re-
suspended in control con-
ditioned RA-FLS medium (n=4). 
 
3.2 Cell-to-cell crosscommunication during TH1 responses 
mediates coordinated expression of modulatory IL-18 
binding protein and inducible NO synthase in adjacent 
local resident cells 
 
IL-18, IL-18 binding protein (IL-18BP), and inducible nitric oxide synthase (iNOS) are 
parameters that mediate important functions in the context of inflammation, infection, and 
cancer. Here we performed coculture studies in order to simulate a TH1 response. In this 
experimental set up we investigated IL-18BP and iNOS gene induction in human DLD-1 
colon carcinoma/epithelial cells cocultured with IL-12/IL-18-activated PBMC (Fig. 8). III. Results 
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Figure 8.    Schematic representation of the indirect transwell-coculture system. 
 
 
 
 
3.2.1  Induction of IL-18BPa in DLD-1 cells cocultured with PBMC 
 
Recently, we reported that stimulation of DLD-1 cells with exogenous IFN-γ  mediates 
expression and release of IL-18BPa. Induction of IL-18BPa correlated with release of an 
activity from DLD-1 cells that impaired IL-12/IL-18-induced release of IFN-γ  from PBMC 
[Mühl  et al., 2000; Paulukat et al., 2001]. That observation appears to be of general 
relevance as this regulatory pathway has been observed in various different cell types. In 
the present study, we investigated whether IL-12/IL-18 can induce IL-18BPa in DLD-1 cells 
in our transwell-coculture system. In contrast to IFN-γ , IL-12/IL-18 were unable to stimulate 
expression of IL-18BPa in DLD-1 cells directly (Fig. 9A). However, in parallel to iNOS and 
production of IFN-γ , IL-18BPa was induced by IL-12/IL-18 in DLD-1 cells cocultured with 
PBMC. Again in accord with data on iNOS, use of neutralizing antibodies revealed that 
production of IFN-γ  by PBMC was a prerequisite for expression of IL-18BPa (Fig. 9B). IL-
18BPa mRNA accumulation in DLD-1 cells was associated with appearance of IFN-γ -
inducible IL-18BPa immunoreactivity as detected by immunoblot analysis of TCA-
precipitated coculture supernatants (Fig. 9C). We also compared inducibility of IL-18BPa 
expression by IFNγ  in PBMC and DLD-1 cells using quantitative real-time PCR. As shown 
in Fig. 10, IL-18BPa mRNA was inducible by IFN-γ  in PBMC. However, induction was far 
more pronounced in DLD-1 cells compared to PBMC (21 ± 5.5 versus 3.3 ± 1.1 fold 
induction relative to GAPDH and compared to unstimulated control). A 21-fold induction in 
DLD-1 cells is in keeping with previous data on IFN-γ -induced IL-18BPa in these cells as 
detected by RNAse protection assay [Mühl et al., 2000]. III. Results 
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Figure 9.  IL-12/IL-18 mediate IFN-γγγγ -dependent induction of IL-18BPa in DLD-1 cells   
cocultured with PBMC. (A) DLD-1 cells were stimulated with IL-12 (20 ng/ml)/IL-18(50 ng/ml) or with IFN-γ  
(20 ng/ml) for 24h. Thereafter, mRNA expression of IL-18BPa was investigated by RT-PCR. One representative 
of three independently performed experiments is shown. (B) Indirect cocultures (transwell-assay) were kept as 
unstimulated controls or stimulated with IL-12 (25 ng/ml)/IL-18 (80 ng/ml) in the presence or absence of anti-
IFN-γ  antibody (20 µ g/ml) or control IgG (20 µ g/ml). After 45h, DLD-1 cells were lysed and iNOS mRNA 
expression was analyzed by RT-PCR. One representative RT-PCR of two independently performed 
experiments is shown. (C) Indirect cocultures (transwell-assay) were kept as unstimulated controls or 
stimulated with IL-12 (20 ng/ml)/IL-18 (100 ng/ml) for 60h. Thereafter, TCA-precipitated supernatants were 
evaluated for IL-18BPa content by immunoblotting analysis. One representative of three independently 
performed blots is shown. 
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Figure 10.  IFN-γγγγ -induced IL-
18BPa in PBMC and DLD-1 cells 
as detected by quantitative real-
time PCR. 
 
PBMC or DLD-1 cells were kept as 
unstimulated control or stimulated with 
IFN-γ  (20 ng/ml). After 21 h cells were 
harvested and total RNA was isolated. 
Expression of IL-18BPa transcripts 
was assessed by quantitativ real-time 
PCR. Data are expressed relative to 
GAPDH and as fold-induction ±  SEM 
compared to unstimulated control (n = 
3). 
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3.2.2  Induction of iNOS in DLD-1 cells cocultured with PBMC 
 
In accord with previous data [Salzman et al., 1996], we confirm that activated DLD-1 cells 
express iNOS. Immunoblotting analysis (Fig. 11A) and RT-PCR (Fig. 11B) analysis 
revealed that IFN-γ  alone is sufficient to trigger iNOS induction. Coincubation with IL-
1β /IFN-γ  resulted in a marked synergistic effect (Fig. 11A). We next sought to investigate a 
possible role for IL-18 in iNOS expression in DLD-1 cells. As IL-12 usually enhances 
actions of IL-18 [Dinarello et al., 1998; Nakanishi et al., 2001], we chose to incubate DLD-1 
cells with the combination of both cytokines. IL-12/IL-18 did not result in upregulation of 
iNOS, neither on the level of mRNA (Fig. 11B), nor on the level of protein (Fig. 11C and 
Fig. 12A). As expected, exposure to IL-12/IL-18 did not induce secretion of IFN-γ  from 
DLD-1 cells (data not shown).  
 
 
 
Figure 11.  IFN-γγγγ , but not IL-12/IL-18 mediates induction of iNOS in DLD-1 cells. (A) Confluent 
DLD-1 cells were stimulated for 48h with IL-1β  (50 ng/ml), IFNγ  (20 ng/ml), with IL-1β  (50 ng/ml) plus IFN-γ  (20 
ng/ml), or as unstimulated control.  Thereafter, iNOS protein expression was investigated by immunoblot-
analysis. One representative of two independently performed experiments is shown. (B) Confluent DLD-1 cells 
were stimulated for 24h with IL-12 (25 ng/ml) plus IL-18 (80 ng/ml), with the indicated concentrations of IFN-γ , 
or kept as unstimulated control. Thereafter, iNOS mRNA expression was evaluated by RT-PCR. (C) Confluent 
DLD-1 cells were stimulated with IL-12 (25 ng/ml) plus IL-18 (80 ng/ml), with IL-1β  (50 ng/ml) plus IFN-γ  (20 ng 
/ml), or as unstimulated control. After 48h, iNOS protein expression was investigated by immunoblot-analysis. 
One representative of three independently performed experiments are shown. 
 
 
We first performed direct cocultures of PBMC and DLD-1 cells (Fig. 12A). Absence of iNOS 
in untreated controls revealed that cell-cell contact between PBMC and DLD-1 colon 
carcinoma cells was not sufficient to trigger induction of iNOS. Consistent with induction of 
IFN-γ  in IL-12/IL-18-activated PBMC, stimulation of cocultures with IL-12/IL-18 resulted in 
release of IFN-γ  from PBMC in all direct coculture experiments performed (n = 3). In all 
cases, this induction of IFN-γ  was accompanied with expression of iNOS in the adherent 
cells (Fig. 12A). Although DLD-1 cells were carefully washed twice with PBS before cell 
lysis was performed, we could not rule out the possibility that adherent mononuclear cells 
might have contributed to iNOS expression under these conditions. Therefore, we III. Results 
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performed indirect cocultures with transwell inserts (Costar) (Fig. 8). Using this method 
iNOS gene induction was analyzed specifically in DLD-1 cells exposed to secretory 
products of PBMC. In all donors/cocultures (transwell-assay) investigated (n = 5), addition 
of IL-12/IL-18 again resulted in release of IFN-γ . This was always paralleled by mRNA (Fig. 
12B) and protein expression (Fig. 12C) of iNOS in DLD-1 cells (n = 5). To investigate the 
role of endogenous IFN-γ  in this process, a neutralizing antibody for IFN-γ  was used. As 
shown in Fig. 12B and Fig. 12C, coincubation of IL-12/IL-18 with this antibody markedly 
reduced induction of iNOS mRNA and protein. 
 
 
 
Figure 12. IL-12/IL-18 mediate IFN-γγγγ -
dependent induction of iNOS in DLD-1 cells 
cocultured with PBMC. 
 
(A) Direct cocultures were stimulated with IL-12 (25 
ng/ml)/IL-18 (80 ng/ml) or kept as unstimulated 
controls. In these same experiments DLD-1 cells were 
also stimulated in the absence of PBMC with IL-12 (25 
ng/ml)/IL-18 (80 ng/ml) or kept as unstimulated control.  
After 45h, adherent cells were lysed for immunoblot 
analysis. One representative of three independently 
performed experiments is shown. Cell-free 
supernatants were assayed for IFN-γ  content by 
ELISA. IFN-γ  levels which correspond to the 
immunoblot shown are given as absolute 
concentrations. 
(B)  Indirect cocultures (transwell-assay) were kept 
as unstimulated controls or stimulated with IL-12 (25 
ng/ml)/IL-18 (80 ng/ml) in the presence or absence of 
anti-IFN-γ  antibody (20 µ g/ml) or control IgG (20 
µ g/ml). After 45h, DLD-1 cells were lysed and iNOS 
mRNA expression was analyzed by RT-PCR. Five 
independent coculture experiments were performed 
that all demonstrate strong IL-12/IL-18-mediated iNOS 
mRNA induction. One representative RT-PCR of two 
independently performed experiments using 
neutralizing antibodies is shown. IFN-γ  levels in cell-
free culture supernatants corresponding to the RT-
PCR experiment displayed are given as absolute 
concentrations. 
 
(C)  Indirect cocultures (transwell-assay) were kept 
as unstimulated controls or stimulated with IL-12 (10 
ng/ml)/IL-18 (20 ng/ml) in the presence or absence of 
anti-IFN-γ  antibody (20 µ g/ml) or control IgG (20 
µ g/ml). After 45h, iNOS expression in DLD-1 cells was 
analyzed by immunoblot-analysis. Five independent 
coculture experiments were performed that 
demonstrate strong IL-12/IL-18-induced iNOS protein 
induction. One representative immunoblot of two 
independently performed experiments using 
neutralizing antibodies is shown. IFN-γ  levels in cell-
free culture supernatants corresponding to the 
immunoblot displayed are given as absolute 
concentrations; nd, denotes non detectable (IFN-γ  < 
32.5 pg/ml). 
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3.3  IL-18 binding protein promoter function 
 
IFN-γ  has been described as potent inducer of IL-18BPa expression on protein and mRNA 
level in different colon carcinoma cell lines, organ cultures of colonic intestinal biopsy 
specimens, HaCaT keratinocytes as well as rheumatoid arthritis fibroblast-like synoviocytes 
(RA-FLS) [Mühl et al., 2000; Paulukat et al.,  2001; Möller et al., 2003]. We therefore 
decided to investigate the IL-18BP promoter function. A recent report defined the 
transcription start site of IL-18BPa [Hurgin et al., 2002]. In the upstream area of this 
determined transcriptional starting point we found different putative sites which might be 
responsible for IFN-γ  mediated IL-18BPa induction as shown in figure 13.  
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Figure 13. Putative IFN-γγγγ  responsive sites responsible for IL-18BPa induction. Different IFN-γ  
responsive sites upstream of the transcription start site are shown. γγγγ -IRE: γ -Interferon responsive element 
ISRE: IFN-stimulated response element GAS: Gamma-activated site. The transcription start has been defined 
to position 785 of the genomic IL-18BP DNA sequence (Gen Bank accession no. AF110798). 
 
 
 
3.3.1  Induction of IL-18BP promoter luciferase constructs by IFN-γγγγ   
 
To further characterize the promoter function in DLD-1 cells, we constructed a luciferase 
reporter vector containing up to 1104 bp (Fig. 14A) corresponding to the DNA sequence 
upstream of base -1. In addition, we generated another luciferase reporter vector that has 
been deleted in the upstream area by 469 bp (Fig. 14B). Subsequently the mechanism of 
IL-18BP gene induction by IFN-γ  has been investigated using the described luciferase 
constructs (Fig. 14). After transfection of human DLD-1 cells with fragment 4 (pGL3 + IL-
18BProm Frag4; Fig. 14A), IFN-γ  stimulation for 6 h increased the luciferase activity by 
15.8 - fold over the unstimulated control (15.8 ±  6.4, Fig. 15). This demonstrates the 
presence of IFN-γ  responsive sites in the investigated fragment, which might be necessary 
for IL-18BP promoter induction. Furthermore we measured the second generated 
luciferase reporter vector fragment 5 (pGL3 + IL-18BProm Frag5; Fig. 14B), which was 
inducible after 6 h IFN-γ  stimulation 23.2-fold over the unstimulated control (23.2 ±  5.8, Fig. III. Results 
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15). Fragment 5 shows higher luciferase activities compared to fragment 4 (Fig. 15) This 
observation might be due to one or more silencer elements located upstream of fragment 5 
which are being part of fragment 4. 
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Figure 14. IL-18BP luciferase reporter constructs generated for promoter analysis. (A) 
Fragment 4 (pGL3 + IL-18BProm Frag4) consists of 1138 bp. Upstream of the transcription start site (TSS) this 
construct contains -1104 bp. (B) The smaller fragment 5 consists of 645 bp. Its region upstream of the TSS 
contains -635 bp. Both fragments include IFN-γ  responsive sites. Compared to fragment 4, fragment 5 lacks an 
upstream γ -IRE site. 
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Figure 15. Luciferase activity of IL-18BP promoter reporter vectors. After transfection of DLD-1 
cells and an additional 42 h incubation period, the cells were stimulated with IFN-γ  (20 ng/ml) for 6 h or kept as 
unstimulated controls. For internal transfection control ß-Gal plasmids were co-transfected. IFN-γ -induced IL-
18BP promoter luciferase activity is shown normalized to β -Gal counts with control conditions set to 1 (Frag4 
n=12, Frag5 n=9; data are expressed as fold induction ±  SD). III. Results 
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3.3.2  Mutagenesis of putative IFN-γγγγ -inducible GAS site 
 
In order to define sites responsible for IFN-γ -mediated induction of IL-18BP 
promoter we mutated the GAS site closely located to the transcription start site. 
Two different mutations (mutGAS 5’/mutGAS 3’) have been synthesized by PCR 
with two complementary mutated primers using fragment 4 (pGL3 + IL18BProm 
Frag4) and fragment 5 (pGL3 + IL18BProm Frag5) as templates. Subsequently, the 
bacteria-derived methylated templates were decomposed by DpnI, whereas the 
newly synthesized PCR products have been transformed into competent E.coli 
strain DH5α . Finally, endotoxinfree preparations of pGL3 + mutGAS 5’/3’ Frag4 and 
pGL3 + mutGAS 5’/3’ Frag5 respectively were transfected into DLD-1 cells to 
investigate responsiveness of the mutated GAS sites toward IFN-γ -stimulation by 
performing luciferase assays. 
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Figure 16. 5’/3’-mutagenesis of GAS site proximal to transcription start site. The two different 
GAS-mutations have been synthesized by PCR using mutated complementary primers and pGL3+IL18BProm 
Frag4/Frag5 (wildtype controls) as template. These modified IL18BP promoter constructs were used for 
transfection and subsequent luciferase assay. 
 
After 6 h IFN-γ  stimulation promoter activity of GAS-mutated fragment 4 (mutGAS 5’/3’) and 
fragment 5 (mutGAS 5’/3’) was decreased compared to non-mutated control. Whereas the 
mutated constructs of fragment 4 (mutGAS 5’: 6.1 ±  1.7 /mutGAS 3’: 6.9 ±  2.6) only show 
half of its wildtype activity (WT Frag4: 13.9 ±  5.8) in luciferase assay, mutated fragment 5-
derived (mutGAS 5’: 7.2 ±  1.6 /mutGAS 3’: 7.2 ±  0.9) promoter activity was decreased by 
71.9 % compared to fragment 5 control (WT Frag5: 25.6 ±  4.5). III. Results 
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According to our observations this mutated GAS site appears to be relevant for IFN-γ -
mediated induction of the IL-18BP promoter as investigated by use of luciferase constructs 
including fragments 4 and 5. 
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Figure 17. Luciferase activity of 5’/3’-GAS-mutated IL-18BP promoter fragment 4 (A) and 
fragment 5 (B). After transfection of DLD-1 cells and an additional 42 h incubation period, the cells were 
stimulated with IFN-γ  (20 ng/ml) for 6 h or kept as unstimulated controls. For internal transfection control ß-Gal 
plasmids were co-transfected. IFN-γ -induced IL-18BP promoter luciferase activity is shown normalized to β -Gal 
counts with control conditions set to 1 (mutGAS 5’/3’ Frag4/5 n=3; data are expressed as fold induction ±  SD). III. Results 
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3.3.3  STAT-1 binding to GAS site following IFN-γγγγ  stimulation 
 
Next we used EMSA to identify protein/ds-DNA interaction at the GAS site proximal to the 
transcription start site within the IL-18BP promoter. Labeled double-stranded DNA probes 
(oligo GAS1) corresponding to bases -18 to -41 (containing GAS) were allowed to bind with 
nuclear extracts of control and IFN-γ -treated DLD-1 cells. A complex of the GAS-containing 
probe and nuclear protein(s) was apparent after incubation of cells for 0.5 h or 2 h with IFN-
γ  (Fig. 18A lane 2 and 18B lane 8). In contrast, no such complex was obtained with extracts 
of untreated control cells (Fig. 18A lane 1 and 18B lane 7). A 10-fold excess of cold oligo 
GAS1 competed with the labeled dsDNA-probe. Thus, no shift was detectable (Fig. 18A 
lane 3 and 18B lane 8). The binding of nuclear proteins to the radioactive ds-
oligonucleotide GAS1 was also abolished by using 10-fold excess of an unlabeled wildtype 
dsDNA probe purchased from Santa Cruz that is known to be specific for GAS (Fig. 18A 
lane 5 and 18B lane 11). In contrast, the mutated version of this Santa Cruz WT dsDNA 
probe, namely Mut Santa Cruz, did not affect nuclear protein binding to the labeled GAS 
containing dsDNA-probe (Fig. 18A lane 4 and 18B lane 10). Finally, addition of a 
monoclonal antibody against STAT-1 caused a “supershift”, which is due to antibody 
binding to the complex of labeled dsDNA probe interacting with STAT-1, that had been 
induced by IFN-γ  (Fig. 18A lane 6 and 18B lane 12). 
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Figure 18. EMSA and ´supershift´ 
analysis after IFN-γγγγ  stimulation of DLD-
1 cells. 
 
 
 
 
(A)  EMSA following 0.5 h IFN-γγγγ  
stimulation. DLD-1 cells were 
stimluted with IFN-γ  (20 ng/ml) for 0.5 
h or kept as unstimulated control. 
Where indicated, the nuclear extracts 
were shifted with the given ds DNA 
probe (lane 2 and 4) respectively 
supershifted with the specified 
antibody (lane 6). Additionally, in lane 
3 and 5 cold ds oligonucleotides have 
been used in 10-fold excess to 
compete for nuclear extract protein 
binding. Arrows indicate shifts and 
supershifts, respectively. 
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B) EMSA following 2 h IFN-γγγγ  stimulation. 
DLD-1 cells were stimluted with IFN-γ  (20 
ng/ml) for 2 h or kept as unstimulated control. 
Where indicated, the nuclear extracts were 
shifted with the given ds DNA probe (lane 8 
and 10) respectively supershifted with the 
specified antibody (lane 12). Additionally, in 
lane 9 and 11 cold ds oligonucleotides have 
been used in 10-fold excess to compete for 
nuclear extract protein binding. Arrows indicate 
shifts and supershifts, respectively. 
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IV 
Discussion 
___________________________________ 
 
4.1  Expression and release of IL-18BPa in response to IFN-γ γ γ γ 
 
IL-18 is a pivotal mediator of a TH1 cytokine response [Nakamura et al. 1989] and its 
naturally occuring inhibitor IL-18 binding protein (IL-18BP) [Novick et al. 1999] are two 
newly described opponents in the cytokine network. Local concentrations of these two 
players may determine biological functions of IL-18 in the context of inflammation, infection, 
and cancer. IL-18 bioactivity is connected with the pathogenesis of several inflammatory 
diseases, for example, septic shock, colitis, Crohn’s disease, myasthenia gravis, multiple 
sclerosis, rheumatoid arthritis, and atherosclerosis. Furthermore, IL-18-promoted TH1 
responses are associated with several autoimmune diseases as well as organ transplant 
rejection. IL-18 action is modulated by IL-18BPa which is the most abundant IL-18BP splice 
variant found in human cDNA libraries. This isoform exhibits greatest affinity for IL-18. In 
the first part of this study we raised the question how IL-18BP expression is regulated on 
mRNA and protein level particularly in different colon carcinoma cells but also in other cell 
types. 
 
4.1.1 IFN-γ γ γ γ     induces expression and release of IL-18BPa in different colon  
carcinoma cell lines, organ cultures of colonic intestinal biopsy 
specimens, and keratinocytes 
 
In this study we demonstrate that IL-18BPa is released by IFN-γ-activated DLD-1 colon 
carcinoma/epithelial cells. IFN-γ induction of IL-18BPa was not only restricted to DLD-1 
cells but was also confirmed in other colon carcinoma cells using LoVo, Caco-2, and 
HCT116 cell lines. Additionally, we detected IL-18BPa release in IFN-γ-stimulated HaCaT 
keratinocytes indicating that IFN-γ-induced IL-18BPa expression is a more general 
phenomenom not being restricted only to colonic epithelial cells. In each cell line the 
secretion of IL-18BPa immunoreactivity coincided with induction of IL-18BPa expression on 
mRNA level. Expression and secretion of IL-18BPa in response to IFN-γ was accompanied 
by appearance of an extracellular activity that was able to impair IL-12/IL-18-induced IFN-γ 
in PBMC. Gene induction of IL-18BPa by IFN-γ was also observed in organ cultures of 
colonic biopsy specimens. These latter results demonstrate upregulation of IL-18BPa gene IV. Discussion 
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expression in an ex vivo setting and underscore the potential significance of the data 
obtained using colon carcinoma/epithelial cell lines. The present data are consistent with 
work by Fantuzzi et al. demonstrating reduced expression of IL-18BP in interferon 
regulatory factor-1 (IRF-1) deficient mice [Fantuzzi et al., 2001]. These observations may 
have important implications for the action of IFN-γ and IL-18 under pathophysiological 
conditions. By inducing IL-18BP, IFN-γ appears to trigger a negative feedback loop which 
limits IFN-γ-dependent and -independent actions of IL-18. Accordingly, overproduction of 
IFN-γ has been observed in IFN-γ receptor-deficient mice used in models of hapten-
induced colitis [Camoglio et al., 2000] and collagen-induced arthritis [Matthys et al., 1998].  
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Figure 19. 
 
Negative feedback regulation of IL-18 
action by IFN-γ γ γ γ-induced IL-18BPa. 
 
IL-18 induces IFN-γ expression in synergism 
with IL-12. IFN-γ itself induces IL-18BP 
expression in colon epithelial and likely also 
in other local cells thereby providing a 
negative regulator for IL-18 action. Sodium 
butyrate suppresses IFN-γ-induced IL-
18BPa expression thus promoting IL-18 
action. 
 
 
 
 
The present data are compatible with data on IL-18BP expression in graft versus host 
disease, where production of IL-18BP increases in parallel with IFN-γ [Nagler et al., 2000]. 
Moreover, in adult Still’s disease serum levels of IL-18 correlate with the presence of an 
inhibitory activity that impairs binding of IL-18 to its membrane receptor [Kawashima et al., 
2001]. Upregulation of IL-18BP might also be involved in the diminished capability of IFN-γ 
production in ex vivo whole blood cultures obtained from patients with septic shock 
[Oberholzer  et al., 2000]. In fact, Novick et al. recently demonstrate augmented serum 
levels of IL-18BP in septic shock patients [Novick et al., 2001]. Therapeutic use of IL-
18BPa may restore a hypothetically disturbed IL-18/IL-18BP balance in diseases that are IV. Discussion 
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associated with augmented production of TH1 cytokines, such as Crohn’s disease. In 
addition, induction of IL-18BP may contribute to protective functions of IFN-γ as seen in 
murine models for rheumatoid and septic arthritis [Vermeire et al., 1997; Puliti et al., 2000], 
and in rheumatoid arthritis patients [German Lymphokine Study Group, 1992]. 
 
 
4.1.2  Influence of short chain fatty acid (SCFA) sodium butyrate on 
 IFN-γ γ γ γ-induced IL-18BPa expression in colon carcinoma cells 
 
IFN-γ induces IL-18BPa expression in different colon carcinoma cell lines as well as in 
cultures of colonic intestinal biopsy specimens. With sodium butyrate we determined an 
inhibitor of IFN-γ induced IL-18BP expression in these cells. This short chain fatty acid is 
formed in the gastrointestinal tract of mammals as a result of anaerobic bacterial 
fermentation of undigested dietary components and is avidly absorbed by the colonic 
epithelium [Velázquez et al., 1996]. 
In the colon butyrate has been shown to be the dominant energy source for epithelial cells. 
Furthermore it affects cellular proliferation and differentiation by yet unknown mechanisms. 
Recent data suggest that the luminal provision of butyrate may be an appropiate means to 
ameliorate symptoms of inflammatory bowel diseases [Wächtersheimer and Stein, 2000]. 
Interestingly, previous reports also demonstrate that butyrate can protect against the 
development of colon cancer [Wächtersheimer and Stein, 2000]. According to our 
observations we suggest that intestinal butyrate may have the capability to strengthen the 
bioactivity of IL-18 at the colonic microenvironment by modulating IFN-γ-induced IL-18BPa 
expression. There is ample evidence that IL-18 is an inhibitor of tumor growth. In this 
context, suppression of a proposed IL-18BP activity should be beneficial. IL-18 acts as 
inhibitor of angiogenesis [Cao et al., 1999] and augments Fas/Fas-ligand dependent CD4
+ 
T cell- and NK cell-cytotoxicity [Dao et al., 1996; Tsutsui et al., 1996; Osaki et al., 1998]. 
Taking into account these antitumor functions of IL-18, the capability of sodium butyrate to 
strengthen the bioactivity of IL-18 through modulation of IL-18BP expression is in accord 
with its tumor-suppressive potential. Actually, sodium butyrate augments the sensitivity of 
colon carcinoma cells towards Fas-mediated apoptosis [Bonnotte et al., 1998] and Fas-
related CD4
+ T cell- and NK cell-cytotoxicity is characteristically enhanced by IL-18 [Dao et 
al., 1996; Tsutsui et al., 1996; Osaki et al., 1998]. Although IFNγ should contribute to tumor 
suppressive actions of IL-18 in vivo, antitumor functions of IL-18 have been observed in an 
IFN-γ-independent manner [Cao et al., 1999; Dao et al., 1996, Osaki et al., 1998]. It is 
noteworthy that under defined conditions IFN-γ in fact appears to be capable of enhancing 
growth of colon carcinomas [Ramani et al., 1987]. Induction of IL-18BP by IFNγ might IV. Discussion 
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contribute to this observation. Altogether, sodium butyrate appears to shift the IL-18/IL-
18BP balance in colon carcinoma cells in favour of IL-18, which may contribute to local 
tumor protection by this compound, likely via IFN-γ-independent tumor-suppressive actions 
of IL-18. However, IL-18 may also augment expression of genes which have been 
associated with cancer progression. For example, IL-18 can upregulate hepatic melanoma 
metastasis via induction of vascular cell adhesion molecule-1 expression [Vidal-
Vanaclocha et al., 2000]. In addition, IL-18 can mediate production of nitric oxide [Zhang et 
al., 1997; Olee et al., 1999], which has been shown to facilitate growth of certain tumors 
among them melanoma (Ekmekcioglu et al., 2000) and colorectal cancer (Ambs et al., 
1998). 
 
 
4.1.3 IFN-γ γ γ γ     induces expression of IL-18BPa in rheumatoid 
  arthritis fibroblast-like synoviocytes (RA-FLS) 
 
IL-18BPa is not only induced by IFN-γ in cells of colonic lineage. This induction seems to 
be a more general phenomenom since this regulatory pathway is observed in several cell 
types. In this study we also observed IFN-γ induced IL-18BPa expression and secretion in 
resident rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS). Furthermore, release 
was accompanied with appearance of an activity associated with IFN-γ-treated RA-FLS 
which was able to impair the production of IFN-γ in PBMC exposed to IL12/IL-18. Induction 
of IL-18BP in RA-FLS might be an important regulative, since IL-18 seems to play an 
important role in the pathogenesis of rheumatoid arthritis (RA) [Dinarello et al., 1998; 
Gracie et al., 1999]. Yet FLS might contribute to the complex network of immunoregulation 
which ensures control of primarily macrophage-derived IL-18 during synovitis. IL-18 is able 
to activate both, T cells and macrophages in the microenviroment of RA synovitis. IFN-γ, IL-
1β, and TNF-α are supposed to be induced in RA joints [Dinarello et al., 1998; Gracie et al., 
1999; Klimiuk et al., 1997] and successful anti-cytokine therapies in RA reflect the 
paramount relevance of the proinflammatory cytokines IL-1β and TNF-α [Feldmann et al., 
1998; Jiang et al., 2000] in this context. IL-18 was first identified as IFN-γ-inducing factor 
[Dinarello  et al., 1998], and is capable of directly inducing expression of the TNF-α 
[Dinarello  et al., 1998; Gracie et al., 1999]. Although IFN-γ levels are often low, it is 
detectable in all histological variants of rheumatoid arthritis synovitis [Klimiuk et al., 1997]. 
But the role of IFN-γ in RA synovitis is somewhat contradictory. Addition of IFN-γ to T 
cell/monocyte co-cultures enhances TNF-α production, which should aggravate the 
disease [Sebbag et al., 1997]. Furthermore, a murine model of septic antigen-induced 
arthritis illustrates that IFN-γ can display proinflammatory properties when given in the IV. Discussion 
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inflammation initiation phase. Here the detrimental functions of IFN-γ may include a more 
effective antigen presentation at the onset of disease. On the other hand, IFN-γ can 
downregulate parameters of joint destruction such as proinflammatory IL-1, matrix-
metalloproteases, and FLS proliferation [Ghezzi et al., 1988; Alvaro-Gracia et al., 1990]. 
Another report provide evidence that IFN-γ ameliorates joint inflammation when given later 
in the inflammatory process. In this state of disease inhibition of IL-18 through IFN-γ-
induced IL-18BPa could represent a negativ feedback mechanism upon established 
inflammation comparable to our proposed model for colonic cells in connection with 
inflammatory bowel diseases (Figure 19). Such a negative feedback principle concurs with 
reported overexpression of IFN-γ in IFN-γ receptor deficient mice evaluated in collagen 
induced arthritis [Matthys et al., 1998]. Additionally, in patients with adult onset Still’s 
disease [Kawashima et al., 2001], in Crohn’s disease [Corbaz et al., 2002], as well as in 
patients with sepsis [Novick et al., 2001], levels of IFN-γ-inducing IL18 activity appear to 
correlate with expression of IL-18BP. All these observations suggest a close association of 
IL-18 with expression of its decoy receptor in inflammatory diseases. Induction of IL-18BPa 
by IFN-γ could prove to be a crucial endogenous corrective that counterregulates IL-18-
mediated leukocyte activation in rheumatoid arthritis. In spite of this functional feedback 
loop in RA materials, there is still IL-18 bioactivity detectable in RA synovial fluids, even 
though an IL-18 inhibitory activity is present [Yamamura et al., 2001]. Therefore, 
therapeutic administration of IL-18BPa in patients may modulate the cytokine balance in 
order to ameliorate established arthritis. This concept has been confirmed recently in a 
murine rheumatoid arthritis animal model [Plater-Zyberk et al., 2001]. 
 
 
4.1.4  Antiinflammatory properties of IFN-γ γ γ γ apart from IL-18BPa induction 
 
IL-18BPa might play an important role in the counterregulation of proinflammatory IL-18 
action. But apart from IL-18BPa induction, IFN-γ also mediates other antiinflammtory 
effects. For instance, IFN-γ induces so-called SOCS proteins  (Suppressor  of  cytokine 
signaling), that are known to be negative regulators of cytokine signaling [Krebs and Hilton, 
2001]. Also known as STAT-induced STAT inhibitors (SSI-1) or JAK (JAB) 2-binding 
proteins, they may act in part in a negative feedback loop. IFN-γ signaling takes place using 
the JAK/STAT-pathway. Once phosphorylated, two STAT-1 proteins homodimerize. 
Subsequently these homodimers are able to induce transcription of SOCS1 and SOCS3. 
Precisely SOCS1 interacts directly with active JAKs in a phosphorylation dependent 
manner and inhibits its catalytic activity whereas SOCS3 binds to JAK-proximal sites and 
inhibits JAK activity. In conclusion, by inducing SOCS proteins IFN-γ-dependent IL-18 IV. Discussion 
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action might be inhibited by interference with the intracellular signal transduction machinery 
responsible for STAT-activation. IFN-γ also shows antiinflammatory properties by 
modulating the bioactivity of pro-inflammatory IL-1. Interestingly, IFN-γ has been reported 
to suppress IL-1-induced transcription of IL-1. This IL-1-mediated induction of its own 
expression is supposed to be part of a self-amplification loop in a variety of inflammatory 
responses. Endogenous regulation of IL-1 production should contribute to the outcome of 
inflammatory responses [Schindler et al., 1990]. IFN-γ-treatment also modulates IL-1 action 
by induction of circulating IL-1 receptor antagonist (IL-1Ra), which is known to be a specific 
inhibitor of IL-1. These regulatory loops may contribute to antiinflammatory effects of IFN-γ 
[Tilg et al., 1993]. 
 
4.1.5  Proapoptotic properties of IFN-γ γ γ γ 
 
IFN-γ does not only exert antiinflammatory properties but also exhibit proapoptotic 
functions. It has been shown that IFN-γ sensitized colonic epithelial cell lines to diverse 
inducers of apoptosis of physiologic or therapeutic relevance to the colon [O’Connell et al., 
2000]. These apoptosis inducers included Fas (CD95/APO-1) ligand (FasL), short- chain 
fatty acids like sodium butyrate, as well as chemotherapeutic drugs. IFN-γ-mediated 
sensitization has been correlated to upregulation of the proapoptotic protease caspase-1 
(ICE) [O’Connell et al., 2000]. In many cell types, including various epithelial cells, 
apoptosis in response to diverse stimuli proceeds via activation of caspase-1 [Boudreau et 
al., 1995; Enari et al., 1995/1996; Kondo et al., 1995; Henkart, 1996; Tamura et al., 1996; 
Los et al., 1997]. Activated caspases induce proteolysis of specific substrates, which 
contributes to apoptotic processes including mitochondrial permeability transitions, DNA 
fragmentation, and phosphatidylserine externalization. By catalyzing IL-18 maturation, 
caspase-1 induced by IFN-γ contributes to its tumorsuppressive properties. 
 
4.2 Cell-to-cell crosscommunication during TH1 responses 
mediates coordinated expression of modulatory iNOS and 
IL-18BP in adjacent local resident cells 
 
So far we reported that IFN-γ induces IL-18BPa expression in different cell types of colonic 
lineage, in keratinocytes as well as in primary cultures of fibroblast-like synoviocytes. We 
therefore concluded that IFN-γ induced IL-18BPa expression seems to be a more general 
phenomenom. All these findings have been achieved performing exposure to exogenous 
recombinant IFN-γ. To be more close to the in vivo situation, we intended to carry out IV. Discussion 
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coculture experiments. This experimental set up allowed us to investigate cell-to-cell 
crosscommunication during TH1 responses. In the present study we report on coordinated 
induction of IL-18BPa and iNOS in adjacent local resident DLD-1 during TH1 responses 
initiated by PBMC exposed to IL-12/IL-18. Both parameters mediate important functions in 
the context of inflammation, infection, and cancer. The induction of IL-18BPa respectively 
iNOS was mediated by endogenously synthesized IFN-γ. 
 
 
4.2.1  Induction of iNOS in DLD-1 cells cocultured with PBMC 
 
Inducible nitric oxide synthase (iNOS) has been recognized as a marker of human 
diseases associated with inflammation and immunoactivation, among them rheumatoid 
arthritis [St. Clair, et al., 1996], glomerulonephritis [Furusu et al., 1998], and inflammatory 
bowel disease [Singer et al., 1996]. iNOS has also been detected in a broad range of 
human malignancies including melanoma and colorectal cancer [Ekmekcioglu et al., 2000; 
Ambs et al., 1998; Ambs et al., 1999]. In these tumors, iNOS is not only expressed in 
invading mononuclear cells, but also in the cancer cells [Ambs et al., 1999]. Accordingly, 
several studies imply a role for NO in carcinogenesis [Ambs et al., 1998; Ambs et al., 1999; 
Jenkins  et al., 1995]. Despite its unambiguous presence in inflammatory diseases and 
cancer, current knowledge of endogenous pathways which establish early expression of 
human iNOS is still incomplete. In vitro, iNOS is inducible by exogenous interferon-γ (IFN-γ) 
in a variety of different cell types e.g. human epithelial-like colon carcinoma cells such as 
DLD-1 cells [Kleinert et al., 1998]. However, little is known about the role of cytokines that 
intervene more upstream in the cytokine cascade. 
Although data on immunoregulatory roles of NO are not entirely uniform [Bogdan, 2001], 
analysis of iNOS knockout mice suggests that high-output production of NO likely 
represents a pathway that inhibits production of IFN-γ [Wei et al., 1995; Shi et al., 2001]. In 
accord with this assumption, it has been reported that endogenous production of NO can 
reduce release of IFN-γ from human natural killer cells [Salvucci et al., 1998]. Different 
mechanisms may account for impaired production of IFN-γ associated with NO: i) NO is 
supposed to interfere with maturation of pro-IL-18 by inhibiting caspase-1 (ICE) activity 
(Figure 20). That mechanism has been documented by use of iNOS knockout mice [Kim et 
al., 1998]. However, mechanisms of pro-IL-18 processing and release have not been fully 
characterized for the human system. Particularly the role of caspase-1 remains elusive. A 
recent study demonstrates that lipopolysaccharide (LPS) alone does not mediate secretion 
of IL-18 from human monocytes. Instead, release of mature IL-18 was induced by the 
combination LPS/ATP. Processing and secretion was, however, independent of caspase-1 IV. Discussion 
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[Mehta et al., 2001]. Constitutive release of mature IL-18 has been observed in ex vivo 
cultures of human whole blood taken from septic patients. Notably, secretion is not 
modulated by inhibition of caspase-1 activity. In contrast, release of mature IL-1β is 
suppressed in these same experiments [Oberholzer et al., 2000]. ii) NO is capable of 
inhibiting proliferation of T-lymphocytes, possibly via disruption of the Jak3/STAT5 
signaling pathway [Bingisser et al., 1998; Koblish et al., 1998] (Figure 20). iii) NO is able to 
impair production of IL-12 by macrophages [Huang et al., 1998]. In conclusion iNOS 
derived NO might provide an inhibitory feedback loop that modulate IFN-γ production at 
different stages. This negative feedback loop is bound up with a postulated second 
inhibitory loop consisting of IFN-γ-induced IL-18BPa [Paulukat et al., 2001] as discussed in 
the following section. 
 
4.2.2  Induction of IL-18BPa in DLD-1 cells cocultured with PBMC 
 
Induction of IL-18BPa by IFN-γ represents a further mode of feedback inhibition that should 
serve to control IL-18 biological activity under pathophysiological conditions (Figure 16). 
Present and previous data from our group suggests that local resident cells may constitute 
an important source of inducible IL-18BP production. Here we present first data that IL-
18BPa is also inducible by IFNγ in PBMC. Although induction was modest compared to 
DLD-1 cells, we cannot entirely exclude that PBMC contributed to secretion of IL-18BP 
protein as detected by immunoblotting in our coculture system. The proposed IFN-γ-driven 
feedback modulation agrees with amplified production of IFN-γ in IFN-γ receptor knockout 
mice, evaluated in models of inflammatory diseases [Camoglio et al., 2000; Matthys et al., 
1998]. In the present context it is noteworthy that an association between IL-18 and 
expression of its decoy receptor has been observed in patients with sepsis [Novick et al., 
2001], Still’s disease [Kawashima et al., 2001], and psoriasis [Ohta et al., 2001]. Altogether, 
induction of both, IL-18BPa and iNOS, may serve to control the strength and duration of 
local IL-18/IFN-γ action and should affect the pathogenesis of inflammatory diseases such 
as Crohn’s disease and autoimmune glomerulonephritis. 
 
 
4.2.3  Synchronized induction of IL-18BPa and iNOS in carcinogenesis 
 
In the context of tumor biology, coordinated induction of IL-18BP and iNOS in cancer cells 
is of particular significance. In several murine models IL-18 exerts either a direct or an 
IFNγ-dependent tumor-suppressive function that is associated with FasL-mediated killing 
and reduction of angiogenesis in the tumor microenviroment [Coughlin et al., 1998; Osaki IV. Discussion 
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et al., 1998; Cao et al., 1999]. Upregulation of iNOS on the other hand has been observed 
in human colorectal cancer [Ambs et al., 1998; Ambs et al., 1999], breast cancer [Thomsen 
et al., 1995], in prostate cancer [Klotz et al., 1998], in lung cancer [Liu et al., 1998], as well 
as in melanomas [Ekmekcioglu et al., 2000], and head and neck cancer [Gallo et al., 1998]. 
Besides suppression of IFNγ production (Figure 20), NO may facilitate tumor growth by 
several additional mechanisms: iNOS in human colon cancer tissues is positively 
correlated with the frequency of mutations in the p53 tumor suppressor gene. NO may thus 
provide a selection pressure for nonfunctional p53, a mechanism which should ultimately 
promote tumor growth [Ambs et al., 1999]. Interestingly, NO has been recognized as an 
inhibitor of apoptotic cell death under certain conditions [Liu and Stamler 1999]. Therefore, 
autocrine NO may increase cancer cell survival. It has also been reported that 
overexpression of iNOS in DLD-1 cells results in enhanced tumor growth in xenografted 
nude mice. Tumors derived from these iNOS overexpressing DLD-1 cells appear markedly 
more vascularized [Jenkins et al., 1995]. Similar observations have been reported using 
Calu-6 lung carcinoma cells [Ambs et al., 1998]. Notably, DLD-1 cells [Kagawa et al., 1997] 
as well as Calu-6 [Ambs et al., 1998] cells do not express wild-type p53. NO-mediated 
promotion of tumor growth agrees as well with a report on head and neck cancer which 
identifies iNOS as a marker of progression that closely correlates with angiogenesis and 
tumor vascularization [Gallo et al., 1998]. Furthermore, iNOS-derived NO should mediate 
vasodilatation at the tumor site. The resulting increase in blood supply will likely favour 
tumor growth [Andrade et al., 1992]. Finally, NO not only appears to be a marker but also a 
mediator of inflammation. Inflammatory actions of NO include activation of the transcription 
factor NF-κB [Lander et al., 1993], as well as augmented production of TNFα and of 
chemokines [Mühl and Dinarello, 1997; Lander et al., 1993; Mühl et al., 2000; Guo et al., 
2001; Walpen et al., 2001], which can mediate leukocyte infiltration into tumor tissues. As 
colonic inflammation and macrophage infiltration are supposed to support progression of 
colorectal cancer [Etoh et al., 2000], these inflammatory actions of NO are compatible with 
NO-mediated tumor promotion. 
 
Lack of IFNγ is associated with distant metastasis and poor prognosis in colorectal cancer 
[Pages et al., 1999]. By counterregulating the IL-18- and IFNγ-dependent arm of immune 
defenses against tumors, both IL-18BP and iNOS, have the potential to promote 
carcinogenesis by mechanisms that likely include tumor-mediated immunosuppression and 
angiogenesis. 
 IV. Discussion 
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Figure 20. 
 
Negative feedback regulation of IL-18 
action by iNOS-derived NO. 
 
IL-18 induces IFN-γ expression in synergism 
with IL-12. IFN-γ in combination with 
costimulant IL-1 induces iNOS expression in 
colon epithelial cells. iNOS derived NO 
negatively modulates IFN-γ production at 
different stages. IFN-γ also induces IL-
18BPa expression as second negative 
feedback loop for IL-18 action. Both proteins 
counterregulate IL-18- and IFN-γ-mediated 
action. This might be of particular 
significance, since IL-18 exerts either a 
direct or an IFN-γ-dependent tumor-
suppressive function. On the other hand 
upregulation of iNOS has been observed in 
different human cancer. 
 
4.3  IL-18 binding protein promoter function 
 
We postulate that IFN-γ-induced IL-18BPa expression seems to be a general phenomenom 
as shown in this study in cells of colonic lineage, keratinocytes and rheumatoid arthritis 
fibroblast-like synoviocytes. There are further reports that IFN-γ-induced IL-18BPa 
expression also take place in renal mesangial cells [Mühl et al., 2000], hepatocytes 
[Rubinstein et al., 2001], PBMC and monocytes [Corbaz et al., 2002] as well as retinal 
pigment epithelial cells (data not shown), and endothelial cells (Huvec) [Corbaz et al., 
2002]. Therefore, we were interested in the mechanism of IFN-γ-mediated IL-18BPa 
induction on promoter level. 
 
4.3.1  Induction of IL-18BP promoter by IFN-γ γ γ γ  
 
We cloned two IL-18BP promoter luciferase reporter vectors which were highly inducible by 
IFN-γ in luciferase assays. Both fragments habored diverse IFN-γ-responsiv elements (γ-
IRE: γ-Interferon responsive element; GAS: Gamma-activated site; ISRE: IFN-stimulated 
response element [Pearse et al., 1991; Decker et al., 1997; Taniguchi et al., 2001] that are 
known to transduce IFN-γ signaling and therefore might be responsible for IL-18BPa 
expression (Figure 21). IV. Discussion 
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Figure 21. IFN-γ γ γ γ responsive sites 
 
IFN-γ signaling is via the Jak /Stat 
pathway (Janus family of protein 
tyrosin kinases/Signal  Transducers 
and  Activators of Transcription 
family). Stat1 is able to bind directly 
to  γ-IRE as well as GAS. 
Furthermore, GAS itself is part of 
the IRF-1 (Interferon  Regulatory 
Factor-1) promoter. Expressed IRF-
1 subsequently can mediate IFN-γ 
signaling by binding to ISRE sites. 
 
 
The 5’ 469 bp shortened fragment 5 showed higher luciferase activities compared to 
fragment 4. This observation might be due to one or more silencer elements located 
upstream of base -635 not yet defined. A recent report confirmed our data suggesting that 
a silencer element resides within bases –656 to –1107 [Hurgin et al., 2002]. To identify 
sites responsible for IFN-γ-mediated induction of the IL-18BP promoter we mutated the 
GAS site closely located to the transcription start site. Our mutagenesis data reveal 
that this site is likely of relevance for IFN-γ-mediated induction of the IL-18BP promoter 
fragments 4 and 5. Whereas the mutated constructs of fragment 4 (pGL3 + mutGAS 5’/3’) 
only showed about half of its wildtype activity in luciferase assay, mutated fragment 5 
vectors (pGL3 + mutGAS 5’/3’) promoter activity were decreased by 71.9 %. 
 
In the present work we focussed on the GAS site (Gamma Activated Site) closely located 
to the IL-18BP gene transcription start site and performed electrophoretic mobility shift 
assays. Our data revealed STAT-1 binding to this GAS element following IFN-γ stimulation. 
Previously it was shown that GAS binds an IFN-γ-induced STAT1 dimer [Shuai et al., 
1994]. This observation is also in accord with other reports, indicating that IFN-γ ligand 
binding leads to receptor oligomerization, with two IFN-γR1 (α) chains bound to one IFN-γ 
homodimer, and the subsequent recruitment of two IFN-γR2 (β) chains to the complex. IFN-
γ-mediated receptor aggregation brings the inactive JAKs associated with the cytoplasmatic 
tails of the α and β chains into close proximity. Once clustered, the JAKs are reciprocally 
activated through sequential auto- and transphosphorylation events. Activated JAKs 
themselves phosphorylate a specific c-terminal located tyrosine residue of each IFN-γR1 
[Tau and Rothman, 1999]. This phosphorylated tyrosine residue pair is embedded within a 
recognition sequence to which STAT-1 binds through its SH2 (src homology 2) domain. By IV. Discussion 
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docking of STAT-1 molecules to this sequence these become phosphorylated by the 
receptor associated JAKs. After phosphorylation two STAT-1 proteins homodimerize and 
finally translocate to the nucleus, where they bind to the consensus sequence TTCN2-
4GAA, known as GAS element [Leonard and O’Shea, 1998; Decker et al., 1997]. A 
recently published report is contradictory to our data. Hurgin et al. (2002) did not see any 
STAT-1 binding to GAS following IFN-γ stimulation in EMSA studies. They suggest that 
IRF-1 also induced by IFN-γ forms a physical complex with C/EBPβ (CCAAT/enhancer 
binding protein β), which subsequently binds not only to the ISRE but also to the GAS-
containing proximal DNA, proclaiming a fundamental role of such a complex in regulating 
further IFN-γ-responsive genes. There is a partial homology between GAS and the C/EBP-
E (C/EBPβ response element) that might provide the basis for the observed binding. 
However, our divergent observations might be due to the employment of another cell 
system. Whereas Hurgin et al. used the hepatocytic cell line Hep G2, we stimulated the 
colon carcinoma cell line DLD-1. GAS also controls expression of IRF-1 (Interferon 
Regulatory Factor-1) [Kumatori et al., 2002]. Accordingly, IFN-γ-induced expression of IRF-
1 is suppressed in STAT-1 KO mice [Meraz,  1996]. By binding of STAT-1 to this GAS 
element IRF-1 expression is induced. The latter might then bind to an ISRE site also 
present in the IL-18BP promoter (see results figure 14). Besides the GAS element under 
investigation, we cannot exclude that other IFN-γ responsive sites might contribute to IFN-γ-
induced IL-18BPa expression. 
 
4.4  Therapeutic use of IL-18BPa 
 
IL-18 is examined as a prime mediator of TH1 responses [Nakamura et al., 1989] that are 
known to be associated with several autoimmune diseases as well as organ transplant 
rejection. Its opponent IL-18 binding protein (IL-18BP) [Novick et al., 1999] is likely 
therapeutic useful in the treatment of diseases such as septic shock, inflammatory bowel 
disease, multiple sclerosis, rheumatoid arthritis, toxic liver damage, lupus erythematosus, 
Still’s disease, psoriasis, graft versus host, as well as transplant rejection [Dinarello, 2000]. 
The most interesting target in counteracting IL-18 action seems to be the IL-18BP splice 
variant a. This naturally occuring inhibitor exhibited the greatest affinity for IL-18 with a Kd 
of 399 pM [Kim et al., 2000]. All four IL-18BP isoforms (IL-18BPa/b/c/d) found in humans 
vary significantly in their ability to neutralize the biological activity of IL-18. Therefore the 
TH1 response will be affected in individuals expressing one isoform preferentially compared 
with another isoform. Perhaps changes in IL-18BP splicing events of hnRNA may provide a 
regulative tool of IL-18 action. In humans, IL-18BP is constitutively expressed in the spleen IV. Discussion 
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and circulates at plasma concentrations of about 2.5 ng/ml [Novick et al., 2001]. Serum IL-
18BP is significantly elevated during sepsis and able to reduce free serum IL-18, indicating 
its role in regulating immune responses in vivo [Novick et al., 2001]. The importance of IL-
18BP is further underscored by the observation that Pox virus encode proteins sharing a 
significant homology to mammalian IL-18BP. Thus infected cells secret a soluble Pox virus-
derived vIL-18BP that may modulate host antiviral responses [Vincent et al., 2000]. As 
shown in previous reports as well as in this study IL-18BPa is induced by IFN-γ in various 
cells suggesting that it serves as a negative feedback inhibitor of the IL-18-mediated 
immune response [Mühl et al., 2000; Paulukat et al., 2001]. This induction is quite specific, 
as it was not triggered by other proinflammatory cytokines. In Hep G2 cells TNF-α and IL-6 
enhanced IFN-γ-induced IL-18BPa [Hurgin et al., 2002]. 
 
The therapeutic use of IL-18BPa depends on its respective function in disease. For 
instance, by stimulating immune cells IL-18 exhibits a strong antitumoral activity, protecting 
experimental animals against repeated challenges with tumor cells [Micallef et al., 1997]. A 
upregulated IL-18BPa expression would therefore probably suppress anti-tumoral activity. 
As reported in the present study IFN-γ induces IL-18BPa expression in different colon 
carcinoma cell lines as well as in cultures of colonic intestinal biopsy specimens. With 
sodium butyrate we found an inhibitor of IFN-γ-induced IL-18BP expression in these cells. 
Its capability to strengthen the bioactivity of IL-18 at the colonic microenviroment might 
explain previous reports demonstrating a protective role of butyrate in colon carcinogenesis 
[Wächtersheimer and Stein, 2000]. 
 
In Crohn’s disease (CD), a chronic inflammatory bowel disease, the situation is different. 
Here IL-18BPa might be an appropiate means to ameliorate disease symptoms. CD is 
characterized by a marked accumulation of activated TH1 cells and macrophages in the 
inflamed intestinal mucosa. There is increasing evidence that an imbalance of TH1/ TH2 
polarization in favor of TH1 cell subsets may be a key pathogenic mechanism in a variety of 
chronic inflammatory disorders and organ-specific autoimmune diseases. Upregulation of 
bioactive IL-18, as prime mediator of a TH1 response, has been reported in CD mucosa 
[Pizarro et al., 1999; Monteleone et al., 1999]. Furthermore, it has been demonstrated that 
the serum level of IL-18 and the expression of IL-18 by macrophages in inflamed intestinal 
mucosa are significantly higher in patients with CD. Additionally, there was significant 
correlation between serum IL-18 concentration and disease severity [Kanai et al., 2000]. 
Different findings suggest that macrophage-derived IL-18 acting synergistically with IL-12 
serves as a potent regulatory factor for intestinal mucosal lymphocytes and contributes to 
chronic intestinal inflammation in CD. Administration of neutralizing anti-IL-18 antibodies to IV. Discussion 
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the TNBS-treated (2,4,6,-trinitro-benzenesulfonic acid) mice led to a striking improvement 
in both clinical and histopathological aspects of the disease and frequently completely 
abrogated the established colitis [Kanai et al., 2001]. Thus macrophage-derived IL-18 
system seems to play an important role in the pathogenesis of CD and inhibitory IL-18BP 
should be therapeutically useful in the treatment of CD patients. 
IL-18 mRNA and protein are also present in rheumatoid synovial macrophages [Yamamura 
et al., 2001], suggesting an important role of this proinflammatory cytokine in the 
pathogenesis of rheumatoid arthritis. The proinflammatory effects of IL-18 include the direct 
stimulation of nitric oxide, GM-CSF, TNF-α, IL-1, as well as IL-6 production by 
macrophages [Gracie et al., 1999; Yamamura et al., 2001; Netea et al., 2000]. The 
combination of IL-12, IL-15, and IL-18 potently induce IFN-γ production in synovial tissues. 
Moreover, TH1 development is further enhanced through IL-1- and TNF-α-stimulated IL-18 
production in cultured rheumatoid synovial fibroblasts. In the present study we report IFN-γ-
induced IL-18BPa expression in fibroblast-like synoviocytes (FLS) isolated from rheumatoid 
arthritis patients. Therefore we postulate that FLS might contribute to the complex network 
of immunoregulation which would ensure control of primarily macrophage-derived IL-18 
during synovitis. Administration of IL-18BP ameliorates collagen-induced arthritis (CIA) in 
mice. Yet the pharmaceutical industry investigates IL-18BPa as therapeutic agent for the 
treatment of rheumatoid arthritis and clinical phase I studies have been completed. 
 
4.5 Summarizing  discussion 
 
IL-18 plays an important role during TH1 responses in the context of inflammation, infection, 
and cancer. Accordingly, IL-18 has been associated with human autoimmune diseases and 
organ transplant rejection. IL-18BPa is a naturally occuring inhibitor that counteracts IL-18 
bioactivity. So far IFN-γ is the only known single stimulus for IL-18BPa expression in 
different human cell lines [Mühl et al., 2000]. In HepG2 cells it has been shown that TNF-α 
and IL-6 synergistically enhance IFN-γ-induced IL-18BPa [Hurgin et al., 2002]. In the 
present study we report IFN-γ-mediated induction of IL-18BPa in different colon carcinoma 
cell lines, in organ cultures of colonic intestinal biopsy specimens, keratinocytes and in 
fibroblast-like synoviocytes isolated from rheumatoid arthritis patients (RA-FLS). Therefore, 
we conclude that IFN-γ-induced IL-18BPa expression likely is a more general 
phenomenom, common to various cell types. By inducing IL-18BPa, IFN-γ triggers a 
negative feedback loop which limits IFN-γ-dependent and –independent actions of IL-18. 
The proposed IFN-γ-driven feedback regulatory pathway agrees with amplified production 
of IFN-γ in IFN-γ receptor knockout mice, evaluated in models of inflammatory diseases IV. Discussion 
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[Camoglio  et al., 2000; Matthys et al., 1998]. Therefore, IL-18BPa has the potential to 
restore a hypothetically disturbed IL-18/IL-18BP balance in autoimmune diseases such as 
rheumatoid arthritis and Crohn’s disease. The association between IL-18 and expression of 
its decoy receptor has been observed in patients with sepsis [Novick et al., 2001], Still’s 
disease [Kawashima et al., 2001], and psoriasis [Ohta et al., 2001]. On the contrary, in the 
case of carcinogenesis IFN-γ-induced IL-18BPa expression might be disadvantageous. In 
particular, when coinduced together with IFN-γ-dependent iNOS, IL-18BPa may facilitate 
tumorgenesis. 
Protective functions of IFN-γ have been shown in murine models for rheumatoid and septic 
arthritis (Vermeire et al., 1997; Puliti et al., 2000), and in rheumatoid arthritis patients 
(German Lymphokine Study Group, 1992). These effects may be due to IL-18BPa 
expression. IFN-γ-mediated induction of IL-18BPa in RA-FLS could be an important 
regulative, since proinflammatory IL-18 appears to play an important role in the 
pathogenesis of rheumatoid arthritis. IL-18 is able to activate T cells and macrophages in 
the microenviroment of RA synovitis. Located upstream in the cascade of proinflammatory 
cytokines, IL-18 can be seen as pivotal inducer of subsequent cardinal inflammatory 
cytokines (e.g. IL-1 and TNF-α) which contribute to the pathogenesis of RA. By producing 
IL-18BPa, FLS may contribute to the complex network of immunoregulation which ensures 
control of IL-18 during synovitis. A recent report provides evidence that IFN-γ ameliorates 
joint inflammation when given later in the inflammatory process. In this state of disease 
inhibition of IL-18 through IFN-γ-induced IL-18BPa should represent a negative feedback 
mechanism upon established inflammation. Indeed, the pharmaceutical industry 
successfully used IL-18BP as therapeutic agent in a murine model of RA [Plater-Zyberk et 
al., 2001]  and in phase I clinical trials [http://www.serono.com/index.jsp]. Another 
autoimmune disease being connected with pathologic IL-18 action is Crohn’s disease (CD). 
CD is characterized by a marked accumulation of activated TH1 type CD4
+ T cells and 
macrophages in inflamed intestinal mucosa. Upregulation of bioactive IL-18 has been 
reported in CD mucosa [Pizarro et al., 1999; Monteleone et al., 1999]. Furthermore, there 
was significant correlation between serum IL-18 concentration and disease severity [Kanai 
et al., 2000]. Therefore, therapeutic use of IL-18BPa may restore a hypothetically disturbed 
IL-18/IL-18BP balance in Crohn’s disease thereby counteracting a TH1-promoted immune 
response. 
 
In contrast, IL-18BPa expression might be disadvantageous, too. There is evidence that IL-
18 is an inhibitor of tumor growth. IL-18 acts as inhibitor of angiogenesis [Cao et al., 1999] 
and augments Fas/Fas-ligand dependent CD4
+ T cell- and NK cell-cytotoxicity [Dao et al., 
1996; Tsutsui et al., 1996; Osaki et al., 1998]. Previous reports demonstrate that sodium IV. Discussion 
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butyrate can be protective against development of colon cancer by augmenting the 
sensitivity of colon carcinoma cells towards Fas-mediated apoptosis [Bonnotte et al., 1998]. 
In our experimental set up butyrate inhibited IFN-γ-induced IL-18BPa expression. Intestinal 
butyrate may therefore have the capability to strengthen the bioactivity of IL-18 at the 
colonic environment, which should be beneficial. IFN-γ itself shows tumor suppressive 
potential, but under defined conditions IFN-γ also appears to be capable of enhancing 
growth of colon carcinomas [Ramani et al., 1987]. This observation might be due to IFN-γ-
mediated induction of IL-18BPa expression. Altogether, sodium butyrate appears to shift 
the IL-18/IL-18BP balance in colon carcinoma cells in favor of IL-18, which may contribute 
to local tumor protection by this compound, likely via IFN-γ-independent tumor-suppressive 
actions of IL-18. To complete the picture it also noteworthy, that IL-18 may also augment 
expression of certain genes which have been associated with cancer progression, e.g. 
adhesion molecules. Accordingly, IL-18 increased metastasis in murine melanoma model 
[Wang et al., 2001]. 
 
The suggested negative feedback model of IL-18 action (figure 17) shown in this study can 
also be observed in the cocultur system, that we employed to simulate an inflammatory TH1 
response. By counterregulating the IL-18 arm of immune defenses against tumors, IL-18BP 
may have the potential to promote carcinogenesis. In several murine models IL-18 exerts 
either a direct or an IFNγ-dependent tumor-suppressive function. These are associated with 
enhanced NK dependent cell killing or with reduction of angiogenesis in the tumor 
microenviroment, respectively [Coughlin et al., 1998; Osaki et al., 1998; Cao et al., 1999]. 
In addition, induction of iNOS may provide a second inhibitory way for tumor suppressive 
effects of IL-18. Upregulation of iNOS has been shown in different types of cancer. 
Although data on immunoregulatory roles of NO are not entirely uniform [Bogdan, 2001], 
analysis of iNOS knockout mice suggests that high-output production of NO likely 
represents a pathway that inhibits production of IFN-γ [Wei et al., 1995; Shi et al., 2001]. 
Different mechanisms for impaired IFN-γ production associated with NO can be envisioned 
(figure 17). NO is supposed to interfere with maturation of pro-IL-18 by inhibiting caspase-1 
(ICE) activity [Kim et al., 1998], but there are also reports of caspase-1 independent IL-18 
processing and secretion [Mehta et al., 2001]. Furthermore, NO is capable of reducing 
proliferation of T-lymphocytes possibly via disruption of the Jak3/STAT5 signaling pathway 
[Bingisser et al., 1998; Koblish et al., 1998]. NO also has been shown to impair IL-12 
production by macrophages [Huang et al., 1998], which usually acts in synergism with IL-
18 to induce IFN-γ. Besides suppression of IFN-γ production, NO may facilitate tumor 
growth by several additional mechanisms. For instance, iNOS in human colon cancer 
tissues is positively correlated with the frequency of mutations in the p53 tumor suppressor IV. Discussion 
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gene. Furthermore, NO has been recognized as an inhibitor of apoptotic cell death under 
certain conditions [Liu and Stamler, 1999]. Tumors derived from iNOS overexpressing 
DLD-1 cells are markedly more vascularized [Jenkins et al., 1995]. Moreover, iNOS-derived 
NO should mediate vasodilatation at the tumor site leading to increased blood supply, 
which will likely favor tumor growth [Andrade et al., 1992]. Finally, NO appears to be a 
mediator of inflammation, leading to leukocyte infiltration into tumor tissues. Colonic 
inflammation and macrophages infiltration are supposed to support progression of 
colorectal cancer [Etoh et al., 2000]. In conclusion, lack of IFN-γ is associated with distant 
metatasis and poor prognosis in colorectal cancer [Pages et al., 1999]. By 
counterregulating the IL-18- and IFNγ-dependent arm of immune defenses against tumors, 
both IL-18BP and iNOS, have the potential to promote carcinogenesis by mechanisms that 
likely include tumor-mediated immunosuppression and angiogenesis. 
As mentioned earlier, IFN-γ is the only known single stimulus for IL-18BPa induction so far 
[Mühl et al., 2000]. In HepG2 cells it has been reported that TNF-α and IL-6 synergize with 
IFN-γ for IL-18BPa expression [Hurgin et al., 2002]. IFN-γ uses the Jak/STAT-pathway for 
signal transduction. Phosphorylated STAT-1 proteins homodimerize and finally translocate 
to the nucleus, where they bind to a consensus sequence called GAS (Gamma-activated-
site). In the present work we identified a GAS element proximal to the start of transcription. 
EMSA analysis revealed STAT-1 binding to this element. Furthermore, two IL-18BP 
promoter fragments containing this GAS element were highly inducible following IFN-γ-
stimulation in luciferase assays. Mutagenesis of this GAS site led to strong reduction of the 
fragments IFN-γ-inducibility. We also found other IFN-γ responsive sites in our promoter 
fragments, namely γ-IRE (γ-Interferon responsive element) and ISRE (IFN-stimulated 
response element). STAT-1 might also directly bind to two γ-IRE sites present in the cloned 
IL-18BP promoter luciferase fragments. Putative induction via ISRE may be mediated by 
STAT-1 induced IRF-1 (Interferon Regulatory Factor-1), since a GAS element controls IRF-
1 expression as well. 
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Summary 
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In this study we investigated the regulation of IL-18BPa by IFN-γ in the context of colon 
cancer and human autoimmune diseases. IL-18BPa is a naturally occuring inhibitor that 
counteracts IL-18 bioactivity. By enhancing IFN-γ production IL-18 has been introduced as 
pivotal mediator of TH1 immune responses. Indeed, many IL-18 effects are mediated by 
IFN-γ. IL-18 bioactivity is connected with the pathogenesis of different inflammatory 
diseases, for instance, septic shock, colitis, Crohn’s disease, myasthenia gravis, multiple 
sclerosis, rheumatoid arthritis, atherosclerosis, and organ transplant rejection. In addition, 
IL-18 has tumor-suppressive properties. IFN-γ induced IL-18BPa expression was shown on 
protein and mRNA level in different colon carcinoma cell lines, organ cultures of colonic 
intestinal biopsy specimens, HaCaT keratinocytes as well as rheumatoid arthritis fibroblast-
like synoviocytes (RA-FLS). The IFN-γ-mediated induction of IL-18BPa appears to be a 
more general phenomenom. The capability of IFN-γ to induce IL-18BPa also has been 
confirmed on the promoter level by performing luciferase reporter gene studies with two IL-
18BP promoter fragments. A GAS-site proximal to the transcription start site has been 
identified to be relevant for IFN-γ-mediated induction of these two IL18BP promoter 
fragments. The induction of IL-18BPa is most likely mediated by STAT-1 in DLD-1 colon 
carcinoma cells. Sodium butyrate inhibited IFN-γ-induced IL-18BPa expression in these 
cells. On the basis of our observations, we postulate a negative feedback mechanism, by 
which IFN-γ-dependent and –independent IL-18 action might be counterregulated. In this 
model sodium butyrate is an additional player, that may interrupt the postulated negative 
feedback loop. A coculture system was performed to simulate an inflammatory TH1 
response. This model which is more close to the in vivo situation, confirmed upregulation of 
IL-18BPa by endogenously produced IFN-γ. 
The role of IL-18BPa is manifold and depends on IL-18 function in each particular case. In 
autoimmune diseases, for instance, which are often characterized by a TH1 polarized 
immune response, IL-18BPa might counterregulate IL-18 and/or IL-18-induced IFN-γ 
bioactivity. Important examples are Crohn’s disease and rheumatoid arthritis. In CD 
therapeutic use of IL-18BPa may therefore restore a hypothetically disturbed IL-18/IL-18BP 
balance. Concerning RA, IL-18BPa expression might contribute to protective functions of 
IFN-γ, observed in different murine models for arthritis and in rheumatoid arthritis patients. V. Summary 
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Moreover, IL-18BPa might inhibit IL-18-mediated induction of subsequent cardinal 
inflammatory cytokines responsible for the pathogenesis of these diseases. Indeed, the 
pharmaceutical industry successfully used IL-18BP as therapeutic agent in a murine model 
of RA and in phase I clinical trials. On the contrary, in the context of carcinogenesis IFN-γ-
mediated IL-18BPa expression might be disadvantageous. By counterregulating the IL-18 
arm of immune defenses against tumors, IL-18BP may have the potential to promote 
carcinogenesis. Our hypothesis is underlined by the observation that sodium butyrate, 
known to be protective in colon cancer, inhibited IFN-γ-induced IL-18BPa expression. In 
parallel, IL-18-induced IFN-γ is also responsible for iNOS induction. iNOS-derived NO 
provides a second possible way for inhibition of IFN-γ-dependent and –independent tumor 
suppressive effects of IL-18. Finally, IFN-γ-induced IL-18BPa expression was confirmed on 
the promoter level. This induction on the promoter level was associated with STAT-1 
binding to the GAS element proximal to the start of transcription. 
 
It is tempting to speculate that blockage of the cytokine cascade upstream of IL-1 and TNF-
α on the level of IL-18 may be of therapeutic benefit. Our data reflect the relationship 
between inflammation and cancer, in that inflammatory cells and cytokines found in tumors 
are likely to contribute to tumor growth, progression, and immunosuppression than they are 
to mount an effective host antitumour response.   VI. References 
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VII 
Appendix 
___________________________________ 
 
7.1 Abbreviations 
 
B sodium  butyrate 
BSA  bovine serum albumin 
Bref A  Brefeldin A 
CD  Crohn’s disease, cluster of differentiation 
cDNA  copy or complementary DNA 
cpm  counts per minute 
C Control 
d Day 
DEPC diethyl  pyrocarbonate 
dest Distilled 
DMEM  Dulbecco´s modified Eagle´s medium 
DMSO dimethylsulfoxide 
DNA Deoxyribonucleic  acid 
DNase deoxyribonuclease 
DTT Dithiothreitol 
E. coli  Escherichia coli 
ECL enhanced  chemiluminescence 
EDTA ethylenediaminetetraacetic  acid 
ELISA  enzyme-linked immunosorbent assay 
et al.  et alter 
FCS  fetal calf serum 
fig Figure 
FLS fibroblast-like  synoviocytes 
γ-IRE  γ-interferon responsive element 
GAPDH  glyceraldehyde 3-phosphate dehydrogenase 
GAS gamma-activated  site 
h hour(s),  human 
HEPES N-(2-hydroxyethyl)piperazine-N´-(2-ethanesulfonic  acid) 
ICE  interleukin-1β converting enzyme 
IFN Interferon 
Ig Immunoglobulin VII. Appendix 
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IGIF  interferon-γ inducing factor 
IL Interleukin 
IL-18BP  interleukin-18 binding protein 
iNOS  inducible nitric oxide synthase 
IPTG isopropylthiogalactoside 
ISRE  IFN-stimulated response element 
kDa kilo  Dalton 
LB Lauria-Bertani 
LPS lipopolysaccharide 
LUC Luciferase 
m mature,  molar 
min minute(s) 
MMP matrix  metalloproteinase 
mRNA messenger  RNA 
nd not  detecable 
NO/NOS  nitric oxide/nitric oxide synthase 
OA ocadaic  acid 
OD optical  density 
PBMC  peripheral blood mononuclear cells 
PBS phosphate-buffered  saline 
PCR  polymerase chain reaction 
pH potentia  hydrogenii 
PVDF polyvinylidene  fluoride 
RA rheumatoid  arhtritis 
RNA ribonucleic  acid 
RNase Ribonuclease 
ROS  reactive oxygen species 
rpm  rounds per minute 
RT  reverse transcription, room temperature 
SD standard  deviation 
SDS  sodium dodecyl sulfate 
sec second(s) 
SEM  standard error of the mean 
TCA trichloroacetic  acid 
TEMED N,N,N´,N´-tetramethylethylenediamine 
Th  T helper cell 
TMB tetramethylbenzidine 
TNF  tumor necrosis factor 
Tris tris(hydroxymethyl)aminomethane 
tRNA transfer  RNA 
U unit(s) VII. Appendix 
 
  103
UV Ultraviolet 
URL  uniform resource locator 
UTP uridine  5´-triphosphate 
v/v  volume per volume 
VEGF  vascular endothelial growth factor 
w/v  weight per volume 
wt wild  type 
X-gal  5-bromo-4-chloro-3-indolyl-β-D-galactoside 
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7.6 Deutsche  Zusammenfassung 
 
Zytokine fungieren als biochemische Botenstoffe zwischen Zellen. Sie sind involviert in 
Prozesse wie der Regulation der Immunantwort, Streß, Zellwachstum und -differenzierung, 
sowie Gewebsregeneration. Die Balance zwischen pro- und antientzündlichen Zytokinen 
bestimmt den Ausgang einer durch Entzündung bedingten Immunantwort. Zytokine 
interagieren mit spezifischen Zytokininhibitoren sowie löslichen Zytokinrezeptoren. Solche 
Mechanismen ermöglichen eine genau abgestimmte Regulation der Immunantwort. Der 
Effekt eines jeden Zytokins ist abhängig von der zeitlichen Zytokin-Freisetzung, dem 
lokalen Milieu in welchem es agiert, der Präsenz von verdrängenden oder synergistischen 
Elementen, der Dichte von Zytokinrezeptoren sowie der gewebeabhängigen Antwort auf 
das jeweilige Zytokin.  
Interleukin 18 (IL-18) als Hauptmediator einer TH1 Immunantwort, sowie sein natürlich 
vorkommender Inhibitor IL-18 Bindeprotein (IL-18BP) sind zwei neu beschriebene 
Kontrahenten im Zytokinnetzwerk. IL-18 verstärkt die IFN-γ Produktion, welche letztendlich 
viele Effekte dieses Zytokins vermittelt. Lokale Konzentrationen beider Gegenspieler, IL-18 
und IL-18BP, bestimmen die biologische Funktion von IL-18 im Zusammenhang mit 
Entzündung, Infektion und Krebs. Die jeweilige IL-18 Bioaktivität steht dabei in Verbindung 
mit der Pathogenese diverser entzündlicher Krankheiten wie z.B. Morbus Crohn, Multiple 
Sklerose, rheumatoide Arthritis (RA) und Atheriosklerose. Durch IL-18 ausgelöste TH1 
Immunantworten sind von Bedeutung bei verschiedenen Autoimmunerkrankungen sowie 
der Abstoßung von transplantierten Organen. Die Bioaktivität von IL-18 wird besonders 
durch IL-18BPa moduliert. Diese Splice-Variante des Bindeproteins wurde als Hauptform in 
verschiedenen humanen cDNA Bibliotheken entdeckt und zeigt höchste Affinität für IL-18. 
IFN-γ scheint der vorherrschende Stimulus für IL-18BPa Expression in verschiedensten 
humanen Zelltypen zu sein [Mühl et al., 2000]. 
 
Mit diesem Hintergrund haben wir die IFN-γ-vermittelte Regulation der Expression von IL-
18BPa sowie dessen Freisetzung untersucht. Die Experimente wurden in verschiedenen 
humanen Zelltypen durchgeführt, welche in Verbindung stehen mit der Etiology von Kolon 
Karzinogenese und Autoimmunerkrankungen, wie z.B. Morbus Crohn und rheumatoide 
Arthritis. In der vorliegenden Arbeit konnten wir die IFN-γ-vermittelte Induktion von IL-
18BPa in verschiedenen Kolon Karzinom Zellinien (DLD-1, LoVo, Caco-2 und HCT116), in 
Kulturen von Dickdarm Biopsien, in Fibroblasten-ähnlichen Synoviozyten isoliert von 
rheumatoide Arthritis - Patienten sowie in HaCat Keratinozyten zeigen. Wir schlossen 
daraus, daß IFN-γ-vermittelte IL-18BPa Expression ein generelles Phänomen ist, das 
verschiedensten Zelltypen eigen zu sein scheint. Durch die Induktion von IL-18BPa durch VII. Appendix 
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IFN-γ wird ein negativer Rückkopplungsmechanismus eingeschaltet, der IFN-γ-abhängige 
und -unabhängige IL-18 Aktivität limitiert. Dieser durch IFN-γ-ausgelöste Rückkopplungs-
mechanismus zeigt seine Berechtigung in der beobachteten vermehrten Produktion von 
IFN-γ in IFN-γ-Rezeptor „Knockout“ Mäusen [Camoglio et al., 2000; Matthys et al., 1998]. 
Auf diese Weise hat IL-18BPa das Potential, eine gestörte TH1/TH2-Balance bei 
Autoimmunerkrankungen wie rheumatoide Arthritis und Morbus Crohn, wiederherzustellen. 
Eine Verbindung zwischen IL-18 sowie der Expression seines inhibitorischen 
Gegenspielers IL-18BPa ist in Patienten mit Sepsis [Novick et al., 2001], Still’s Krankheit 
[Kawashima et al., 2001] und Schuppenflechte [Ohta et al., 2001] beobachtet worden. An 
dieser Stelle sei aber auch erwähnt, daß IL-18BPa eine komplexe vielfältige Rolle spielt, 
die von der IL-18 Funktion im jeweiligen speziellen Fall abhängig ist. So könnte sich die 
IFN-γ-induzierte IL-18BPa Expression im Zusammenhang mit Karzinogenese nachteilig 
auswirken und das Tumorwachstum verstärken. 
Protektive Funktionen von IFN-γ sind gezeigt worden in murinen Modellen für rheumatoide 
und septische Arthritis (Vermeire et al., 1997; Puliti et al., 2000) sowie in RA-Patienten 
(German Lymphokine Study Group, 1992). Diese Effekte könnten auf die Induktion des IL-
18BPa zurückgeführt werden. IFN-γ-vermittelte Expression von IL-18BPa in RA-
fibroblasten-ähnlichen Synoviozyten wäre somit ein wichtiges Regulativ für IL-18 Aktivität, 
welche eine wichtige Rolle in der Pathogenese von rheumatoider Arthritis zu spielen 
scheint [Dayer, 1999]. IL-18 ist in der Lage, T Zellen und Makrophagen in der 
Mikroumgebung der rheumatoide Arthritis Synovitis zu aktivieren. In der Kaskade von 
proentzündlichen Zytokinen proximal angesiedelt, kann IL-18 als ursprünglicher Auslöser 
von nachfolgenden kardinalen inflammatorischen Zytokinen angesehen werden. Dazu 
gehören IL-1 und TNF-α, welche entscheidend zur Pathogenese von rheumatoider Arthritis 
beitragen. Durch die Synthese von IL-18BPa könnten Fibroblasten-ähnlichen Synoviozyten 
zum komplexen immunoregulatorischen Netzwerk beitragen, das die Kontrolle von IL-18 
Aktivität während Synovitis sicherstellt. Aktuelle Daten aus Tiermodellen belegen, daß   
IFN-γ die Symptomatik einer Gelenkentzündung verbessern kann, wenn es spät im 
entzündlichen Prozeß verabreicht wird. In diesem Stadium der Krankheit könnte die 
Hemmung von IL-18 durch IFN-γ-induziertes IL-18BPa einen negativen Rück-
kopplungsmechanismus gegenüber fortwährender Entzündung repräsentieren. In der Tat 
wird IL-18BPa zur Zeit in klinischen Phase I [http://www.serono.com/index.jsp] Studien zur 
späteren Behandlung der rheumatoiden Arthritis getestet. 
Eine weitere Autoimmunerkrankung, die in enger Verbindung steht mit pathologischer IL-18 
Aktivität, ist Morbus Crohn. Diese ist charakterisiert durch eine auffällige Akkumulation von 
aktivierten CD4
+ T Zellen vom TH1-Typ und Makrophagen in der entzündeten intestinalen 
Mucosa. Eine vermehrte Produktion von bioaktiven IL-18 ist in der Mucosa von Morbus VII. Appendix 
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Crohn Patienten gezeigt worden [Pizarro et al., 1999; Monteleone et al., 1999]. Weiterhin 
war eine signifikante Korrelation zwischen Serum IL-18 Konzentrationen und der jeweiligen 
Schwere der Erkrankung auffällig [Kanai et al., 2000]. IL-18BPa könnte aus diesen 
angeführten Gründen von therapeutischem Nutzen sein, indem es eine hypothetisch 
gestörte IL-18/IL-18BPa Balance bei Morbus Crohn wiederherstellt und somit einer 
vorangetriebenen TH1-Immunantwort entgegenwirkt. 
 
Eine erhöhte IL-18BPa Expression könnte sich im Rahmen der Kolon Karzinogenese 
nachteilig auswirken. So gibt es Hinweise, daß IL-18 als Inhibitor von Tumor Wachstum 
fungiert, indem es als Angiogenese Hemmer [Cao et al., 1999] arbeitet und die Fas/Fas-
Ligand abhängige CD4
+ T Zell- und NK Zell-Zytotoxicität verstärkt [Dao et al.1996; Tsutsui 
et al., 1996; Osaki et al., 1998]. Da gezeigt worden ist, daß Butyrat in punkto Entwicklung 
von Kolon Krebs potentiell protektiv ist, haben wir uns für den Einfluß von Butyrat auf die 
IL-18BPa Expression interessiert. Wir konnten zeigen, daß Butyrat die IFN-γ-induzierte IL-
18BPa Expression und Freisetzung aus DLD-1 Zellen hemmt. Intestinales Butyrat könnte 
daher die Fähigkeit haben, die Bioaktivität von IL-18 in der Umgebung des Dickdarms zu 
verstärken. Dies wäre ein durch IL-18 vermittelter tumor-suppressiver Effekt des Butyrat, 
welcher übereinstimmt mit der Beobachtung, daß diese kurzkettige Fettsäure die 
Sensitivität von Kolon Karzinom Zellen gegenüber Fas-vermittelter Apoptose erhöht 
[Bonnotte et al., 1998]. Interessanterweise scheint IFN-γ unter definierten Bedingungen in 
der Lage zu sein, das Wachstum von Kolon Karzinomzellen zu verstärken [Ramani et al., 
1987]. Diese Beobachtung könnte sich erklären aus IFN-γ-vermittelter Induktion von IL-
18BPa Expression. Zusammengefaßt läßt sich festhalten, daß Butyrat die IL-18/IL-18BPa 
Balance in Kolon Karzinomzellen in Richtung von IL-18 verschiebt, was zur lokalen 
Tumorprotektion durch diese Substanz beitragen könnte. 
 
Bisher haben wir berichtet, daß IFN-γ IL-18BPa Expression in verschiedenen Kolon 
Zelltypen, Keratinozyten, sowie Primärkulturen von fibroblasten-ähnlichen Synoviozyten 
induziert. Unsere Daten stammen aus Stimulationsexperimenten mit exogen 
hinzugegebenen rekombinanten IFN-γ. Um eher einer in vivo Situation zu entsprechen, 
entschieden wir uns für Kokultur Experimente, welche uns die Simulation einer TH1-
Immunantwort erlaubten. In diesem experimentellen Aufbau untersuchten wir die IL-18BP- 
sowie induzierbare NO-Synthase (iNOS) - Geninduktion in humanen DLD-1 Kolon 
Karzinom/Epithelzellen, die mit IL-12/IL-18 aktivierten PBMC in einem „Transwell“-System 
kokultiviert wurden. Ebenso wie IL-18 vermittelt die iNOS wichtige Funktionen im 
Zusammenhang mit Entzündung, Infektion und Krebs. In verschiedenen Typen von Krebs 
ist eine Hochregulation der iNOS tatsächlich beschrieben worden. In unseren Kokulturen VII. Appendix 
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wurden iNOS und IL-18BPa in DLD-1 Zellen nur in Gegenwart von IL-12/IL-18-stimulierten 
PBMC exprimiert. Diese Induktion von iNOS und IL-18BPa war abhängig von endogen 
produziertem IFN-γ, das von IL-12/IL-18-aktivierten T und NK Zellen freigesetzt wurde. 
 
Auch innerhalb dieses Kokultursystems konnte also der von uns vorgeschlagene negative 
Rückkopplungsmechanismus (IL-18 => IFN-γ => IL-18BPa) beobachtet werden. IL-18BPa 
hat hierbei das Potential, Karzinogenese zu fördern, indem es den IL-18 Arm der 
Immunabwehr gegenüber Tumoren schwächt. Die Induktion der iNOS parallel zu IL-18BPa 
stellt einen weiteren Weg dar, der das Tumorwachstum begünstigen könnte. Obwohl die 
Datenlage für die immunregulatorische Rolle von NO nicht einheitlich ist [Bogdan, 2001], 
zeigt die Analyse von iNOS Knockout Mäusen, daß die verstärkte Produktion von NO 
wahrscheinlich einen inhibitorischen Weg für IFN-γ Produktion repräsentiert [Wei et al., 
1995; Shi et al., 2001]. Dabei sind verschiedene Mechanismen vorstellbar: Einerseits wird 
diskutiert, daß NO mit der Reifung von pro-IL-18 interferiert durch Hemmung der Caspase-
1 (ICE) Aktivität [Kim et al., 1998]. Andererseits gibt es auch Berichte über Caspase-1 
unabhängiges IL-18 „Processing“ im humanen System [Mehta et al., 2001]. Insofern steht 
der Nachweis der Relevanz für das humane System in Bezug auf die Hemmung der 
Caspase-1 durch NO noch aus. Daneben kann NO die Proliferation von T-Lymphozyten 
einschränken. Dies geschieht wahrscheinlich durch die Unterbrechung des Jak3/STAT5 
Signaltransduktionsweges [Bingisser et al., 1998; Koblish et al., 1998]. Es konnte auch 
gezeigt werden, daß NO die IL-12 Produktion von Makrophagen beeinträchtigt, welches 
häufig mit IL-18 synergistisch zur Induktion von IFN-γ beiträgt. Neben der Unterdrückung 
der IFN-γ Produktion, kann NO Tumorwachstum durch einige weitere Mechanismen 
erleichtern. Beispielsweise korreliert die iNOS in humanen Kolonkrebs Geweben positiv mit 
der Frequenz von Mutationen im p53 Tumor Suppressor Gen. Ein weiterer Beleg für die 
Tumorwachstum fördernde Wirkung von NO ist die Beobachtung, daß iNOS-
überexprimierende Tumore deutlich stärker vaskularisiert sind [Jenkins et al., 1995]. 
Darüberhinaus kann durch iNOS gebildetes NO zur Vasodilatation im Tumor führen. Dies 
hat eine gesteigerte Blutzufuhr und Energieversorgung im Tumor zur Folge und würde 
zwangsläufig das Tumorwachstum begünstigen. Weiterhin scheint NO ein 
Entzündungsmediator zu sein, der eine verstärkte Infiltration von Leukozyten ins 
Tumorgewebe nach sich zieht. Dies ist relevant, weil gastrointestinale Entzündungen als 
Präkanzerosen die Progression von Kolontumoren begünstigen. Es konnte gezeigt werden, 
daß das Fehlen von IFN-γ verbunden ist mit der Bildung von entfernten Metastasen und 
schlechter Prognose in punkto Dickdarm Krebs [Pages et al., 1999]. Durch 
Gegenregulation des IL-18- und IFN-γ-abhängigen Armes der Immunabwehr gegenüber 
Tumoren haben IL-18BP und iNOS das Potential, eine Karzinogenese zu fördern. VII. Appendix 
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Negativer Rückkopplungsmechanismus 
reguliert die Bioaktivität von IL-18 und die 
Produktion von IFN-γ γ γ γ. 
 
Zwei verschiedene negative Rückkopplungs-
mechanismen sind denkbar, welche die 
Bioaktivität von IL-18 und die Produktion von 
IFN-γ inhibieren können. Dabei induziert 
zunächst IL-18 die Expression von IFN-γ in 
Synergismus mit IL-12. 
 
1) IFN-γ  vermittelt die Expression der iNOS in 
Kolon Epithelzellen. Hohe Konzentrationen 
des durch die iNOS gebildeten NOs modu-
lieren die IFN-γ Produktion an verschiedenen 
Stellen. 
 
2) IFN-γ induziert die Expression von IL-18BPa 
in Kolon Epithelzellen. 
Butyrat unterdrückt die IFN-γ-induzierte IL-
18BPa Expression und fördert damit die IL-18 
Bioaktivität. 
 
 
Wir stellten bereits fest, daß die IFN-γ-induzierte IL-18BPa Expression ein generelles 
Phänomen zu sein scheint, welches nicht nur auf Epithelzellen im Dickdarm beschränkt ist. 
Weitere Publikationen berichten über die IFN-γ-induzierte IL-18BPa Expression auch in 
renalen Mesangiumzellen [Mühl et al., 2000], Hepatozyten [Rubinstein et al., 2001] PBMCs 
und Monozyten [Corbaz et al., 2002], sowie endotheliale HUVEC („human umbilical vein 
endothelial cells“) Zellen [Corbaz et al., 2002]. Daher entschlossen wir uns dazu, den 
Mechanismus der IFN-γ-vermittelten IL-18BPa Induktion näher auf Ebene des Promoters 
zu untersuchen. Wie bereits erwähnt ist IFN-γ der Hauptstimulus einer IL-18BPa Induktion. 
In der vorliegenden Arbeit wurde von uns ein GAS („Gamma activated site“) Element 
proximal zum Transkriptionstart identifiziert. Mit Hilfe einer EMSA Analyse konnte die 
Bindung des Transkriptionsfaktors STAT-1 an dieses Element nachgewiesen werden. 
Weiterhin wurden zwei IL-18BP Promoter Fragmente kloniert, bei denen das beschriebene 
GAS Element im 3’-Bereich lokalisiert ist. Diese Konstrukte waren nach IFN-γ Stimulation 
stark induzierbar im Luciferase-Assay. Mutagenese des GAS Elements hingegen führte zur 
starken Reduktion der Induzierbarkeit beider Fragmente durch IFN-γ. Neben GAS wurden 
von uns noch weitere Elemente im IL-18BP Promoter entdeckt, die auf IFN-γ reagieren 
können, wie z.B. γ-IRE („γ-Interferon responsive element“) und ISRE („IFN-stimulated 
response element“). STAT-1 könnte daher ebenfalls direkt an zwei γ-IRE Regionen binden, VII. Appendix 
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welche Bestandteil der von uns klonierten IL-18BP Promoter Luciferase Fragmente sind. 
Ebenso denkbar wäre eine putative Induktion über ISRE vermittelt durch STAT-1 
induziertes IRF-1 („Interferon Regulatory Factor-1“), da ein GAS Element auch die 
Expression von IRF-1 kontrolliert. Nachfolgende Arbeiten werden diese Fragestellung im 
einzelnen behandeln. 
 
Aufgrund der Datenlage ist man versucht zu schließen, daß eine Blockade der Zytokine 
Kaskade oberhalb von IL-1 und TNF-α auf der Ebene von IL-18 einen therapeutischen 
Nutzen bringen könnte. Die endogene Produktion von IL-18BPa nach IFN-γ stellt einen 
negativen Rückkopplungsmechanismus dar, der einerseits Entzündungsreaktionen limitiert, 
andererseits aber auch tumorsuppressive Eigenschaften von IL-18 einschränkt und so im 
Rahmen der Tumorabwehr kontraproduktiv sein kann. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 